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Clinical aspects of human 
inflammatory bowel diseases 
Introduction 
Crohn’s disease and ulcerative colitis, collectively referred to as inflammatory bowel 
diseases (IBD), are chronic idiopathic inflammatory diseases of the gastrointestinal tract. IBD is 
generally regarded as a “Western” world disease and its frequency has increased considerably 
over the past few decades. Quality of life is severely affected in IBD patients, mainly due to the 
chronic relapses of disease. Complications such as stenoses and strictures are frequent in Crohn’s 
disease, leading to multiple resections of affected parts of the gastrointestinal tract. In addition, 
chronic ulcerative colitis is associated with an increased frequency of colonic adenocarcinoma. 
Each of these factors highlights the importance of developing a better understanding of IBD. 
The incidence of IBD has either continued to increase or has stabilized at a high rate in 
most developed countries. Even in less developed regions where IBD has been less common, the 
incidence is now increasing. This increase is the result of a combination of previously rising 
incidence and improved survival.1 In 1998, a prospective study reported an incidence as high as 
6.9 and 10.0 cases per 100,000 inhabitants per year of Crohn’s disease and ulcerative colitis in 
Zuid-Limburg, The Netherlands, respectively.2,3 The onset of both diseases occurs most 
frequently between the age of 15 and 30. 
 
Crohn’s disease 
Although Crohn’s disease and ulcerative colitis are both inflammatory disorders of the 
intestinal tract, they each have distinct patterns of symptoms and therapeutic strategies. Crohn’s 
disease was first described in 1932 by Crohn, Ginsberg, and Oppenheimer as “ileitis regionalis”, 
to be distinguished from intestinal tuberculosis.4 Although Crohn’s disease can occur at any 
location in the intestinal tract, the highest incidences are reported in the distal ileum, cecum, and 
right-sided colon. Clinical symptoms are diverse and involve nonbloody diarrhea, abdominal 
cramps, fever, weight loss, and perianal manifestations. Associated complications include fistula 
to skin and internal organs, strictures, and perirectal abscess formation. Gross appearance shows a 
thickened intestinal wall with a narrowed lumen, which can lead to bowel obstruction. In more 
advanced stages of the disease, the mucosa has a nodular appearance, often referred to as 
”cobblestones”. Characteristic histopathologic features of Crohn’s disease that do not occur in 
ulcerative colitis are transmural inflammation affecting all layers of the intestinal wall and 
mesenteric lymph nodes, and chronic non-caseating granulomatous inflammation. The intestinal 
tract shows a discontinuous pattern: severely affected regions alternate with normal parts, the so-
called “skip-lesions”. Current treatments for mild-moderate Crohn’s disease include steroids, 5-
aminosalicylic acid, and antibiotics. More severe and recurrent Crohn’s disease requires 
azathioprine/6-mercaptopurine, methotrexate, and/or anti-TNF therapy. Surgical interventions are 
necessary to treat complications and drug-resistant patients. 
 
Ulcerative colitis 
Ulcerative colitis was first described by Wilks in 1859.5 Ulcerative colitis is always 
restricted to the colon and involves the rectum. Major symptoms reflect colonic inflammation: 
diarrhea, rectal bleeding, and abdominal pain, often accompanied by fever and weight loss. The 
inflammation primarily involves the colonic mucosa, is uniform and continuous, and always 
progresses proximally. Pseudopolyps are commonly found during endoscopy. Initial microscopic 
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findings include goblet cell depletion, crypt hyperplasia, and neutrophilic infiltration. Chronic 
ulcerative colitis can lead to dysplasia, with increased risk for colorectal cancer in later stages of 
disease. Laboratory findings show perinuclear staining for antineutrophil cytoplasmic antibodies 
in 70% of ulcerative colitis patients. Medical treatment of ulcerative colitis includes systemic and 
topical steroids and 5-aminosalicylic acid for mild to moderate ulcerative colitis. More severe 
disease requires azathioprine/6-mercaptopurine or intravenous cyclosporine. Since ulcerative 
colitis is restricted to the colon, surgical treatment by total colectomy will cure the disease. 
In this thesis, characteristics of experimental colitis are the main focus. Although the 
following sections will initially refer to mainly human IBD, during the course of this introduction 
background on experimental colitis will be provided as well. 
 
 
Etiology of inflammatory bowel disease 
Genetic factors 
There is overwhelming evidence that genetic factors play an important role in IBD, and 
that the association is stronger for Crohn’s disease than for ulcerative colitis. For example, 15-
20% of all IBD patients have at least one affected relative, usually a first-degree relative. The 
absolute risk of IBD for first-degree family members is approximately 7%.8,9 Disease concordance 
for IBD is higher in monozygotic twins (44-50%) than in dizygotic twins (0-4%).8 These 
percentages are much lower for ulcerative colitis, indicating that genetic influences might be 
stronger in Crohn’s disease than in ulcerative colitis. It is interesting that the concordance in 
monozygotic twins does not exceed 50%, indicating that environmental factors also play an 
important role in the onset of IBD. There are also differences in prevalence among the different 
ethnic groups. IBD is most frequent in Ashkenazi Jews, and high in Caucasians, but lower for 
Blacks. For example, mutations in the NOD2/CARD15 gene have been demonstrated to predict 
an earlier age-of-onset in Ashkenazi Jewish patients.10 Progress in the field of genetics and in IBD 
research will continue to provide more insight into the variations observed between the different 
ethnic groups. 
The absence of simple Mendelian inheritance patterns for predicting the risk of IBD 
development suggest that multiple genetic mutations are associated with IBD. The most important 
mutation discovered involves the gene on chromosome 16, encoding for NOD2/CARD15.11,12 
NOD2/CARD15 is an intracellular pattern-recognition receptor that recognizes muramyl 
dipeptide, a component of peptidoglycan-polysaccharide (PG-PS) present on bacterial cell 
walls.13,14 NOD2 is present in numerous immune cells, including dendritic cells, monocytes, and 
epithelial cells.15 It activates the nuclear factor κB (NF-κB) pathway, which is an intracellular 
signaling cascade crucial to the initiation of proinflammatory responses and protection against 
pathogens, as outlined in Chapter 2. Malfunction of NOD2 and the subsequent lack of NF-κB 
activation can lead to insufficient removal of pathogens.16 Recently, this concept was revised 
using Card15-/- mice.119 In the latter study, intact NOD2 signaling inhibited TLR-2-driven 
activation of NF-κB. Moreover, NOD2 deficiency or the presence of a Crohn’s disease-like 
Card15 mutation increased TLR-2-mediated activation of NF-κB, and TH1 responses were 
enhanced. Thus, CARD15 mutations may lead to disease by causing excessive TH1 responses. 
This is one potential explanation for the relationship between NOD2/CARD15 mutations and the 
induction of inflammation. 
Patients homozygote for the NOD2 mutation have a relative risk of 38 for developing 
Crohn’s disease. This same factor is only 3 for heterozygotes.12 However, some individuals who 
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are homozygote for the NOD2 mutation do not develop IBD and NOD2 polymorphisms only 
occur in a subgroup of patients.17 Therefore, it is likely that susceptibility loci for IBD on other 
chromosomes are involved.18 Of interest, two variants in the organic cation transporter cluster at 
5q31, a previously reported locus (IBD5) associated with Crohn’s disease, form a haplotype 
associated with susceptibility to Crohn disease.120 These variants alter transcription and 
transporter functions of the organic cation transporters and interact with variants in CARD15, to 
increase the risk of Crohn’s disease. 
Increasing evidence suggests that genetic mutations may correlate with the phenotype of 
disease. This has been shown for location and aggressiveness of disease, and also for 
complications of IBD.19 For example, common NOD2/CARD15 variants are associated with ileal 
disease and a fibrogenic, stenotic phenotype.20-22 Furthermore, genes are involved in the efficacy 
and toxicity of therapy.19 For example, expression of the glucocorticoid receptor β (GRβ) alters 
the corticosteroid response in IBD.23 This receptor does not signal after binding to corticosteroids, 
in contrast to GRα which continues to signal. 83% of glucocorticoid-resistant ulcerative colitis 
patients expressed GRβ, whereas only 9% expressed GRβ in normal responders. 
Genetic factors in the pathogenesis of IBD are supported by numerous animal models that 
have been developed using genetic manipulation. The genetically susceptible host develops 
intestinal inflammation due to the absence (e.g. IL-10 deficient (IL-10-/-) mice) or overexpression 
(e.g. HLA-B27 transgenic rat) of specific genes.24 Their wild-type littermates remain disease-free, 
emphasizing that a single genetic mutation can play a major role in the onset of severe 
inflammation. Animal models will be discussed in depth in the following paragraphs. In 
conclusion, identifying and understanding genetic mutations is crucial for predicting the onset of 
disease, resistance to therapy, and the risk factors for family members of patients with IBD. 
 
Environmental factors 
Evidence for environmental factors affecting the incidence of IBD is drawn from the 
increased incidence of IBD in the developed countries.1,25,26 Dietary factors and Western public 
health greatly influence the incidence of Crohn’s disease and ulcerative colitis. Additionally, the 
incidence of IBD changes when populations move between different regions. This is illustrated by 
the increasing incidence of IBD among Japanese immigrants in the United States.27 There is also a 
decreased incidence of Crohn’s disease among Ashkenazi Jews who moved from east-Europe to 
Israel.28 More evidence for the influence of environmental factors is provided by the low 
concordance rates in monozygotic versus dizygotic twins, as discussed before.8 
Environmental factors that can increase the risk of IBD include smoking, the use of 
NSAIDs, stress, and acute infections.27 The best example of an environmental factor that 
influences IBD incidence is cigarette smoking. The risk of ulcerative colitis is increased for non-
smokers, and especially for smokers who have recently quit,29,30 whereas smoking increases the 
risk of Crohn’s disease.31 When combined with oral contraceptives, almost all IBD patients who 
smoke will experience exacerbation of disease. This figure is only 40% in patients who have only 
one of the two risk factors.32 Therefore, although genetic susceptibility is required to develop IBD, 
environmental factors determine the onset and progression of disease. 
 
Microbiological factors 
Bacteria are crucial environmental factors that influence IBD. Many animal models of 
chronic intestinal inflammation have demonstrated the importance of the commensal intestinal 
bacteria for the onset and progression of disease. This is shown in HLA-B27/β2 microglobulin 
transgenic rats,33,34 IL-2-/-,35 IL-10-/-,81 TCRα-/-,36 SAMP-1/Yit,37 and CD3ε26 transgenic mice38 in 
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which the germ-free state prevents disease development and immune activation. The importance 
of intestinal bacteria in the pathogenesis of experimental colitis was further emphasized after 
showing that broad spectrum antibiotics can both prevent and treat colitis in HLA-B27 transgenic 
rats. Antibiotics have a similar effect in dextran sulfate sodium (DSS)-induced colitis in BALB/c 
mice39 and in IL-10-/- mice.40 Moreover, cecal bacterial overgrowth within an experimental blind 
loop exacerbates colitis in HLA-B27 transgenic rats, whereas a bypass of the cecum attenuates the 
disease in this model.41 Thus, animal models of experimental colitis have shown that commensal 
bacteria and their products are required for induction and perpetuation of colitis. 
Monoassociation studies have provided inside into the role of specific bacterial strains in 
the pathogenesis of colitis. Bacteria can be disease-inducing, neutral, or protective. For example, 
Bacteroides vulgatus (B. vulgatus) preferentially induces colitis in HLA-B27 transgenic rats after 
monoassociation for 4 weeks, whereas monoassociation with Escherichia coli (E. coli) does not 
cause disease.42 Protective bacteria are called “probiotics” and one example of its protective 
effects is the prevention of inflammation by Lactobacillus rhamnosus GG (Lactobacillus GG) in 
HLA-B27 transgenic rats.43 Host-specificity has been shown by the observation that E. coli 
induces colitis in IL-10-/- mice but not in HLA-B27 transgenic rats.42,44 Moreover, regional 
specificity is evident for different bacteria. Enterococcus faecalis (E. faecalis) induced mild distal 
colitis, whereas E. coli caused a cecal inflammation in IL-10-/- mice.44 
Many studies have attempted to locate pathogens associated with human IBD. One 
bacterial species associated with IBD is E. coli. Its role in chronic intestinal inflammation was 
demonstrated by the observation that ileal mucosa from Crohn’s patients with postoperative 
recurrence contained more enteroadherent/invasive E. coli strains than healthy controls.45 This 
association only applied to the ileum of healthy and diseased Crohn’s disease patients, but not for 
colonic Crohn’s disease nor ulcerative colitis patients.46 In addition, IBD patients have increased 
serum and mucosal antibody responses to several commensal bacteria, including E. coli.47-49 T-
cell clones from mucosal biopsies showed specific responses to selective commensal bacteria, 
including Bacteroides, Bifidobacteria, and E. coli.50,51 
Studies in animal models and human IBD patients highlight the importance of commensal 
bacteria for the induction and perpetuation of IBD. The balance between protective and disease-
inducing bacteria determines the effects on host homeostasis. While significant steps have been 
made to identify those bacteria, more than half of the bacteria found in the colon are not cultivable 
and therefore difficult to study. Further studies are needed to investigate the role of individual 
commensal bacterial strains in the pathogenesis of IBD. 
 
Immunological factors 
The presence of pathogenic and non-pathogenic microorganisms induces innate and 
adaptive immune responses and lead to the activation of a complex gene program aimed at re-
establishing host homeostasis. The initiation of innate immunity is a critical feature of host 
homeostasis, and failure to regulate and/or terminate this response can have deleterious 
consequences for the host. For example, IBD is associated with both dysregulated innate and 
adaptive immune responses to luminal non-pathogenic bacteria.24,52-54 The following sections will 
introduce both innate and adaptive immunity in IBD. Additionally, in Chapter 2, a more extensive 
overview of innate immune responses is provided. 
 
Innate immune system 
From an evolutionary perspective, the innate immune system is an old system, well 
conserved in plants and animals. It functions as a first line of defense against pathogens, and uses 
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toll-like receptors (TLR) as mediators of innate immune responses.55 Bacterial products act as 
ligands for TLR, and subsequently activate various transcription factors, such as NF-κB. This 
activation results in cytokine secretion and upregulation of costimulatory molecules that alter 
adaptive immune responses, leading to regulatory or proinflammatory immune responses. This 
link between the innate immune system and the adaptive immune system is of high relevance to 
IBD, because in IBD patients it is well known that commensal bacteria activate the innate immune 
system. In turn, Crohn’s disease is a T helper-1 (TH1)-mediated disease, driven by T lymphocytes 
that are partially induced by innate immune responses. Important cells and their cytokines 
involved in innate immune responses, such as epithelial cells, dendritic cells, and macrophages, 
are discussed in Chapter 2. 
 
Adaptive immune system 
Immune cells from the lymphoid lineage, which include B and T lymphocytes, respond to 
stimuli in an antigen-specific manner. This feature allows the adaptive immune system to respond 
in a highly specific manner to a tremendous variety of antigens present in the intestinal lumen. 
Regulating these responses is crucial to ensure the intestinal homeostasis. This is highly relevant 
to IBD, since the commensal microflora drives immune responses and therefore requires tight 
regulation. Dysregulation can have deleterious consequences, as shown in various animal models, 
such as the IL-10-/- mouse model. 
T cells recognize a wide variety of antigens presented by antigen-presenting cells using 
the T cell receptor (TCR) repertoire. The TCR forms a complex with antigens, followed by 
activation of a cascade resulting in the secretion of proinflammatory cytokines by effector T cells, 
categorized by TH1 and TH2 responses. TH1 responses are characterized by increased secretion of 
interferon-γ (IFN-γ) and tumor necrosis factor (TNF), whereas TH2 responses involve secretion of 
IL-4, IL-5, and/or IL-13. Uncontrolled secretion of these cytokines by T cells can induce 
inflammation. Interleukin (IL)-12, IL-18 and IL-23 from antigen-presenting cells stimulate TH1 
lymphocytes, while IL-10 activates regulatory cells. In genetically engineered animal models, T 
cells have been shown to be crucial to the development of inflammation. This has been 
demonstrated in IL-2-/- mice,56 IL-10-/- mice,57 TCRα-/- mice,58 Tgε26 mice,59 and transfer of either 
CD45RBhigh or T cells into either severe-combined immunodeficient (SCID) mice60 or athymic 
rats,61 respectively. In the HLA-B27 transgenic rat model, Breban et al previously showed that 
nude athymic (rnu/rnu) HLA-B27 transgenic rats lacking T cells do not develop colitis under 
specific pathogen-free conditions, and that CD4+ T cells can transfer disease.62 
In human IBD, TH1 responses are mainly detected in Crohn’s disease patients, whereas 
ulcerative colitis is characterized by activation of TH2-like or IL-13 NK T cell mediated 
pathways.121 Therapeutic approaches targeting T cells have shown their efficacy. For example, 
anti-TNF therapy can attenuate intestinal inflammation by induction of apoptosis in lamina 
propria T-lymphocytes of patients with Crohn's disease.63 
However, T cells also have regulatory functions. Regulatory T (TR) cells secrete IL-10 and 
transforming growth factor β (TGF-β) that are capable of regulating inflammatory responses. The 
importance of these cytokines has been demonstrated by the fact that TGF-β-/- mice die within five 
weeks of severe multiple organ inflammation,64 and the severe intestinal inflammation that 
develops in IL-10-/- mice.65 
Several subsets of T cells contribute to regulation of immune responses. CD4+ TR cells 
constitutively express CD25 on their surface and induce TH3 responses by secreting TGF-β. 
Studies in animal models have helped to identify the regulatory functions of CD4+ T cells. In an 
elegant study, Powrie et al showed that transfer of CD4+CD45RBhi T cells from normal mice 
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induced colitis in SCID mice. This inflammatory process could be prevented by co-transfer of 
CD4+ cells that express low levels of CD45RB from normal mice.60 The same principle was 
shown in the athymic rat, where the transfer of T cells that express high levels of the CD45 
isoform, designated CD45RC, mediated inflammation in several different organ systems, and the 
severity of inflammation was greatly reduced by co-transfer of a CD4+CD45RClo cell 
population.61 The mechanisms of TR cell development has been unknown for a long time. 
However, recently Foxp3 has been recognized as a key regulatory gene for the development of 
these regulatory T cells.66 This finding allows better distinction of TR cells and provides more 
insight in the development of a naïve T cell into a TR cells. 
A second example of a subset of regulatory T cells are TR1 cells that secrete IL-10. TR1 
cells inhibited colitis in SCID mice after transfer of CD4+CD45RBhigh cells, mediated by the 
secretion of IL-10.67 Thus, different subsets of T cells can induce either inflammatory or 
regulatory responses to intestinal bacteria. The ratio of these two responses will determine the 
outcome: homeostasis or inflammation. 
 
Until recently, the role of B cells in the mechanisms of colitis was thought to be minor. 
However, in recent years, reports showed that B cells are not merely bystanders, but actively 
participate in onset and perpetuation of disease. B cells have numerous immune functions, such as 
production of immunoglobulins (Igs) and cytokines, antigen presentation, and the regulation of 
dendritic cell function.68-70 Similar to the distinction between proinflammatory and regulatory T 
cells, B cells also have distinct functions.71 B cells are required for the development of several 
autoimmune disorders by the secretion of pathogenic Igs.71 In contrast, Mizoguchi et al 
demonstrated that IL-10-producing B cells expressing CD1d are protective, since B cell/TCRα 
double deficient mice had more colitis than TCRα deficient mice with competent B cells.72,73 The 
role of B cell-secreted IL-10 was further demonstrated by the observation that the transfer of B 
cells from IL-10/TCRα double deficient mice was unable to suppress chronic intestinal 
inflammation in B cell/TCRα double deficient mice.72 Thus, T cells are required for the induction 
of colitis in many models of experimental inflammation, but T and B cells can also regulate 
inflammation. Although not fully understood, the fine interplay between the several subsets of 






Animal models of experimental colitis have contributed to the enormous progress made in 
the last decade to our further understanding of IBD. Although there are no animal models that 
identically replicate human IBD, numerous characteristics can be found in each individual model, 
and the combination of knowledge acquired helps us to better understand IBD. One way of 
categorizing animal models of intestinal inflammation is to distinguish between induced and 
spontaneous colitis. Chemical-induced colitis is reproducible and relatively easy to perform, 
however, only certain characteristics are relevant to human IBD. Chemical inducers of colitis 
include DSS, acetic acid, and trinitrobenzenesulfonic acid (TNBS).74 
Genetically engineered models resemble human IBD better than chemically induced 
models of colitis. These models illustrate the relevance of specific genes for the development of 
chronic intestinal inflammation. In order to accomplish this, genes of interest are either deleted, 
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‘knock-out’, or inserted, ‘knock-in’.24 Two models of spontaneous colitis are extensively used 
throughout this thesis: IL-10-/- mice and HLA-B27 transgenic rats. 
 
HLA-B27 transgenic rats 
HLA-B27 transgenic rats overexpress the human MHC class I molecule HLA-B27 and 
β2-microglobulin. Under specific pathogen-free conditions, these animals develop spontaneous 
colitis and gastritis starting at 10 weeks of age, while their non-transgenic littermates remain 
disease-free.75 Disease-susceptible transgenic animals have diarrhea, and often display signs of 
arthritis and uveitis. Inflammation is characterized by crypt hyperplasia, mucosal thickening, 
mononuclear cell infiltration, and crypt abscesses in later stages of disease. 
Studies in rnu/rnu rats, which are congenitally athymic and do not have T lymphocytes, 
have helped us better understand the development of TH1 mediated colitis in this model. Even if 
they carry the disease-prone B27 transgenic locus rnu/rnu transgenic rats are protected from 
disease, whereas the presence of T cells in their heterozygous nude (rnu/+) transgenic littermates 
coincides with development of colitis under specific pathogen-free conditions.62 The critical role 
of T cells in inducing intestinal inflammation in this model was further emphasized by the 
induction of colitis by the transfer of T cells into specific pathogen-free rnu/rnu HLA-B27 
transgenic recipients, with CD4+ T cells being more efficient than CD8+ T cells in transferring 
disease.62 
HLA-B27 rats raised in a germ-free environment fail to develop intestinal inflammation 
and arthritis,33,34 however, they will develop colitis and gastritis within one month after transfer to 
a specific pathogen-free environment and colonization with nonpathogenic commensal bacteria.34 
More evidence for the role of commensal bacteria in the pathogenesis of colitis in this model is 
provided by the prevention and treatment of colitis by broad spectrum antibiotics.39 Furthermore, 
monoassociation studies showed selectivity for the induction of colitis. B. vulgatus induced 
colitis, whereas E. coli did not induce disease.42 Lactobacillus GG prevented recurrence of disease 
after antibiotic treatment, indicating that bacteria can also have beneficial effects in this model.43 
The HLA-B27 rat model represents a larger group of diseases, referred to as 
spondyloarthropathies.76 This group includes colitis, arthritis, orchitis, and psoriasis-like skin 
lesions.75,77 In patients, the overexpression of HLA-B27 does not lead to colitis, but it does 
increase the risk of extra-intestinal manifestations. The overexpression of a gene involved in 
human disease, and extra-intestinal manifestations of disease, make this rat model therefore highly 
relevant for human IBD. 
 
IL-10-/- mice 
Deletion of the gene encoding IL-10 causes the absence of production of the 
immunoregulatory cytokine IL-10, and leads to TH1-mediated colitis. IL-10-/- mice develop 
predominantly cecal inflammation shortly after weaning when susceptible strains (129 SvEv or 
mixed 129/C57Bl/6 background) are colonized with specific pathogen-free bacteria.65,78 As 
disease progresses, inflammation develops in the ascending and transverse colon, and finally in 
the remainder of the colon and rectum. Rectal prolapses and diarrhea are frequently observed. 
Histologic features of chronic intestinal inflammation include crypt hyperplasia, neutrophilic 
infiltrations, ulcers, and crypt abscesses. 
T cells are required for the induction of intestinal inflammation in this model as the 
transfer of CD4+ T cells from IL-10-/- donors into recombinant-activating genes deficient (RAG-/-) 
mice induced colitis.57 B cells are not required, as similar colitis developed in B cell-/-IL-10-/- mice 
versus IL-10-/- mice.57 The proinflammatory cytokine IL-12 is a key mediator of inflammation, 
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since IL-12 blocking antibodies prevented disease in IL-10-/- mice.79 Interestingly, recombinant 
IL-10 prevents the onset of disease, but does not treat established colitis.57 The molecular 
mechanisms for the immunoregulatory effects of IL-10 are largely unknown. Therefore, the IL-10 
deficient mouse provides a model of experimental colitis in which the role of endogenous IL-10 
can be studied. 
Bacteria and their products are required for inflammation in IL-10-/- mice. Conventially 
housed IL-10-/- mice develop lethal enterocolitis, whereas specific pathogen-free conditions result 
in aggressive, non-lethal inflammation.65 Monoassociation studies demonstrated that single 
bacterial strains induce phenotypically different colitis. E. faecalis induced a mild distal colitis 
with a slow onset of disease while E. coli induced rapid intestinal inflammation, predominantly in 
the cecum.44,80 Germ-free IL-10-/- mice do not develop disease, and do not show any signs of 
immune activation.81 
Also antibiotics can prevent disease,40 a finding used in Chapter 3 to study to local effects 
of antibiotics in more detail. Bacteria also exert protective effects, as demonstrated by attenuation 
of disease by probiotics in murine models of colitis.82,83 Thus, bacteria are required in IL-10-/- 
mice to develop a TH1-mediated colitis with increased IL-12 secretion and activated CD4+ T cells. 
 
 
Manipulating the intestinal microflora 
Introduction 
Under normal conditions intestinal homeostasis is well maintained in the presence of 
commensal non-pathogenic bacteria. However, in the genetically susceptible host, chronic 
intestinal inflammation can develop in response to the same residential intestinal bacteria.24 
Luminal bacteria are present in high concentrations, as high as 1011 organisms/gram luminal 
contents.84 Moreover, Crohn’s disease occurs at sites with the highest levels of anaerobic bacteria. 
Manipulating the intestinal microflora may be of importance in changing the natural course of 
colitis. Treatments that target the bacterial load and the composition of the luminal microflora 
include antibiotics, probiotics, and prebiotics. 
 
Antibiotics 
Broad spectrum antibiotics have proved to be beneficial in treating chronic intestinal 
inflammation. Most clinicians use broad spectrum antibiotics for septic complications, and as 
adjuvant therapy in fulminant colitis and toxic megacolon. Selective antibiotics are used mainly in 
Crohn’s disease. In Crohn’s disease, metronidazole was effective in treating colonic 
inflammation.85,86 Metronidazole in combination with ciprofloxacin is preferentially used for 
colonic inflammation.87-89 Although controversial, ciprofloxacin has been used in clinical trials 
and treated Crohn’s disease.90,91 In both fistulizing Crohn’s disease and in pouchitis there is a role 
for metronidazole.92,93,94,95 Only a few well-designed clinical trials support the use of antibiotics in 
ulcerative colitis patients.96,97 
Most studies in animal models of colitis support the use of antibiotics. A combination of 
metronidazole and neomycin prevented and treated colitis in IL-10-/- mice.40 Vancomycin-
imipenem prevented and treated colitis in HLA-B27 rats, DSS-induced colitis in mice 39, and 
TNBS-induced experimental colitis in rats.98 The combination of ciprofloxacin and metronidazole 
prevented and treated inflammation in the SAMP1/Yit spontaneous ileitis model 99 and it 
improved acute but not chronic DSS-induced colitis in mice.100 An interesting observation from 
studies in animal models is that antibiotics are more effective in prevention than treatment of 
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chronic colitis. Ciprofloxacin prevented the induction of colitis in IL-10-/- mice born under 
specific pathogen-free conditions, but showed only minor effects in established colitis.40 
Moreover, in HLA-B27 transgenic rats and DSS-treated mice, oral administration of either 




Probiotics are living commensal microorganisms that are important to the health and well-
being of the host.101 The most convincing evidence so far is derived from a clinical trial with 
VSL#3. VSL#3 is a cocktail of eight different probiotic species that was very effective in 
preventing chronic pouchitis after antibiotic-induced remission,102 and in treating ulcerative colitis 
patients.103,104 Single probiotic species have also been identified and shown to improve disease in 
ulcerative colitis patients, as shown for the E. coli 1917 Nissle.105 
Certain probiotic bacteria, such as Lactobacillus species, showed protection in several 
experimental models of chronic intestinal inflammation, including specific pathogen-free HLA-
B27 transgenic rats and IL-10-/- mice.43,82,83 Interestingly, the specificity of probiotics and the 
background of the host is important. Lactobacillus GG prevented colitis in HLA-B27 transgenic 
rats but not in IL-10-/- mice. In contrast, Lactobacillus plantarum was effective in IL-10-/- mice but 
had no effect in HLA-B27 transgenic rats after antibiotic treatment.43,83 
Relatively little is known about the mechanisms for the protective effects of probiotic 
bacteria. The protective mechanisms suggested can be broadly categorized into three groups. 
First, probiotics exert their beneficial effects by suppression of growth or function of pathogenic 
bacteria. Bifidobacteria infantis protected the gut epithelial layer from being invaded by 
Bacteroides, thereby suppressing the systemic antibody response raised by Bacteroides.106 
Second, probiotics can improve the intestinal barrier function. This was demonstrated by the 
decreased epithelial permeability in IL-10-/- mice after treatment with VSL#3.82 Third, probiotics 
have immunoregulatory activities. Dieleman et al showed increased cecal IL-10 and decreased IL-
1β secretion after Lactobacillus GG treatment in HLA-B27 transgenic rats.43 Also, non-viable 
probiotic DNA isolated from the probiotic cocktail VSL#3 attenuated intestinal inflammation in 
IL-10-/- mice, which effect was mediated by TLR-9.107 The clinical use for probiotics is emerging, 
and the advances made in explaining the mechanisms of probiotics are promising. 
 
Prebiotics 
Prebiotics are non-digestible food ingredients which beneficially affect the host by 
selectively stimulating growth, activity, or both of selective intestinal (probiotic) bacteria.108 
Prebiotics are easy to administer and do not require live bacteria. Because of these characteristics 
prebiotics can be of value for treatment of IBD. However, clinical experience with prebiotic 
treatment is very limited. Only few small clinical trials have demonstrated the efficacy for 
prebiotics in human IBD. For example, germinated barley food extracts decreased clinical and 
endoscopic inflammation in mild-moderate ulcerative colitis.109,110 
Animal models of inflammation have provided some insight in the effects of prebiotics. In 
rats, oral inulin decreased distal colonic lesions in DSS-induced colitis,111 and oral fructo-
oligosaccharides decreased TNBS-induced colitis, although its effects were apparent only after 14 
days of feeding.112 No effects were seen after oral administration of trans-galacto-oligosaccharide 
started before or during TNBS-colitis induction, indicating that prebiotics are not equally effective 
in preventing disease.113 
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Oral prebiotics administration is associated with increased luminal concentrations of 
probiotic bacteria, such as Bifidobacteria and Lactobacilli species.109,111,112,114,115 Adding 
Lactobacilli and Bifidobacteria to topical butyrate solutions in rats with TNBS-induced colitis 
was necessary to induce a similar improvement as shown by oral fructo-oligosaccharides 
administration suggesting that increased concentrations of probiotic bacteria mediated the clinical 
efficacy of prebiotics.112 A second potential mechanism for prebiotics to attenuate colitis is 
increased levels of short-chain fatty acids (SCFA). The end-products of prebiotic fermentation by 
commensal organisms present in the colon lead to the production of lactate and SCFA. This 
results in increased acidity, which may inhibit the growth of disease-inducing bacteria.112 Changes 
in SCFA production, especially increased luminal butyrate concentrations can also affect 
proliferation and differentiation,116 tight junction permeability117 and epithelial restitution.118 
Moreover, butyrate exerts immunomodulatory effects and decreases NF-κB activity.109 Taken 
together, although progress has been made in the last years, our understanding of prebiotics is still 




As described in the introduction, the pathogenesis of inflammatory bowel disease involves 
an overly aggressive immune response to commensal luminal bacteria. Therefore, this thesis 
addresses 
 
1. The attenuation of bacterial-induced experimental colitis by manipulating the intestinal 
microflora.  
2. The regulation of bacterial-induced innate and adaptive immune responses. 
 
Chapter 1 and 2 give an overview of genetic, microbiological, and immunological aspects 
of the pathogenesis of IBD. It is concluded that IBD is now considered an overly aggressive 
immune response of the genetically susceptible host to luminal commensal bacteria. Various 
treatment strategies are discussed that can alter the microflora, thereby preventing and treating 
experimental colitis. Furthermore, the importance of various cell types, cytokine secretion, and 
signaling pathways in innate and adaptive immunity is explained. 
Part I describes attenuation of colitis by manipulating the intestinal microflora. In Chapter 
3 the effect of selective and broad spectrum antibiotic treatment was studied in IL-10-/- mice. Aim 
was to assess the specific local effects in the intestinal tract exerted by the various antibiotic 
treatments. Fluorescent in situ hybridization (FISH) and bacterial cultures were used to quantify 
specific bacterial strains before and after treatment, and the severity of inflammation was 
determined by gut cultures and histology scores. In Chapter 4, we investigated if the probiotic 
Lactobacillus GG can prevent colitis in HLA-B27 transgenic rats monoassociated with B. 
vulgatus. Furthermore, we intended to determine if Lactobacillus GG or Lactobacillus plantarum 
can treat established colitis in specific pathogen-free transgenic rats and prevent recurrent disease 
after antibiotics were stopped. Prior to monoassociation with B. vulgatus, HLA-B27 transgenic 
rats were colonized with Lactobacillus GG or no bacteria. Secondly, specific pathogen-free HLA-
B27 transgenic rats received oral vancomycin-imipenem for 2 weeks, or water alone, followed by 
4 weeks treatment with either oral Lactobacillus GG, Lactobacillus plantarum or water only. 
Disease activity was quantified by blinded gross and histologic scores, cecal myeloperoxidase 
(MPO), and the proinflammatory cecal cytokines IL-1β and TNF, and the regulatory cytokines 
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TGF-β and IL-10. Chapter 5 describes the effects of prebiotic treatment on colitis in HLA-B27 
transgenic rats. Aim was to investigate the course of colitis and to identify protective mechanisms 
of the prebiotic combination inulin/oligofructose. Cecal IL-1β and MPO, mesenteric lymph node 
cell cytokine secretion, and histology scores were used to assess inflammation. FISH and PCR-
denaturing gradient gel electrophoresis (PCR-DGGE) were used to quantify specific bacterial 
strains before and after treatment. 
In Part II, bacterial-induced innate and adaptive immune responses in HLA-B27 
transgenic rats and IL-10-/-mice were studied. Chapter 6 describes cytokine profiles in mesenteric 
lymph node cells from HLA-B27 transgenic rats. The ratio of proinflammatory cytokines (IFN-γ, 
IL-12) versus anti-inflammatory cytokines (IL-10, TGF-β) can determine the outcome of immune 
responses. Therefore, aim of this study was to characterize the different subsets of cells and their 
cytokine secretion in response to commensal bacteria in transgenic and non-transgenic HLA-B27 
rats. Chapter 7 was designed to investigate whether athymic rnu/rnu HLA-B27 transgenic rats 
develop colitis in a model of monoassociation with the non-pathogenic bacterial strain B. 
vulgatus. The requirement of T cells for induction of disease was tested by transfer of CD4+ T 
cells into athymic recipients that do not have T cells. Inflammatory parameters were measured, 
such as cecal IL-1β and MPO, mesenteric lymph node cell cytokine secretion, and histologic 
scores. In Chapter 8 we used adoptive transfer of immune cells into athymic rnu/rnu HLA-B27 
transgenic rats to investigate the role of the antigen presenting cells carrying the HLA-B27 
molecule on the onset of disease. Non-transgenic and transgenic mesenteric lymph node cells 
were injected into nude non-transgenic and transgenic recipients lacking T cells. Development of 
colitis was assessed by cecal IL-1β and MPO, mesenteric lymph node cells cytokine secretion, 
and histologic scores. Labeling of donor cells with carboxyfluorescein diacetate succinimidyl 
ester (CFSE) allowed us to monitor cell proliferation in recipients over time. In Chapter 9, 
bacterial-induced innate immune responses were studied. Bone marrow-derived dendritic cells 
(BMDC) from wild-type and IL-10-/- mice were used to investigate the molecular mechanisms of 
the dysregulated IL-12 responses in IL-10-/- mice compared to their wild-type littermates. 
Activation of the NF-κB pathway, and the role of IL-10-activated signal transducer and activator 
of transcription (STAT) 3 were investigated. 
Chapter 10 contains the general discussion. After the introduction, the effects of 
manipulating the microflora in models of experimental colitis are discussed. Furthermore, 
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Innate immune responses 
Introduction 
Activated innate immune cells mediate a variety of protective and proinflammatory 
mucosal immune responses with key roles in clearance of microbial pathogens, recruitment of 
effector cells into the inflammatory focus, tissue destruction and remodeling, and antigen 
presentation. These activities are relevant to both acute and chronic inflammatory processes at 
mucosal surfaces, including IBD, infection, asthma, periodontal disease, bronchitis and cystic 
fibrosis. Inflammatory cytokines, most notably IL-1, TNF, IL-6, and multiple chemokines, are 
secreted by a variety of activated innate immune cells of hematologic, mesenchymal, epithelial 
and endothelial origin (table 1). In contrast, the TH1 polarizing cytokines IL-12, IL-18 and IL-23 
are more selectively secreted by antigen presenting cells, such as dendritic cells, macrophages, 
and in the case of IL-18, epithelial cells. 
 
     
 Cell type Function Primarily cytokine profile  
 Bone marrow-derived    
 Dendritic cells1 APC IL-10, 12, 18, 23, T cell, 
chemokines 
 
 Neutrophil Phagocytic, effector IL-1, 6, TNF  
 Eosinophil Effector, phagocytic IL-1, TNF  
 Mast cell Effector  IL-1, IL-6, TNF  
 Natural killer cell Effector IFN-γ  
     
 Epithelial origin    
 Epithelial Effector, barrier function, APC Chemokines, IL-18, IL-1RA  
 Paneth cell Effector   
     
 Mesenchymal origin    
 Smooth muscle, fibroblast, 
myofibroblast 
Motility, matrix secretion, 
tissue remodeling, effector 
IL-1, 6, TNF, chemokines  
 Endothelial cell Adhesion molecules, effector IL-1, 6, TNF, chemokines  
     
 
Table 1. Secretion of proinflammatory cytokines by mucosal innate immune cells. 
1 dendritic cell subsets: myeloid, lymphoid, plasmacytoid 
 
Many microbial products and proinflammatory molecules activate innate immune 
responses, culminating in increased transcription and secretion of proinflammatory cytokines. 
Microbial products stimulate cells through a family of pattern recognition receptors that induce 
signals through NF-κB and mitogen activated protein kinases (MAPK). In addition, innate 
immune cells can be activated by proinflammatory cytokines (IL-1 and TNF), reactive oxygen 
metabolites and products of the coagulation and complement cascades. 
Maintenance of mucosal homeostasis depends on the ability of activated innate immune 
cells to appropriately downregulate the inflammatory response to microbial and inflammatory 
signals through secreted and cytoplasmic regulatory molecules (table 2). Mechanisms of 
inhibition include suppressing responses to inflammatory signals by downregulating membrane 
receptors, i.e. CD14 and TLR, which promotes unresponsiveness to ubiquitous stimuli by 
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emigrating monocytes and maturing epithelial cells, as well as upregulation of suppressive 
molecules, including PPARγ, prostaglandins, suppressor of cytokine signaling (SOCS) and A20. 
 
     
 Molecule Function Primarily Induced By  
 Secreted    
 IL-10 Inhibits macrophage and APC 
activation, induces SOCS3 
IL-1, TNF, IFN-γ, CD40L  
 Anti-IL-1 receptor Inhibits IL-1α & β binding IL-1, TNF  
 PGE2, PGI2, PGJ2 Inhibits macrophage 
activation 
IL-1, TNF  
 Corticosteroids Blocks NF-κB, chemotaxis IL-1, TNF, IL-6  
 IL-1RII Binds IL-1 without signaling IL-4  
 TNFRI (p55) Binds TNF, LTα without 
signaling 
IFN-α  
     
 Cytoplasmic    
 A20 Inhibits TNF signaling TNF  
 IκBα Inhibits NF-κB activation IL-1, TNF, bacterial products 
(NF-κB activation) 
 
 PPARγ Inhibits NF-κB activation Bacterial products,  
(NF-κB activation) 
 
 COX 2 Inhibits macrophage 
activation 
IL-1, TNF, IL-6, bacterial 
products (NF-κB activation) 
 
 iNOS Inhibits NF-κB activation IL-1, TNF, IL-6, bacterial 
products (NF-κB activation) 
 
     
 
Table 2. Regulatory molecules induced by proinflammatory cytokines. 
 
This chapter describes the biologic activities, signaling pathways, and regulatory 
mechanisms of the most common proinflammatory cytokines. The reader is referred to other 
reviews on this topic.1,2 
 
 
Profile of cytokines secreted 
by innate immune cells 
Introduction 
Bone marrow-derived, epithelial, mesenchymal and endothelial innate immune cells each 
secrete a unique characteristic profile of cytokines, inflammatory mediators and antimicrobial 
peptides when stimulated with a variety of microbial products (table 1). Due to conserved 
signaling pathways proinflammatory cytokines induce expression of identical molecules in 
different cells, thereby amplifying the inflammatory response in cells not exposed to the original 
inciting agent and also broadening the repertoire of activating signals. Moreover, members of 
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Mucosal epithelial cells act as sensors of microbial invasion and secreted toxins by 
liberating chemokines and, to a lesser degree, proinflammatory molecules.3 These molecules 
activate protective mucosal inflammatory and immune responses by stimulating the emigration 
and activation of a variety of effector cells to respond to the inciting stimulus. Expression of 
chemotactic signals is temporally and spatially coordinated, leading to the emigration of first 
neutrophils, then monocytes and finally lymphocytes. Furthermore, chemokines recruiting a 
single class of effector cells can be biphasic, so that the emigration of these cells can be 
prolonged. For example, Salmonella invasion of cultured colonic epithelial cell monolayers 
induces maximal expression of IL-8, which selectively recruits and activates neutrophils, at four 
to six hours, while epithelial neutrophil activating protein-78 is maximally expressed 18-24 hours 
after bacterial invasion.4,5 IL-6 secreted by epithelial cells can promote the transition from acute to 
chronic inflammation by altering chemokine profiles to favor monocyte recruitment.6 This 
sequential activation of chemokines leads to progressive recruitment of effector cells with distinct 
functions, and also prolongs chemotactic signals to ensure efficient protective innate and acquired 
immune responses. In addition to chemotactic signals, activated NF-κB and MAP kinases in 
epithelial cells stimulate expression of adhesion molecules, including ICAM-1, MHC Class II 
molecules, cyclooxygenase-2 (COX-2), CARD15/NOD2 and certain proinflammatory cytokines, 
including IL-6.7-10 These molecules expand the immunologic function of mucosal epithelial cells 
beyond being merely a sensor of injury to that of actively participating in the inflammatory 
response.8 Mucosal defenses are further mediated by epithelial cell secretion of antimicrobial 
peptides, including α and β defensins, bacterial permeability-inducing peptide, lysozyme and 
mucins. Proinflammatory cytokines stimulate expression of β defensins and secretion of mucus.11 
 
Macrophages 
Resident mucosal macrophages, which comprise 8-15% of intestinal lamina propria 
mononuclear cells, are less responsive to bacterial adjuvants and inflammatory signals than are 
newly recruited monocytes due to low membrane expression of CD14 (LPS binding cofactor), 
CD11b (complement receptor 3) and CD16 (FcγIII receptor).12-15 This relative non-responsiveness 
provides one protective mechanism preventing pathogenic responses to luminal commensal 
bacteria and accounts for the observation that the majority of cytokines produced in active IBD 
are derived from freshly emigrated immature macrophages.13 Chemotactic signals that selectively 
stimulate monocyte migration include MIP-1α and β, MCP-1 and MCP-2.16 Macrophages are 
scattered throughout the lamina propria and are preferentially positioned under the subepithelial 
basement membrane, where they can easily respond to invading pathogens and translocating 
microbial products. Bacterial components primarily induce expression of proinflammatory 
molecules (IL-1, TNF, IL-6) and chemokines. In addition, mucosal macrophages secrete abundant 
IL-10 in response to bacterial stimulants and proinflammatory molecules, serving to downregulate 
the inflammatory response. The importance in macrophages and neutrophils in inducing and 
maintaining intestinal inflammation is demonstrated by therapeutic responses of ulcerative colitis 
patients to granulocyte and monocyte aphoresis, leading to decreased mucosal production of TNF, 
IL-1, IL-6 and IL-8.17,18 In addition, elimination of mucosal macrophages with rectal microspheres 





Dendritic cells are efficient mucosal antigen presenting cells due to their avid uptake of 
soluble antigens, efficient antigen processing and presentation, full complement of costimulatory 
molecules and secretion of IL-12, IL-18 and IL-23 upon exposure to microbial adjuvants. 
Different types of dendritic cells (myeloid, lymphoid and plasmacytoid) occupy various regions of 
organized mucosal lymphoid follicles20 in the resting state, while myeloid dendritic cells are 
dramatically increased during mucosal inflammation.21 Migration of these cells to inflamed 
mucosal surfaces is governed by CCL 20 (MIP-3α) and CCL 9 (MIP-1γ), the expression of which 
is upregulated during inflammation, and perhaps β7 integrin.21,22 M-DC8+ monocyte precursors 
are preferentially located in subepithelial areas of Peyer’s patches and secrete large amounts of 
TNF; these are increased in Crohn’s disease and decreased by corticosteroids.23 Maturation of 
dendritic cells is stimulated by exposure to bacterial microbial adjuvants, that signal through TLR 
membrane receptors, NOD intracellular receptors and NF-κB, while MHC II expression is 
stimulated by IFN-γ exposure as well as by NF-κB activation by bacterial adjuvants, IL-1 and 
TNF. Co-stimulatory molecules in mucosal antigen presenting cells are also upregulated by IL-1, 
TNF and microbial adjuvants.24 
 
Mast cells 
Mast cells comprise 2-5% of intestinal lamina propria mononuclear cells and are located 
in all layers of the intestine and stomach. Mucosal mast cells are preferentially located adjacent to 
neuronal synapses25 and are activated by substance P, other neuropeptides, IgE binding to the IgE 
Fc receptor, activated complement, IL-3 and stem cell factor (C-kit).26 Stimulated mast cells 
primarily secrete preformed granule constituents, such as histamine, serotonin and proteases, but 
also produce proinflammatory cytokines and arachidonic acid metabolites. Distinctive mucosal 




Mucosal eosinophils primarily secrete arachidonic acid metabolites and preformed 
biologically active molecules stored in granules, including eosinophilic cationic protein, major 
basic protein and peroxidase, but also can produce proinflammatory cytokines. These cells are 
activated by exposure to IgE, and to a lesser extent IgA and IgG, and are attracted to mucosal 
surfaces by eotaxin, MCP-3 and IL-8. The C-C chemokine eotaxin is selectively upregulated in 
intestinal epithelial cells by IL-4, but not by IFN-γ,27 with contribution by IL-5.28 In addition, 
ENA-78/CXCL5, IL-8/CXCL8 and TNF production by eosinophils is induced by TNF, but 
decreased by IFN-γ.29 Eosinophils contribute to clearance of helminths, gastrointestinal injury and 
nerve damage in TH2-mediated hypersensitivity reactions.30 
 
Natural killer (NK) cells 
NK cells are large granular lymphocytes that can express CD2 and αα homochimeric 
CD8, respond to IL-2, and produce IFN-γ, but do not express T cell receptors or surface 
immunoglobulin. Instead, they can coexpress myeloid markers such as CD11b and c, CD14 and 




Innate immune responses 
Mesenchymal cells 
In addition to secretion of matrix components, including collagen and fibronectin that 
mediate fibrosis, and matrix metalloproteases that are involved in tissue remodeling and activation 
of latent TGF-β, mucosal fibroblasts, myofibroblasts and smooth muscle cells are active 
participants in innate immune responses. These cells can be activated by proinflammatory 
cytokines, bacterial products and TGF-β to proliferate, migrate and secrete IL-1, TNF, IL-6, IL-8, 
M-CSF, GM-CSF, metalloproteases, and express bioactive CD40 and adhesion molecules.31-35 
 
Endothelial cells 
Likewise, endothelial cells respond to proinflammatory molecules and bacterial products 
by expressing adhesion molecules such as ICAM-1, ECAM-1 (etc, etc) involved in the initial 
phase of cellular recruitment into an inflammatory focus, but also actively participate in 




Mechanisms of stimulating 
cytokine expression 
Introduction 
Innate immune cells can be activated by a variety of mechanisms, including bacterial 
products and inflammatory mediators, such as IL-1, TNF, IL-6, neuropeptides and reactive 
oxygen metabolites. However, these diverse stimuli induce cytokine transcription through two 
dominant intracellular kinase signaling cascades, NF-κB and MAP kinases, thereby activating 
similar patterns of cytokine expression (figure 1). Different bacterial components selectively bind 
to various pattern recognition receptors to trigger NF-κB and MAPK.37 Bacterial peptidoglycan, 
mycobacterial lipoarabinomannan, mycoplasma lipopeptides and heat shock protein 60 (HSP 60) 
bind to TLR-2, which can complex with TLR-3 or 6, viral DNA binds TLR-3, LPS selectively 
ligates TLR-4, flagellin binds to TLR-5, and the bacterial DNA motif CpG ligates TLR-9. 
Intracellular bacterial recognition is accomplished by CARD4/NOD 1 (ligates diaminopimelic 
acid), which is constitutively expressed in most intestinal cells, including epithelial cells, and by 
CARD15/NOD-2 (binds muramyl dipeptide), which is constitutively expressed in monocytes, 
dendritic cells and Paneth cells and is induced in intestinal epithelial cells by IFN-γ and TNF.38-41 
The complexity of this system is increased by the ability of various TLR moieties to 
interact and by the ability of proinflammatory cytokines to affect expression of TLR and NOD 
molecules. For example, TLR-2 complexes with homologous TLR-1 to bind mycobacterial 
lipoarabinomannan and mycoplasma triacylated lipopeptides, while mycoplasma diacylated 
lipopeptides bind to TLR-2/TLR-6 complexes.42,43 These combinatorial repertoires are postulated 
to enhance the ability of the host to discriminate diverse bacterial products.44 In addition, efficacy 
of LPS binding to TLR-4 is markedly enhanced by co-ligation of LPS binding protein and CD14. 
As mentioned in earlier, intestinal macrophages have lower expression of CD14 than do 
monocytes, providing a mechanism for relative non-responsiveness to LPS produced by 
commensal enteric bacteria. Likewise, TLR and CARD15/NOD2 expression by native intestinal 
epithelial cells is relatively low, although Haller et al have demonstrated that B. vulgatus can 
stimulate expression of IL-6 and activate NF-κB in colonic epithelial cells after in vivo luminal 



























Figure 1. Activation of innate immune responses via ligation of pattern recognition receptors. A wide range of 
microbial adjuvants selectively bind to homologous membrane-bound TLR or to intracellular CARD/NOD 
receptors. These pattern recognition receptors, the IL-1 receptor (IL-1R) and tumor necrosis factor receptor 
(TNFR) signal through the central NF-κB and MAPK pathways to activate transcription of a large number of 
proinflammatory and protective molecules. 
 
Similarly, feeding DNA from probiotic bacteria or E. coli can prevent and treat 
experimental colitis through interaction with TLR-9.47 TLR-2 is expressed in human alveolar type 
II epithelial cells and macrophagesn.48 IFN-γ upregulates expression, with resultant enhanced 
function, of CARD4/NOD1 and the TLR-4/MD-2 complex on intestinal epithelial cells49,50 while 
TNF stimulates CARD15/NOD2 expression in epithelial cells.9,10 
Once ligation of various TLR molecules and bacterial products occurs, signaling 
converges on central pathways that are shared proximally by the IL-1/IL-1 receptor (IL-1R) and 
more distally by the CARD/NOD and TNF signaling pathways (figure 2). The TLR and IL-1 
signaling pathways require activation of toll-IL-1-1R (TIR) domain adaptor proteins, including 
MyD88, TIRAP and TRIF. Although transcription of most proinflammatory cytokines requires 
MyD88, ligation of TLR-3 and 4 can proceed through a MyD88-independent pathway mediated 
by TRIF. A TRIF-related adapter protein (TRAM) is required for TLR-4-specific induction of 
IFN-β, but not TLR-3 stimulated responses.51 MyD88 dependent and independent TLR, IL-1β, 
TNF and CARD/NOD pathways activate NF-κB through activation of the IKK complex to 
phosphorylate IκBα, which is the ubiquinated and degraded by the 700 kDa proteasome complex, 
thereby freeing the previously complexed NF-κB heterodimer to be phosphorylated and 
translocate to the nucleus.8 Once NF-κB has homed to the nucleus, it stimulates transcription of 
multiple cytokines by binding to κB regulatory elements on the promoter region of the cytokine 
genes (figure 1). In addition to transcriptional regulation by NF-κB and other relevant 
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transcription factors (figure 1), production and secretion of proinflammatory cytokines is 
dependent on stabilization of mRNA, protein translation, post-translational modification and in 
some cases, such as IL-1 and IL-18, processing by precursor molecules. 
TNF receptor ligation will also activate NF-κB, but uses a different set of post-receptor 
scaffolding proteins (including TRAF6; figure 2). Similarly, CARD4/NOD1 and 
CARD15/NOD2, which selectively bind a diaminopimelic acid tripeptide from Gram-negative 
bacteria and muramyl dipeptide, respectively41 activate NF-κB through the intermediate kinase 
Rip2 (RICK/CARDIAK), which appears to contribute to TLR, IL-1 and IL-18 signaling as well.52 
Of considerable interest to the pathogenesis of Crohn’s disease, the three most common 
polymorphisms of CARD15/NOD 2, which are in the leucin rich repeat region that binds bacterial 
cell wall peptides, diminish NF-κB activation.53 
Both IL-1, TNF and TLR activate parallel pathways in addition to NF-κB. A complex 
cascade of kinases lead to phosphorylation of c-jun NH2 terminal kinase (JNK) and p38 MAPK 
(figure 3). These kinases activate c-fos and c-jun, the heterodimers of the AP-1 transcription 
factor complex. AP-1 transcriptionally regulates most proinflammatory cytokines, many in 
conjunction with NF-κB.  
 





















Figure 2A. Parallel signaling mechanisms of the IL-1R and TLR pathways. Ligation of IL-1 or LPS to IL-1R 
and TLR-4 respectively, activates signals through parallel signaling pathways involving a series of adaptor and 
scaffolding proteins and kinases. Activated kinases ultimately lead to the phosphorylation and degradation of 
IκBα. This releases NF-κB, which is phosphorylated and translocates to the nucleus, where it initiates 





















Figure 2B. Activation of multiple signaling and apoptotic pathways by TNF family member ligands. TNF 
(TNFα) or lymphotoxin (TNFβ) bind to specific receptors that can activate either the NF-κB or MAPK signaling 
cascades through a series of specific adaptor molecules. In addition, TNF can initiate apoptosis through death 
domain adaptor molecules and caspases. 
 
Of considerable relevance to bacterial homeostasis, response to infection and treatment of 
inflammation, selective blockade of JNK and p38 MAPK can have different effects, as suggested 
by their independent activation, function and regulation. JNK, p38 MAPK, and extracellular 
signal-regulated protein kinase (ERK 1/2) are phosphorylated in active IBD,54,55 and an 
uncontrolled study with an inhibitor of both p38 MAPK and JNK impressively inhibits active 
Crohn’s disease.56 However, low dose LPS administration to human volunteers selectively 
activated p38 MAPK but not JNK in PBMNC.54 Furthermore, a selective p38 MAPK inhibitor 
caused increased weight loss and higher levels of colonic cell TNF production in a TNBS model 
of colitis, although it decreased TNF production (S. van Deventer, unpublished observations). 
Thus, these pathways must be considered separately in mucosal inflammation. 
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Figure 3. Activation of MAP kinases by multiple stimuli. A variety of stimuli, including growth factors, 
hormones and proinflammatory cytokines (TNF, IL-1, etc) can activate a series of kinases that lead to liberation 
of transcription factors that operate in parallel with NF-κB. the MAPK effector molecules c-Jun and c-Fos can 
heterodimerize to form AP-1, or these molecules and ATF 1/2 can bind to DNA regulatory elements alone or in 
various combinations to regulate gene transcription. 
 
IP3/AKT stimulates intracellular calcium fluxes, but also mediates calcium/calmodulin-
dependent protein kinases kinase suppression of IL-1 and TLR signaling by uncoupling IRAK-1 
and MyD88 activity. In addition, TNF inhibits AKT phosphorylation, which is decreased in portal 
hypertensive gastropathy. Inhibition of AKT is postulated to contribute to gastric epithelial injury, 
since AKT stimulates epithelial cell proliferation, migration and survival. Anti-TNF treatment 
restored gastric AKT levels and induced healing.58 IL-1, TNF and IL-6 activate NF IL-6, a 
transcription factor binding along with NF-κB and AP-1 to the promoters of IL-6 and IL-8 to 
positively regulate transcription of these cytokines.59 Finally, IL-1β can stimulate the ERK 1/2 
and AKT pathways via the association of phosphorylated SHPS and SHP-2.60 LPS or LPS plus 
IFN-γ stimulation of dendritic cells increases ERK and p38 MAPK while stimulating IL-10 and 
IL-12. Blockade of ERK selectively decreases IL-10 and enhances IL-12 production, suggesting 
that ERK selectively induces IL-10, an endogenous inhibitor of IL-12.61 
The regulation of these interacting pathways is extremely complex and has been evaluated 
predominantly in isolated cell lines and in PBMNC. It remains to be determined whether mucosal 
innate immune cells follow these paradigms or whether they exhibit unique regulatory features. 
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Mechanisms of inhibiting proinflammatory 
cytokine expression and function 
Regulation of the expression and activity of proinflammatory cytokines is a key 
component of maintaining mucosal homeostasis and preventing excessive tissue injury after an 
inflammatory event. In addition, therapeutic blockade of innate immune responses is vital to 
treating mucosal inflammation. 
 
Endogenous inhibitory mechanisms 
Activation of signaling pathways by inflammatory cytokines or bacterial products 
stimulates a number of overlapping protective pathways that inhibit proinflammatory cytokine 
production by innate immune cells (table 2). Many of these protective mechanisms can be induced 
by multiple cytokines, while others are selectively induced by a single stimulant. For example, IL-
1, TNF and IL-6 activate the hypothalamic/pituitary/adrenal (HPA) axis culminating in the release 
of immunosuppressive corticosteroids. The importance of this protective pathway is illustrated by 
the increased intensity and prolongation of experimental inflammation accompanied by increased 
IL-1 and TNF levels in adrenalectomized rats or following pharmacological blockade of 
corticotrophin releasing hormone.62 In addition to the more widely recognized proinflammatory 
molecules induced by IL-1, TNF and bacterial molecules, NF-κB activation leads to increased 
expression of multiple protective genes, including IκBα, COX-2, inducible nitric oxide synthetase 
(iNOS) and PPARγ. Production of IκBα is important in deactivating NF-κB by complexing 
nuclear p65/p50 heterodimers in interrupting gene transcription and transporting this complex 
back to the cytoplasm where it exists in an inactive complexed form. Although PGE2, PGI2 and 
other prostaglandins released during inflammation  enhance epithelial chloride secretion, increase 
vascular permeability and stimulate smooth muscle contractions thereby causing diarrhea, edema 
and hypermotility, these products also inhibit proinflammatory cytokine production63 and 
stimulate mucosal healing.64 PGJ2 may mediate protective effects through PPARγ activation. The 
importance of prostaglandin production in mucosal homeostasis, resolution of inflammation, and 
downregulation of inflammatory cytokines is illustrated by small intestinal and colonic 
inflammation following two doses of indomethacin in susceptible rat strains,65 piroxicam 
triggering colitis in IL-10-/- mice on a resistant (C57BL/6) background,66 potentiation of DSS-
induced colitis in COX-2 deficient mice,67 and inhibition of DSS-induced colitis by ligation of 
EP4, the PGE2 receptor.68 In each of these models mucosal IL-1 and TNF are increased. Similarly, 
nitric oxide produced as a consequence of proinflammatory cytokine stimulation of iNOS has 
important protective properties. Nitric oxide inhibits NF-κB activation by blocking the 
IRAK/TRAF-6 interaction69 and inhibits caspase 1/IL-1β converting enzyme (ICE) activity by 5-
nitrosylation.70 IL-10 is induced by a number of agents, including IL-1, TNF, IL-6, IL-12, IFN-γ 
and bacterial products. Of interest, the induction of IL-10 by bacterial products lags behind that of 
proinflammatory cytokines. Incubating unfractionated mesenteric lymph node cells or splenocytes 
with LPS induces maximum TNF production by 4 hours, IL-1 by 6-8 hours, and IL-12 by 24 
hours, but IL-10 secretion reaches maximal concentrations only after 72 hours of stimulation.71 
This progressive induction of first proinflammatory and then protective cytokines suggests a 
compensatory regulatory mechanism to downregulate responses to an inflammatory stimulus. The 
importance of endogenous IL-10 in host protection to the aggressive luminal environment is 
dramatically illustrated by spontaneous colitis in IL-10-/- mice raised in the presence of 
commensal bacteria72,73 and strikingly elevated IL-1β, TNF, IL-12 and IFN-γ secretion by LPS or 
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cecal bacterial lysates stimulated mesenteric lymph node cells in IL-10-/- versus wild-type mice.71 
Secretion of soluble receptors by activated cells can bind IL-1 and TNF, thereby neutralizing their 
biologic effects. Finally, a number of inflammatory stimuli, including IL-1β, can stimulate 
expression of IL-1 receptor antagonist (IL-1RA), which competitively inhibits IL-1 receptor 
binding and downstream signaling.74 Of interest, IL-10 selectively inhibits IL-1β to a greater 
extent than IL-1RA in splenocytes exposed to LPS, profoundly altering the IL-1RA/IL-1 ratio to a 
less inflammatory profile. 
Proinflammatory cytokines can selectively stimulate inhibitors that provide negative 
feedback on the inflammatory response. For example, TNF stimulates intracellular A20, which 
inhibits TNF signaling.75 The importance of A20 in mucosal protection is evident by the colitis 
that develops in A20-/- mice.75 Although not selective, the concept of an inflammatory pathway 
stimulating production of an inhibitor that suppresses functions of the inductive stimulus is well 
documented, with IL-1 stimulating IL-1RA and NF-κB increasing expression of IκBα being two 
obvious examples.8,74 
Mechanisms by which endogenous inhibitory molecules exert their protective effects are 
still not entirely clear. Many immunosuppressive molecules have multiple modes of action and 
target central signaling pathways. For example, corticosteroids inhibit phospholipase A2, thereby 
blocking arachidonic acid liberation, blocks NF-κB activity, suppresses transcription by binding 
to the glucocorticoid regulatory element and the promoter of many proinflammatory molecules, 
prevents transcription factor binding to promoters by histone deacetylation, stabilizes lysomal 
membranes, and inhibits adhesion of effector cells to endothelial cells.76 Similarly, IL-10 inhibits 
NF-κB by multiple mechanisms, yet to be fully understood. IL-10 transiently delays IκBα 
degradation after an inflammatory stimulus, but its probable mode of action is to inhibit p65 
binding to DNA, although it does not block NF-κB p65/p50 nuclear transmigration.77 In addition, 
IL-10 phosphorylates STAT3 and stimulates production of the inhibitory molecule SOCS3.78,79 
TGF-β regulates aggressive T cell function by suppressing lymphocyte proliferation and 
activation, but also stimulates IL-10 expression, perhaps explaining some of its diverse biologic 
activities.80 TGF-β phosphorylates SMAD2 and 3, leading to activation of SMAD4. 
Phosphorylation of SMAD2 in colonic epithelial cells is evident 7 days after selective 
colonization of germ-free rats with B. vulgatus, which is temporally related to downregulation of 
in vitro epithelial NF-κB stimulation and IL-6 production.46 In vitro studies showed that 
endogenous TGF-β could suppress LPS-induced IL-6 secretion by cultured colonic epithelial cells 
and affect NF-κB activation by blocking histone H3 acetylation.46 
 
Exogenous compounds inhibiting proinflammatory cytokines 
Although beyond the scope of this chapter, multiple clinically relevant pharmacological 
agents, including translational clinical comments as well as biologic agents, have proven abilities 
to suppress proinflammatory cytokine transcription and biologic activity (table 3). Therapeutic 
effects of these compounds, particularly those selectively active for individual cytokines, in 
clinical use and experimental intestinal inflammation confirm the key contribution of 
proinflammatory cytokines in acute and chronic mucosal inflammation.  Examples of the 
beneficial activities of compounds with selective activities are provided in sections describing 




     
 Approach Target Mechanism  
 Corticosteroids IL-1, 6, 12, TNF, chemokines Inhibits NF-κB, cytokine 
transcription 
 
 IL-10 (recombinant bacteria, 
transfected T cells) 
APC, IL-12, IL-1, TNF, IL-6, 
chemokines 
Inhibits NF-κB, APC 
activation 
 
 Block TNF–monoclonal 
antibodies, binding proteins, 
receptors 
TNF Inactivate secreted TNF, 
induce apoptosis of cells with 
membrane–bound TNF 
 
 Thalidomide analogues TNF, IL-1 Inhibit synthesis  
 Pentoxifylline TNF, IL-1 Inhibit synthesis  
 NF-κB–p65 antisense 
oligonucleotides, proteosome 
inhibitor 
IL-1, TNF, IL-6, IL-12, 
chemokines 
Block transcription  
 MAPK inhibitors–p38 MAPK, 
JNK 
IL-1, 6, 12, TNF, chemokines Block transcription  
     
 




Structure and function of individual 
proinflammatory cytokines 
Consistent with their shared signaling pathways and receptors, many proinflammatory 
cytokines and chemokines have overlapping functions, yet each retains a unique pattern of 
responses. For example, IL-1 and TNF receptor ligation both stimulate NF-κB, MAP kinases and 
AKT, yet TNF has a greater ability to activate TH1 lymphocyte responses and has an independent 
effect on apoptosis. Many chemokines share common heterodimeric molecules and receptors, yet 
recruit different cell populations. These differential properties may be due to selective production 
by different cells or a result of differential kinetics of production. Many cytokine responses are 
either autocrine or paracrine in nature, such that biologic activity depends on the local cellular 
milieu. In addition, the activation state of a target cell can profoundly affect its response to a given 
stimulus as a result of up or downregulation of membrane receptors, induction of endogenous 
protective molecules or the degree of phosphorylation or dephosphorylation of signaling 
molecules. 
Because of shared inductive mechanisms, in large part via NF-κB and AP-1 signaling 
pathways, proinflammatory cytokines tend to be expressed in tandem. For example, IL-1β, TNF, 
IL-6 and various chemokines are all induced in active IBD,2,81,82 while a characteristic profile of 
cytokines is induced by IL-1, TNF or invasive bacteria in cultured colonic epithelial cells.7 Thus, 
it is physiologically and pathophysiologically important to consider interactive, additive and 
synergistic activities of cytokines rather than isolated expression and activities. However, the 
present discussion will artificially consider the biologic effects of individual cytokines. Although 
many of the examples supporting physiologic and pathophysiologic effects of these cytokines are 
44 
Innate immune responses 
related to intestinal inflammation because of the wealth of investigations in this field and the 
particular expertise of the author, similar activities are found at other mucosal sites. 
 
IL-1 family (IL-1α, IL-1β, IL-1RA and IL-1β converting enzyme) 
Structure and secretion 
IL-1 occurs in two forms, IL-1α and IL-1β, which share similar receptor binding 
properties, and hence overlapping function. IL-1α is membrane bound or intracellular, therefore 
mediates its effects by cell contact or following liberation following cell lysis. Pro IL-1α (31 kDa) 
is cleaved by calpain or by extracellular proteases to a 17 dDa form. In contrast, IL-1β is 6 as an 
18 kDa precursor that lacks a leader sequence, therefore remains in an intracellular cytoplasmic 
location unless activated by cleavage of ICE (caspase 1).83 ICE itself is constitutively expressed as 
a 45 kDa inactive precursor that is cleaved at two locations to form an active heterodimer. ICE is 
cleaved by various caspases, including ICE itself, following cellular activation by bacterial 
products, proinflammatory cytokines or CD40 ligation, but caspase activity is inhibited by nitric 
oxide. Following cleavage, biologically active IL-1β is secreted. IL-1RA is also present in two 
forms. A 22 kDa secreted form competitively inhibits IL-1 bioactivity by competitively binding to 
the two IL-1 receptor isoforms. A second splice variant form lacking a leader sequence remains in 
an intracellular cytoplasmic location.84 
 
Expression 
IL-1α and IL-1β are induced by multiple proinflammatory signals and are expressed in a 
variety of cell types. Levels are low in the normal intestine, but are dramatically increased during 
active inflammation.81,85-89 Tissue staining and cell extraction demonstrate that lamina propria 
macrophages, particularly newly immigrated cells with monocyte features, account for the 
majority of IL-1 production, although mesenchymal cells, endothelial cells and to a lesser extent 
epithelial cells express mRNA and produce protein.14,89,90 IL-1RA is constitutively expressed in 
the normal intestine and in increased amounts following inflammation. Intracellular IL-1RA is 
constitutively expressed in intestinal epithelial cells, with mRNA expression in the crypt and 
accumulation of protein with cellular maturation.91 ICE is constitutively expressed, with 
expression but not cleavage upregulated by IFN-γ. 
 
Signaling 
IL-1α and IL-1β bind to two receptor isoforms that are selectively expressed on different 
cell types relevant to mucosal tissues. IL-1RI is present on intestinal epithelial cells, endothelial 
cells, mesenchymal cells and T lymphocytes, while IL-1RII is expressed on 
monocytes/macrophages, neutrophils and B cells. IL-1RII binds IL-1 but does not transduce 
signals, raising the concept of a secreted “decoy” receptor that can inhibit responses.92 Ligation of 
either receptor transduces signals through a complex of kinases and scaffolding proteins (IRAK-1, 
TRAF-6, TAK1/TAB and Rip 2) to activate the NF-κB pathways (figure 2). A comprehensive 
study by Mifflin et al shows that IL-1α stimulates COX-2 mRNA transcription in intestinal 
myofibroblasts by activating the NF-κB, ERK, and protein kinase C (PKC) pathways.31 In 
parallel, IL-1α-stimulated p38 MAPK stabilizes COX-2 mRNA. 
 
Function 
Activation of NF-κB, MAPK and AKT by ligation of the IL-1 receptors by IL-1α or β 
increases expression of a number of molecules involved in the inflammatory response (figure 1). 
Induction of IL-1, TNF, IL-6, IL-12 and chemokines by lamina propria innate immune cells and 
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mesenchymal cells amplify the inflammatory response, while stimulation of chemokine secretion 
and expression of adhesion molecules on mucosal epithelial cells leads to the emigration, 
transmigration and excretion of effector cells.82 IL-1 stimulates expression of costimulatory 
molecules on antigen presenting cells and upregulates IL-12 secretion, thereby enhancing T cell 
activation. Induction of metalloproteases results in matrix destruction, ulceration and possibly 
fistula formation. Finally, enhanced expression of COX-2 leads to rapid production of eicosanoids 
that mediate epithelial chloride secretion and block sodium absorption, leading to diarrhea and 
bronchial secretion, smooth muscle contractions resulting in cramps, airway spasm and diarrhea, 
and increased vascular permeability. Induction of iNOS, with resultant nitric oxide synthesis, 
enhances intracellular killing of phagocytosed microbial agents, inhibits smooth muscle 
contractions, possibly leading to ileus associated with intestinal inflammation, and regulates 
mucosal blood flow. Finally, IL-1 mediates anorexia associated with experimental colitis through 
induction of 5-HT in the hypothalamus.93 In addition to proinflammatory effects, IL-1 stimulates 
production of anti-inflammatory molecules such as prostaglandins, nitric oxide and IL-1RA that 
inhibit inflammation. For example, IL-1β stimulates production of PGE2, 6-keto PGI2 and 
thromboxane B2 in the rabbit colon94 and administration of IL-1β 24 hours before administration 
of formalin and immune complexes in rabbits attenuates colitis through stimulation of endogenous 
prostaglandins.95 
The net proinflammatory properties of endogenous IL-1 are documented by the ability of 
recombinant IL-1RA to attenuate experimental colitis in a number of models.85,86,96 
Administration of IL-1RA not only decreases inflammation, but also inhibits expression of a 
number of proinflammatory cytokines by the inflamed colon.86 A trial of subcutaneous rIL-1RA 
in ulcerative colitis was not completed. Local mucosal administration via engineered bacteria may 
prove to be a better approach than systemic administration. Colonization of IL-2-/- mice with IL-
1RA-secreting Streptococcus gordinii enhanced weight gain, although the colon was not 
examined.97 Attenuation of acute and chronic colitis in ICE-/- mice98 and the ability secreted IL-1 
to predict relapse of inactive Crohn’s disease provide additional evidence of a pathogenic role of 
IL-1 (and IL-18).99 
Bioactivity of IL-1α and IL-1β is dependent on ligation of either IL-1RI or RII. Thus, the 
balance of IL-1 and IL-1RA determines receptor activation. Although the levels of IL-1RA are 
increased and the IL-1/IL-1RA ratio is decreased during intestinal inflammation due to increase of 
IL-1 to a greater degree than IL-1RA.81,86,87,100 This abnormal ratio may be a secondary 
phenomenon since the ratio correlated with disease activity of IBD and was also decreased in 
nonspecific mucosal inflammation.86,100 However, an etiologic role for defective IL-1RA activity 
is suggested by the association of polymorphisms in allele 2 of IL-1RA with ulcerative colitis and 
pouchitis by some, but not all authors.101-104 
 
TNF and lymphotoxin 
Structure and secretion 
TNF (TNFα, cachexin) is a 17 kDa protein that is produced as a 26 kDa precursor (pro-
TNF). Pro-TNF is cleaved by TNFα cleavage enzyme (TACE or ADAM-17) or ADAM-10, 
which are zinc binding metalloprotease disintegrin members of the adamalysin family.105,106 
Secreted TNF forms trimeric complexes that optimally bind receptors. Structurally related 
lymphotoxin (TNFβ, LTa) is also secreted as a trimer, but can also complex with LTβ to form a 
membrane-bound heterodimer that has distinct functions. The TNF family of ligands and 
receptors comprise a complex and rapidly evolving group of immunologically relevant proteins 
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and costimulatory molecules that include TNF, LTα, LTα/β, Light, FasL, CD40L, TRAIL, 
RANKL, 4-1BBL, OC40L, GITRL and BAFF.107 
 
Expression 
Numerous cells in the inflamed mucosa produce TNF, including macrophages, TH1 
lymphocytes, mast cells, mesenchymal cells, endothelial cells and even epithelial cells, with 
activated macrophages being the primary source. Constitutive expression in the noninflamed gut 
is low, but is dramatically increased during infection or inflammation in response to NF-κB and 
MAPK activation by bacterial products and IL-1. Tissue levels of TNF mRNA and protein in IBD 
have been somewhat controversial, with some investigators showing increases in Crohn’s disease 
tissue and stool that correlates with disease activity and others finding no consistent 
elevation.81,108-110 One reason for these inconsistent results is the relative instability of TNF 
mRNA, which is dependent on the Au-rich elements (ARE) in the 3 prime untranslated region of 
the gene. Deletion of this ARE region leads to increased circulating and intestinal levels of 
TNF.111 TNF is primarily produced by lamina propria macrophages, but is also expressed in 
subepithelial dendritic cell precursors ands activated TH1 cells.23,108 
LTα is expressed in the same cell populations as TNF and is also increased in inflamed 
mucosal tissues. LTα secretion by colonic biopsy explants is increased in Crohn’s disease relative 
to ulcerative colitis.112 LTβ is more selectively expressed by lymphoid cells. 
 
Signaling 
TNF binds to two membrane bound receptors, TNFRI (p55) and TNFRII (p75), that are 
expressed in epithelial, bone marrow derived, mesenchymal and endothelial cells at mucosal 
surfaces.113 Expression of TNFRII is increased in colonic epithelial cells during experimental 
colitis and active IBD.114 Ligation of TNFRII by TNF or LTα trimers results in activation of 
proinflammatory effects mediated by stimulation of NF-κB, MAPK, PKC and AKT (figure 2). 
Ligation of TNFRI by TNF or LTα selectively induces apoptosis through a series of death 
domains (Fas-activated death domain, FADD, etc). The TNF receptor-associated death domain 
(TRADD) is common to both pathways, which then diverge along two pathways regulated by 
TNF receptor-associated factor (TRAF) isoforms. TRAF 1 and 2 stimulate NF-κB and MAPK, 




TNF stimulates both inflammatory responses in a variety of mucosal cell populations and 
induces apoptosis of epithelial cells. The ability of TNF to induce apoptosis is augmented by 
synergistic activities with IFN-γ.115,116 The inflammatory effects are quite similar to those of IL-1, 
since both molecules activate NF-κB, MAPK and AKT (figure 1), although cellular targets may 
vary due to differential expression of IL-1 and TNF receptors on different cell populations. The 
expression of TNFRII on epithelial cells may relate to mechanisms of mucosal hyperplasia during 
inflammation.114 Transfer of CD4+ CD45RBhi T cells from wild-type and TNF-/- mice into wild-
type or TNF-/- RAG2-/- mice demonstrates the importance of TNF production by non-T cells.117 
Like IL-1, TNF stimulates production of a variety of proinflammatory cytokines, chemokines, 
adhesion molecules, costimulatory molecules, COX-2, iNOS and secreted matrix 
metalloproteases. In addition, TNF activates osteoclasts and inhibits osteoblast function, leading 
to bone resorption. Furthermore, TNF stimulates activity of lipoprotein lipase, decreases appetite 
at the hypothalamic level, leading to weight loss, hence its original name cachexin. Systemic 
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injection of TNF induces mid small bowel inflammation and necrosis, possibly mediated through 
induction of platelet activating factor118 and ∆ARE transgenic mice overexpressing TNF 
spontaneously develop ileal inflammation, arthritis and eventually multiorgan failure.111 Ileal 
inflammation in this model depends on the presence of both TNFRI and II, CD8+ T cells, IFN-γ 
and IL-12 and is mediated by either myeloid or T cell-derived TNF.119 TNF neutralization 
attenuates inflammation in a variety of experimental colitis models120-122 as well as ileal disease in 
the SAMP 1/Yit T cell transfer model.123 However, in these models blockade of endogenous TNF 
was not as effective as inhibition of IL-12 in preventing or reversing intestinal inflammation. 
However, a chimeric IgG 1 antibody to TNF (infliximab) has dramatic results in Crohn’s disease, 
inducing responses in 65% of patients with luminal inflammation124 and 68% of patients with 
fistulae.125 However, these impressive results appear to be due to induction of apoptosis of 
activated T cells and monocytes bearing membrane-bound TNF rather than neutralizing free TNF 
since etanercept, a fusion protein of the extracellular domain of the p75 TNF receptor and the Fc 
portion of IgG, is not effective in Crohn’s disease, despite equal binding affinity to TNF as 
infliximab.126-128 Whether the decreased efficacy of other more fully humanized anti-TNF 
antibodies in Crohn’s disease relates to decreased induction of apoptosis remains to be 
determined,129 and will determine the effectiveness of PEGylated antibodies undergoing trials in 
Crohn’s disease. Finally, thalidomide, a TNF synthesis inhibitor, is effective in Crohn’s disease, 
but well documented toxicities preclude its widespread use.130,131 The effectiveness of infliximab 
in ulcerative colitis is being evaluated by a large trial to resolve divergent early results.132,133 TNF 
is an important mediator of intracellular bacterial killing through upregulation of iNOS. Blockade 
of TNF is associated with increased bacterial infections (abscesses, sepsis) as well as reactivation 
and dissemination of mycobacterial infections.127 In an intestinal xenograft model of amebic 
colitis, TNF blockade was more effective than IL-1R blockade in decreasing explant 
inflammation, although E. histolytica invasion was unchanged.121 
Animal models demonstrate an important function of LTα/β in mucosal immune 
development and inflammation. LTα/β, with IL-7, regulates lymphoid tissue development, 
notably Peyer’s patches and mesenteric lymph nodes, during embryogenesis and maintains 
secondary lymphoid structure in adults.134 In addition, LTβ R signaling is required for formation 
and maintenance of follicular dendritic cell networks. More vigorous colitis in mice deficient in 
organized lymphoid tissue following neonatal blockade of LTβ R suggests that cells in these 
tissues are protective.135 In contrast, inhibition of LTα/β and Light activity by soluble LTβ R Ig 
fusion protein attenuated T cell-mediated colitis as effectively as anti-TNF antibody.136 The latter 
results suggest that both LTα/β and TNF mediate chronic colitis. 
 
IL-6, soluble IL-6 receptor (IL-6R and gp130) 
Structure and secretion 
IL-6 is secreted without processing. Its receptor complex consists of two distinct 
membrane-bound glycoproteins: an 80 kDa cognate receptor (IL-6R) and a 130 kDa signal 
transducing element (gp130). Membrane bound IL-6R can be shed after proteolytic cleavage by 
bacterial-derived metalloproteases and a yet to be fully defined mammalian metalloprotease 
distinct from TACE.137 An alternative mechanism is differential mRNA splicing leading to an 
isoform that lacks membrane-spanning and cytoplasmic domains.137 
 
Expression 
IL-6 is produced by a variety of cells at mucosal surfaces, including macrophages, 
epithelial cells, mesenchymal and endothelial cells. The normal intestine has detectable amounts 
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of IL-6, which is dramatically upregulated in the inflamed intestine of patients with Crohn’s 
disease, ulcerative colitis and nonspecific inflammation, as well as during experimental colitis, 
with tissue levels correlating with the degree of inflammation.138-143 Similarly, circulating levels of 
IL-6 and sIL-6R correspond with the activity of intestinal inflammation and have been proposed 
as indicators of disease activity.144,145 IL-6 expression is induced by IL-1, TNF (through NF-κB 
and MAPK), IFN-γ (through STAT-1), LPS (through NF-κB), TGF-β, heat shock proteins and 
prostaglandins.46,146,147 IL-1β induces expression of IL-6 through transient activation of NF-κB; 
this is potentiated by IFN-γ through prolongation of NF-κB activation.147 Polymorphisms of the 
IL-6 gene are not associated with Crohn’s disease.148 
Gp 130 is constitutively expressed on most cells, while membrane bound IL-6R is 
selectively expressed on monocytes, neutrophils, T and B lymphocytes and hepatocytes. sIL-6R 
shedding by monocytic cell lines is enhanced by exposure to phorbol esters and certain bacterial 
toxins, but not IL-1β, TNF, IFN-γ, IL-4, IL-6, IL-10, chemokines or growth factors.149 However, 




IL-6 can transduce signals in two ways (figure 4).137 IL-6 ligation of membrane-bound IL-
6R induces homodimerization of membrane bound gp130. Stimulation of this complex activates 
gp130-associated cytoplasmic tyrosine kinases (JAK1, JAK2 and Tyk2), which phosphorylate 
STAT3. An alternative mechanism of activating cells that express only gp130 is trans-signaling, 
which is mediated by ligation of sIL-6R–IL-6 complexes with membrane bound gp130.151 Trans-
signaling then causes homodimerization of membrane gp130 and identical intracellular 
phosphorylation of STAT3. In parallel, either mechanism of signaling activates AP-1 and NF-IL-6 
through the Ras/Raf pathway. A mechanism of regulating this pathology is provided by secretion 
of soluble gp130, which when bound to IL-6/sIL-6R prevents trans-signaling. IL-11 also 
transduces signals through gp130. 
 
Function 
IL-6 has pleiotropic effects on many cells, with both pro- and anti-inflammatory 
properties. IL-6 can promote mucosal inflammation by inducing proliferation, activation and 
prevention of apoptosis of T lymphocytes, differentiation of B cells and stimulation of 
immunoglobulin production. At the same time, this molecule promotes neutrophil clearance from 
inflammatory foci,147 decreases neutrophil chemokine production, activates the acute phase 
response (hepatic synthesis of CRP, serum amyloid A and haploglobulin), and induces expression 
of IL-1RA and the soluble p55 TNFR.137 IL-6 mediates IFN-γ-induced neutrophil clearance by 
decreasing KC production and enhancing PMN apoptosis through induction of caspase 3.147 IL-6 
also promotes the transition from acute to chronic inflammation by recruitment of monocytes by 
altering chemokine profiles.6 In contrast, trans-activation of T cells through ligation of the sIL-
6R/IL-6 complex with membrane gp130 inhibits apoptosis of activated T cells from Crohn’s 
disease patients and mice with TH1-mediated colitis through induction of the anti apoptotic genes 
























Figure 4. IL-6 signaling pathways. IL-6 can signal by 2 pathways. Ligation of membrane-bound IL-6 receptor 
(IL-6R) causes homodimerization of membrane-bound gp130. This complex activates tyrosine kinases that 
phosphorylate STAT3, which homodimerizes to activate AP-1 or NF-IL-6. These transcription factors activate 
expression of a number of proinflammatory genes. An alternative transsignaling pathway is mediated by 
complexing secreted IL-6 with soluble IL-6 receptor (sIL-6R), which then binds to membrane-bound gp130. 
Subsequent signaling mechanisms are identical to ligation of membrane-bound receptor. 
 
A net proinflammatory effect of the trans-activating properties of experimental TH1-
mediated colitis is demonstrated by attenuation of disease by blocking sIL-1R-mediated signaling 
by anti-IL-6R antibodies or a gp130-Fc fusion protein.151-154 However, IL-6-/- mice exhibit 
increased expression of TNF, IFN-γ, GM-CSF and MIP-2, as well as neutrophilia during acute 
inflammation.155 Thus it is probable that IL-6 stimulates both protective and inflammatory 
pathways in intestinal inflammation, perhaps by downregulating acute innate-mediated effects and 
stimulating T cell-mediated events. A primary role for circulating IL-6 in bone resorption is 
suggested by antibody blockade experiments using serum from patients with active Crohn’s 
disease.156 
 
IL-12 and IL-23 
These immunoregulatory cytokines that polarize TH1 immune responses are briefly 
mentioned since they are produced by activated innate immune cells in response to many of the 
same stimuli that activate proinflammatory cytokines. 
 
Structure 
IL-12 is a homodimeric 70 kDa protein composed of p40 and p35 subsets. IL-12 p40 can 
also engage p19 to form IL-23, which has many functions overlapping with IL-12. 
50 
Innate immune responses 
 
Expression 
IL-12 is produced primarily by activated antigen-presenting cells, especially dendritic 
cells as well as activated macrophages. Although noninflamed CD8+ lymphoid dendritic cells 
produce IL-12 in preference to IL-10 and CD11b+ myeloid dendritic cells have very little IL-12 
production but high levels of IL-10 in the normal intestine.157 IL-12 production by mucosal 
CD11c+ dendritic cells and CD11b+ cells (macrophages and myeloid dendritic cells) is 
dramatically increased during TH1-mediated colitis in myeloid STAT3 conditional knockout 
mice.158 Likewise, IL-10-/- myeloid dendritic cells stimulated with LPS or cecal bacterial lysate 
secrete high concentrations of IL-12 p40.159 These results indicate that endogenous IL-10 
regulates IL-12 and IL-23 expression and that dendritic cells producing IL-12 are expanded 
during TH1 driven responses. TGF-β also inhibits IL-12 responses by downregulating IL-12, IL-
12RB2 and IL-12RB2 subunits.160 Mucosal expression of IL-12 in the normal intestinal mucosa is 
very low, but is substantially increased in experimental TH1-mediated colitis and human Crohn’s 
disease. IL-12 expression is stimulated by NF-κB signaling in response to bacterial products (via 
TLR), TNF, IL-1β as well as IFN-γ and CD40-CD40L ligation.161 
 
Signaling 
IL-12 binds to a high affinity complex of 2 receptors, β1 and β2. IL-12 and IL-23 signals 
are mediated by JAK2 and Tyk2, which phosphorylate STAT4.162 Accordingly, IL-12 stimulation 
of IFN-γ, TH1 responses and NK cells are absent in STAT4-/- mice.163 
 
Function 
IL-12 and IL-23 polarize TH1 responses by inducing IFN-γ and TNF. In addition, IL-12 
activates NK cells and stimulates cytotoxic T cells. IL-12 p40 expression, and hence IL-12 and 
IL-23 activity, is markedly increased in TH1-mediated intestinal inflammation, including 
experimental colitis and Crohn’s disease.72,164-167 A key role of IL-12 in the pathogenesis of 
intestinal inflammation is documented by potentiation of colitis by administering recombinant IL-
12 or the combination of rIL-12/IL-18,168,169 and by near complete prevention and treatment of 
TH1-mediated colitis by anti-IL-12 antibody.164,165 Fuss et al demonstrated that this pronounced 
protection was accompanied by apoptosis of TH1 lymphocytes.170 Studies of tissue IL-12 
expression and antibody blockade demonstrate that IL-12 mediates the early phase, but not the 
late stage of colitis in IL-10-/- mice on a resistant C57BL/6 background.171 A multicenter blinded 
study of anti-IL-12 monoclonal antibody in the treatment of Crohn’s disease is in progress. 
Moreover, IL-12 and IL-18 can break oral tolerance in animal models, providing an additional 
mechanism to induce chronic inflammation.172,173 
 
IL-18 
This TH1 polarizing cytokine has structural and signaling similarities to IL-1β and 
functional overlap with IL-12. 
 
Structure and secretion 
IL-18 is an 18 kDa single peptide chain produced as a 24 kDa precursor protein that is 
activated by ICE (Caspase 1) as well as proteinase 3, the same enzymes that secretion of mature 
IL-1β.83,174 Like IL-1β, IL-18 lacks a leader sequence and accumulates in the cytoplasm prior to 





IL-18 is produced in the intestine by epithelial cells, lamina propria macrophages and 
dendritic cells.13 Expression of this cytokine is increased in active Crohn’s disease, but not in 
ulcerative colitis.13,175 Moreover, lamina propria mononuclear cells express IL-18 receptors.176 
LPMNC from Crohn’s disease patients proliferate to a greater degree than do those from normals 
when stimulated with IL-18. IL-18 gene expression is upregulated by IFN-γ, IFNα/β or LPS 
through IFN consensus sequence-binding protein (ICSBP) and Pu.1 binding to regulatory 
elements on the 2 IL-18 promoters.174 
 
Signaling 
The IL-18 receptor is a heterodimer consisting of a ligand-binding subunit, IL-18Rα, 
which is identical to IL-1R-related protein, and a signaling subunit, IL-18Rβ, which is 
homologous to IL-1 RAcP. IL-18 binding protein (IL-18BP) is a soluble decoy receptor that can 
block binding of mature IL-18 with IL-18R, thereby inhibiting its biologic activity. Signaling 
proceeds through the IL-1R pathway involving the adapter protein MyD88, IRAK and TRAF6 
(figure 2). Stimulation of this complex activates the NF-κB and MAPK/AP-1 pathways. IL-18 
activation of TH1 cells involves protein tyrosine kinase and the Src kinase LCK. 
 
Function 
IL-18 and IL-12 synergistically induce expression of IFN-γ through induction of NF-κB, 
AP-1 (IL-18) and STAT4 (IL-12). By itself, IL-18 has minor effects, but the combination of IL-12 
and IL-18 induces far more IFN-γ in T cells than either stimulus alone. These synergistic activities 
are evident in vivo, with no intestinal inflammation induced by injection of IL-18 alone, mild 
disease with IL-12 alone, but severe colitis, weight loss and increased mortality with both IL-12 
and IL-18.169 This intestinal inflammation is IFN-γ dependent.177 In addition, IL-18 stimulates 
production of TNF, IL-1β, C-C and C-X-C chemokines by PBMNC and production of Fas-L and 
TNF by T cells and NK cells.174,178 The contribution of IL-18 to intestinal inflammation is 
demonstrated by consistent attenuation of experimental colitis in multiple T cell mediated and 
innate immune cell models (DSS, TNBS, T cell transfer to SCID mice) by a variety of IL-18 
inhibitory strategies (antibody neutralization, IL-18BP binding and antisense mRNA).98,176,179-181 
Furthermore, IL-18 transgenic mice are more susceptible to low dose DSS-induced colitis, 
although macrophages appear to be more activated and more numerous than T lymphocytes.182 Of 
interest, IL-18BP expression and IL-18/IL-18BP complexes are increased in Crohn’s disease, 
perhaps as a compensatory protective mechanism, although free (noncomplexed) IL-18 is found at 
the same time.183 As mentioned, IL-18 can break oral tolerance in mice.173 
 
Other cytokines 
Cytokines produced by both innate and cognate immune cells are being discovered at a 
rapid pace. This chapter emphasizes those molecules produced by innate immune cells that have 
been studied in the intestine, therefore additional molecules will be only briefly mentioned. 
 
Chemokines 
The rapidly expanding family of C-C and CXC chemokines is thoroughly covered in other 
comprehensive reviews16 and is not emphasized in this discussion. 
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IFN-α, IFN-β 
These molecules structurally related to IFN-γ are primarily secreted by activated 
macrophages. IFN-α has some anti-inflammatory effects, including induction of IL-1RA and 
sTNFRI (p55) as well as inhibition of IL-5 and IL-13. Although an uncontrolled study showed a 
beneficial effect of IFN-α in ulcerative colitis,184 a controlled study showed no benefit.185 IFN-β 
also has net anti-inflammatory effects, with suppression of IFN-γ and TNF expression and 
stimulation of IL-10 expression and T cell suppressor activity. Small open label and controlled 
studies with IFN-β inhibited ulcerative colitis activity.186,187 
 
M-CSF and GM-CSF 
These growth factors have cytokine-like properties including increasing the number and 
activation state of monocytes, macrophages, myeloid dendritic cells and neutrophils (GM-CSF). 
G-CSF and CM-CSF production by LPMNC is increased in active IBD.112,188 A protective role for 
GM-CSF in Crohn’s disease is supported by responses to recombinant protein in an open label 
study.189 The authors suggest that the beneficial effects of GM-CSF are mediated through 




Proinflammatory cytokines induced by activated innate immune cells have an essential 
role in clearing enteric pathogens, mediating acute and chronic intestinal inflammation, and 
stimulating the effector T cell responses. Expansion of these cytokines is dependent on central 
transcription factors (NF-κB, AP-1, NF IL-6, JAK/STAT) that also serve to signal responses after 
receptor ligation by these same gene products. This conservation of redundant signaling pathways, 
together with widespread expression of cytokine receptors in many mucosal cell types and 
recruitment of additional effector cells through chemokines, leads to amplification of the 
inflammatory responses. This amplification is necessary to effectively clear invading pathogens, 
yet can lead to irreversible tissue injury if not appropriately curtailed once the inciting stimulus is 
resolved.  The inflammatory response is efficiently suppressed in normal hosts by redundant 
inhibitory molecules that are induced by proinflammatory cytokines, bacterial products and 
immunosuppressive molecules liberated by regulatory T cells subsets, thus restoring immunologic 
tolerance and homeostasis with the commensal enteric microflora. Genetically susceptible 
individuals who are unable to mount appropriate suppressive signals develop chronic 
inflammation driven by overly aggressive innate and acquired immune responses to commensal 
bacteria. Most of the currently available therapies effective in IBD suppress proinflammatory 
cytokine transcription or function by inhibiting central signaling pathways or inducing apoptosis 
of key effector cells. Improved understanding of the regulation of expression and mode of action 
of these cytokines will lead to the development of new pharmacologic inhibitors that selective 
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Antibiotics in experimental colitis 
Abstract 
Background and aims 
Multiple rodent models implicate resident intestinal bacteria in the pathogenesis of 
chronic immune-mediated intestinal inflammation. Specific pathogen-free IL-10-/- mice develop 
colitis, which does not occur in the germ-free state. We investigated whether broad or selective 
antibiotics affect onset and progression of disease in various regions of IL-10-/- mice. 
 
Methods 
Metronidazole, ciprofloxacin, vancomycin-imipenem (50 mg/kg/day) or water (control) 
was administered orally before (prevention) or two weeks after (treatment) colonization of germ-
free IL-10-/- mice with specific pathogen-free bacteria. After four weeks, colonic histology scores 
and cytokine production by colonic explants were determined. Cecal and colonic contents were 
collected for quantitative bacterial analysis.  
 
Results 
In the prevention study, all antibiotics decreased inflammation in the cecum and colon. 
However, in the treatment study ciprofloxacin and vancomycin-imipenem decreased cecal 
inflammation, and reduced E. coli and E. faecalis concentrations, whereas only vancomycin-
imipenem lowered direct microscopic bacterial counts. In contrast, metronidazole and 




Both selective and broad spectrum antibiotics can prevent disease, but treatment of 
established colitis is more selective. Ciprofloxacin is most effective in treatment of cecal 
inflammation, metronidazole preferentially treats the colon, whereas vancomycin-imipenem 
definitively treats both regions. These results suggest that subsets of aerobic or anaerobic bacteria 




In recent years multiple studies have emphasized the role of commensal intestinal bacteria 
in the pathogenesis of IBD.1-2 In several genetically engineered and induced rodent models of 
chronic immune-mediated intestinal inflammation susceptible hosts develop spontaneous colitis in 
the presence of non-pathogenic resident intestinal bacteria, which does not occur in the germ-free 
state.3 
In a well-characterized murine model of TH1-mediated colitis IL-10-/- mice develop 
predominantly cecal inflammation shortly after weaning when susceptible strains (129 SvEv or 
mixed 129/C57Bl/6 background) are colonized with specific pathogen-free bacteria.4-5 As disease 
progresses inflammation also develops in the ascending and transverse colon, and finally in the 
remainder of the colon and rectum.4-5 In contrast, germ-free conditions prevent development of 
inflammation in this model, emphasizing the essential role of commensal intestinal organisms in 
the pathogenesis of chronic intestinal inflammation.5 These observations are consistent with 
results in other models of chronic intestinal inflammation, such as in HLA-B27/β2 microglobulin 
transgenic rats, IL-2-/-, TCRα-/-, SAMP-1/Yit, and CD3ε26 transgenic mice in which the germ-free 
state prevents disease development and immune activation.6-12 The role of intestinal bacteria in the 
pathogenesis of experimental colitis was further emphasized after showing that broad spectrum 
antibiotics can both prevent and treat colitis in HLA-B27 transgenic rats and DSS-induced colitis 
in BALB/c mice,13 as well as in IL-10-/- mice.14 
However, it is relatively unknown how different subsets of aerobic or anaerobic bacteria 
influence the onset and perpetuation of experimental colitis. We describe a study in gnotobiotic 
IL-10-/- mice which were colonized with specific pathogen-free bacteria that had the following 
objectives: (1) investigate whether selective antibiotics affect onset and progression of colitis, (2) 
explore regional differences in the prevention and treatment of colonic and cecal inflammation by 
antibiotic administration and (3) correlate the therapeutic effects of selective antibiotic treatment 
with the composition of intestinal aerobic and anaerobic bacteria. 
 
 
Materials and methods 
Mice 
Germ-free IL-10-/- mice (C57BL/6 x 129/Ola mixed background) were originally derived 
at the University of Wisconsin, Gnotobiotic Laboratory, Madison, WI, and bred at the gnotobiotic 
Rodent Care Facility of the Center for Gastrointestinal Biology and Disease at the College of 
Veterinary Medicine, North Carolina State University, Raleigh, NC. 
 
Experimental design 
IL-10-/- mice, 2-5 months old and raised under germ-free conditions, were transferred to 
specific pathogen-free conditions where bedding from Helicobacter-species free specific 
pathogen-free mice was added to each cage. The mice were colonized with Helicobacter-species 
free specific pathogen-free bacteria by oral and rectal swabbing with slurry of freshly passed 
feces, as described previously.5,15 
In the prevention study metronidazole, ciprofloxacin or a combination of vancomycin-
imipenem was administered in the drinking water at 50 mg/kg body weight/day starting at the 
time of specific pathogen-free bacterial colonization; control mice received only water. Each 
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group consisted of four or five mice. After four weeks the mice were killed, the cecum and 
various parts of the colon were collected for histology and colonic explants cultures. 
In the treatment study gnotobiotic IL-10-/- mice did not receive any treatment for two 
weeks after colonization with specific pathogen-free fecal bacteria. Subsequently, metronidazole, 
ciprofloxacin or vancomycin-imipenem was administered in the drinking water at 50 mg/kg body 
weight/day; control mice received only water. Each treatment group consisted of four or five 
mice. At four weeks after the start of antibiotic treatment the mice were killed and the cecum and 
colon were collected for histology and colonic explants cultures. Cecal and colonic contents were 
obtained for quantitative bacteriology and FISH as described below. All studies were approved by 
University of North Carolina at Chapel Hill Institutional Animal Care and Use Committee. 
 
Histology 
At necropsy transverse and longitudinal sections of the cecum and proximal, transverse 
and distal parts of the colon were obtained and prepared as previously described.5,15 Briefly, 
tissues were fixed in 10% formalin, embedded in paraffin and stained with hematoxylin and eosin. 
A validated histologic inflammatory score ranging from 0 to 4 was used for blinded evaluation, 
based on the degree of cellular infiltration, crypt hyperplasia, goblet cell depletion, and 
architectural distortion.5,15 
 
Colonic tissue fragment cultures 
Cultures of colonic fragments were prepared following published methods16 as 
described.5,15 Cecal fragments were not studied because the amounts of available cecal tissue were 
too small. Briefly, colonic tissue was fragmented and the precise weight per well was determined, 
which was always in a 50-100 mg range. The colonic tissue was cultured at 37°C in 1 ml of 
complete RPMI medium, as described5 and supernatants were collected after 18 hours and stored 
at –20°C until assay. IL-1β and IL-12 production were measured and results were normalized for 
the exact tissue weight used per well. Under these conditions autolysis of colonic fragments, 
especially epithelial cells, is expected. However, autolysis is expected to be consistent in all 
treatment groups, and therefore should not affect the outcome. 
 
Cytokine measurements 
We used commercially available anti-mouse IL-1β and IL-12 reagents (BD Pharmingen, 
San Diego, CA) in validated ELISA protocols to measure amounts of IL-1β and IL-12 in the 
colonic culture supernatants.5,15 Cytokine levels were measured in duplicates and compared to 
standard curves using recombinant murine cytokines. 
 
Quantitative bacteriology of cecal and colonic luminal content 
Cecal and colonic contents were collected and serially diluted at 10-fold dilutions in 1x 
PBS. For aerobic culture the diluted contents were plated and cultured at 37°C for 24 hours on 
sheep blood agar (total aerobes), Mac Conkey (E. coli), and Bile Esculin with Azide 
(Enterococci) agar plates. For anaerobic cultures cecal and colonic contents were plated within 1 
hour on BHI (total anaerobes) or Bacteroides Bile Esculin (BBE) agar plates in anaerobic Gas Pak 
jars (BBL, Cockeysville, MD) at 37°C for 48 hours. Bacterial colonies were counted, 
identification of specific organisms was performed by Gram staining, biochemical 
characterization using standard biochemical tests and confirmed by FISH, as described below. 
Direct microscopic bacterial counts of cecal and colonic content were assessed using a 
Petroffhauser counting chamber prior to bacterial culture, therefore providing an independent 




Fluorescent in-situ hybridization 
An accurately weighed portion of approximately 100 mg of cecal or colonic luminal was 
diluted 10 times with filtered (0.2 µm pore size) PBS. The diluted samples were homogenized by 
vortexing for 3 min with glass beads. The samples were diluted 1:3 with fresh 4% (w/v) 
paraformaldehyde in PBS, fixed overnight at 4º C and then stored at -80ºC until required. Total 
hybridizable cell numbers were counted by diamidino-2-phenylindole (DAPI) staining.17 Probe 
BAC303 was used for the detection of the Bacteroides/Prevotella genera.18 Probe EC1531 
specific for E. coli and other Enterobacteriaceae was used to detect E. coli.19 The probe Lab158 
was used to detect Lactobacilli and Enterococci.20 Enterococci were discriminated from the 
Lactobacilli using probe Efs, as described previously.20 Dilutions of the fixed samples in PBS 
were applied to slides with 8 wells of 1 cm x 1 cm (CBN, Drachten, The Netherlands).21 The 
slides were either hybridized with 100 µl hybridization buffer (20 mM Tris-HCl, 0.9 M NaCl, 
0.1% SDS, pH 7.2) containing 5 ng/µl of one of the probes described above or stained with DAPI 
as described.17 The hybridization assays were carried out overnight at 50ºC in a dark humid 
chamber (3 hours for the Bac303 and the EC23S probes). After hybridization, the slides were 
washed, air dried and subsequently mounted with Vecta Shield™ (Vector Lab., Burlingame, CA). 
The fluorescent cells in the samples were counted automatically with a Leica DMRXA 
epifluorescence microscope (Leica, Wetzlar, Germany).21 However, when the cell number was 
lower than 4x108 cells/g wet weight the cells were counted visually using an Olympus BH2 
epifluorescence microscope. All results are stated as bacterial count/g luminal content, thus 
normalized for the weight of luminal contents used during FISH analysis. Oligonucleotides probes 
were synthesized and purified by Eurogentec (Seraing, Belgium). 
 
Statistical analysis 
All data are expressed as mean ± standard error of the mean (SEM). Data were analyzed 
using the paired Student's t-test or the non-parametric Mann-Whitney test. Statistical significance 
was defined as P < 0.05 compared to mice from the water control group. The Spearman 
correlation coefficient was computed to measure the association between histology scores and 
bacterial counts, denoted by r. Positive values indicate a positive correlation, negative values 
indicate a negative correlation, and a value of one indicates perfect correlation of the ranks. Since 
several comparisons were made P < 0.01 was considered statistically significant rather than the 




We first studied the ability of selective and broad spectrum antibiotics to prevent onset of 
colitis in germ-free IL-10-/- mice given antibiotics at the time of colonization with specific 
pathogen-free fecal bacteria. 
 
Histology scores 
Figure 1A shows that vancomycin-imipenem was most effective in preventing both cecal 
(0.1 ± 0.2 versus 4.0 ± 0.2 water, P < 0.01) and colonic inflammation (0.1 ± 0.2 versus 2.9 ± 0.2 
water, P < 0.01, figure 1A). Ciprofloxacin and metronidazole partially prevented cecal (1.2 ± 0.3 
ciprofloxacin and 2.8 ± 0.4 metronidazole versus 4.0 ± 0.2 water, P < 0.05 for both) and colonic 
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(0.7 ± 0.2 ciprofloxacin, 1.2 ± 0.2 metronidazole versus 2.9 ± 0.2 water, P < 0.05 for both) 
inflammation. 
 
Colonic cytokine production 
All antibiotics significantly decreased IL-1β production by colonic explants cultures: 
ciprofloxacin (2.4 ± 0.8 ng/g tissue, P < 0.05), metronidazole (4.0 ± 0.1 ng/g tissue, P < 0.05) as 
well as vancomycin-imipenem preventive therapy (0.4 ± 0.1 ng/g tissue, P < 0.01) compared to 
the water control group (19.6 ± 4.6 ng/g tissue, figure 1B). Colonic IL-12 production followed the 
same trend as IL-1β and was significantly decreased by ciprofloxacin (3.5 ± 0.8 ng/g tissue, P < 
0.05), metronidazole (5.8 ± 0.9 ng/g tissue, P < 0.05), and vancomycin-imipenem treatment (1.0 ± 





























































Figure 1. Prevention study. Histologic scores (0-4) and colonic cytokine secretion (ng/g colonic tissue) in 
gnotobiotic IL-10-/- mice four weeks after specific pathogen-free colonization, which were simultaneously 
treated with water, oral ciprofloxacin, metronidazole, or vancomycin-imipenem (50 mg/kg body weight/day). 
Each group consisted of four or five mice. Values represent mean ± SEM. *P < 0.05, **P < 0.01 versus untreated 
controls. 
A: Blinded total colonic inflammatory scores. 
B: Spontaneous IL-1β and IL-12 production in colonic explants cultured for 18 hours. 
 
Treatment study 
We then determined whether these antibiotics could reverse established colitis. We have 
previously reported that germ-free IL-10-/- mice colonized with specific pathogen-free bacteria 
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develop significant mucosal inflammation by one week of bacterial colonization, especially 
prominent in the cecum (cecal histologic score 2.5 ± 0.4 in specific pathogen-free versus 0.2 ± 0.2 
in germ-free IL-10-/- mice, P < 0.001, colonic score 1.9 ± 0.3) which progressively increased to 
submucosal involvement by three weeks (histologic score cecum 2.9 ± 0.6, colon 1.8 ± 0.3).15 
Thus, germ-free IL-10-/- mice two weeks after colonization with specific pathogen-free bacteria 
have well established colitis. 
 
Histology scores 
Six weeks after specific pathogen-free colonization, and four weeks after antibiotic 
treatment was started, vancomycin-imipenem was most effective in reversing both established 
cecal (0.2 ± 0.2 versus 3.9 ± 0.2 water, P < 0.01) and colonic inflammation (0.2 ± 0.2 versus 3.0 ± 
0.3, P < 0.01, figure 2A). Ciprofloxacin partially decreased cecal (1.4 ± 0.5 versus 3.9 ± 0.2 
water, P < 0.05) but not colonic (2.3 ± 0.3, NS) inflammation, whereas metronidazole had no 
effect on cecal inflammation (3.4 ± 0.5, NS) but did partially treat colonic inflammation (1.0 ± 0.3 
metronidazole versus 3.0 ± 0.3 water control, P < 0.05). 
 
Colonic cytokine production 
IL-1β production by colonic explants was significantly decreased by metronidazole (1.5 ± 
0.3 ng/g tissue, P < 0.01) and vancomycin-imipenem (0.8 ± 0.4 ng/g tissue, P < 0.01) compared to 
the control group (18.0 ± 5.3 ng/g tissue, figure 2B). However, ciprofloxacin failed to 
significantly reduce colonic IL-1β production (12.2 ± 4.4 ng/g tissue, NS). IL-12 production by 
colonic explants was decreased by metronidazole (6.7 ± 1.2 ng/g tissue, P < 0.05) and 
vancomycin-imipenem (3.3 ± 0.3 ng/g tissue, P < 0.05) versus water control mice (21.4 ± 1.5 ng/g 
tissue, figure 2B). Ciprofloxacin did not have any effect on colonic IL-12 production (21.5 ± 1.3 
ng/g tissue, NS) compared to the water control group. 
 
Quantitative bacteriology of cecal and colonic contents  
Direct microscopic bacterial counts of cecal contents were 1-2 log lower in the 
vancomycin-imipenem group compared to water controls and was unchanged from controls in 
ciprofloxacin or metronidazole treated mice (table 1). Although DAPI-stained cell counting only 
showed a 5-fold reduction of total microbial cells in vancomycin-imipenem-treated mice versus 
other groups, most of these were identified as yeasts (table 2). The number of cecal total aerobic 
bacteria was significantly lower in ciprofloxacin-treated mice versus other groups. The amounts 
of E. coli and Enterococci spp were significantly decreased by ciprofloxacin and vancomycin-
imipenem treatment (table 1). 
Metronidazole treatment significantly increased amounts of luminal E. coli. These results 
were confirmed by FISH of the same cecal contents, which also identified that Enterococci spp 
were mainly E. faecalis (table 2). Total anaerobic bacterial amounts were significantly decreased 
by metronidazole as well as vancomycin-imipenem treatment with far greater effects seen with 
the combination treatment, as shown in table 1. FISH detected large populations of Lactobacilli in 
the control mice, which were significantly decreased by ciprofloxacin and eliminated by 
vancomycin-imipenem treatment. Both metronidazole and vancomycin-imipenem decreased 
Bacteroides spp amounts below detectable levels, which was confirmed by FISH (table 1 and 2). 
No significant differences were observed between quantitative bacteriological results from cecal 
versus colonic bacterial contents (data not shown). 
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Figure 2. Treatment study. Histologic scores (0-4) and colonic cytokine secretion (ng/g colonic tissue) in 
gnotobiotic IL-10-/- mice six weeks after specific pathogen-free colonization. Two weeks after specific pathogen-
free colonization resulting in established colitis, antibiotic treatment (50 mg/kg body weight/day) started with 
water, oral ciprofloxacin, metronidazole, or vancomycin-imipenem. Each group consisted of four or five mice. 
Values represent mean ± SEM. *P < 0.05, **P < 0.01 versus untreated controls. 
A: Blinded total colonic inflammatory scores. 
B: Spontaneous IL-1β and IL-12 production in colonic explants cultured for 18 hours. 
 
We then investigated statistical correlations between histologic inflammation and bacterial 
counts, using the Spearman correlation coefficient as a nonparametric measure of the correlation 
of ranks. The correlation of ranks instead of the correlation of the raw data was computed because 
the data were skewed and the assumptions required to do hypothesis testing on the parametric 
correlation coefficient were not satisfied. We merged all treatment groups, to see whether we 
could show a threshold for either total microbes or any of the species cultured, related to the 

















8) (x107) (x107) (x107) (x108) (x107)  
 Water 38 ± 12 5 ± 2 7 ± 3 48 ± 20 86 ± 30 32 ± 8  
 MNZ 43 ± 7 20 ± 10 84 ± 13
a 57 ± 30 4.8 ± 5 b < 0.001 a  
 Cipro 24 ± 6 < 0.001
 a < 0.001 a 0.2 ± 0.1 a 96 ± 50 28 ± 5  
 V + I 1 ± 0.1
a 21 ± 10 < 0.001 a < 0.001 a < 0.001 a < 0.001 a  
 
Table 1. Quantitative bacteriology of cecal content by bacterial cultures. Direct microscopic bacterial counts and 
cecal concentrations of aerobic bacteria, E coli, Enterococci, as well as total anaerobic bacteria, including 
Bacteroides spp, in gnotobiotic IL-10-/- mice colonized with specific pathogen-free flora and treated with 
ciprofloxacin (Cipro), metronidazole (MNZ) or vancomycin-imipenem (V+I). Values are given as mean ± SEM 
colony forming units per gram cecal contents. a P< 0.01 versus water controls, b P< 0.05 versus water controls. 
 
Direct microscopic bacterial counts strongly correlated with cecal inflammation (r = 0.77, 
P = 0.0002), but to a lesser extent with colonic inflammation (r = 0.53, P = 0.02). Total aerobic 
counts did not correlate with overall disease, and in fact were negatively correlated with colonic 
inflammation (r = -0.73, P = 0.0006). Cecal but not colonic inflammation correlated with E. coli 
concentrations (r = 0.76, P = 0.0003) and with E. faecalis concentrations (r = 0.70, P = 0.001). In 
contrast, colonic but not cecal inflammation strongly correlated with total anaerobes (r = 0.79, P = 











 Treatment (x 108) (x 107) (x 107) (x 107) (x 107)  
 Water 86 ± 21 6 ± 2 40 ± 38 114 ± 39 141 ± 40  
 MNZ 85 ± 9 171 ± 47 a 78 ± 40 <1 a 247 ± 48  
 Cipro 31 ± 7 <1 a <1 a 61 ± 12 11 ± 5 a  
 V + I 18 ± 1 a <1 a <1 a <1 a <1 a  
 
Table 2. Quantitative bacteriology of cecal content by FISH. Cecal luminal concentrations of E coli, 
Enterococci, Bacteroides spp, and Lactobacilli spp in gnotobiotic IL-10-/- mice colonized with specific pathogen-
free flora and treated with ciprofloxacin (Cipro), metronidazole (MNZ) or vancomycin-imipenem (V+I). Values 
are given as mean ± SEM per gram of cecal content, measured by fluorescent in-situ hybridization using probes 
specific for 16S ribosomal RNA of E. coli, E. faecalis, Bacteroides spp, and Lactobacilli spp.  <1 below 
detection limit of 107 bacteria/gram content. a P< 0.01 versus water controls. 
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Discussion 
Bacteria and their products play a crucial role in the pathogenesis of chronic intestinal 
inflammation in animal models and human IBD, providing therapeutic potential for antibiotics to 
manipulate the intestinal flora in order to influence the onset and course of disease.1-2 Germ-free 
IL-10-/- mice do not have colitis in the absence of intestinal bacteria, but we showed previously 
that they rapidly develop a TH1-mediated transmural acute and chronic inflammation within 1 
week after colonization with specific pathogen-free bacteria.15 Therefore, following identical 
protocols,15 this model provided us the opportunity to investigate established colitis two weeks 
after specific pathogen-free colonization. In our studies 4-6 weeks after specific pathogen-free 
bacteria, the cecum was consistently more affected than the colon in IL-10-/- mice. 
We first showed that the broad spectrum combination vancomycin-imipenem almost 
completely prevented and treated both cecal and colonic inflammation, in agreement with 
previous reports by several authors in various models. A combination of metronidazole and 
neomycin prevented and treated colitis in IL-10-/- mice.14 Vancomycin-imipenem prevented and 
treated colitis in HLA-B27 rats, DSS-induced colitis in mice,13 as well as TNBS-induced 
experimental colitis in rats.22 However, although the combination of ciprofloxacin and 
metronidazole prevented and treated inflammation in the SAMP1/Yit spontaneous ileitis model23 
it improved acute but not chronic DSS-induced colitis in mice.24 In human studies the 
combination of ciprofloxacin and metronidazole was reported to be effective in treating refractory 
pouchitis25 as well as active Crohn's disease.26-27 
We also showed that selective antibiotics such as ciprofloxacin or metronidazole could 
prevent cecal and colonic inflammation in gnotobiotic IL-10-/- mice after specific pathogen-free 
colonization, but only selectively reversed established colitis. The higher efficacy of selective 
antibiotics for prevention rather than treatment of colitis is in agreement with previous studies. 
For example, ciprofloxacin prevented the induction of colitis in IL-10-/- mice born under specific 
pathogen-free conditions, but showed only minor effects in established colitis.14 Metronidazole 
prevented DSS-induced colitis in mice, but this antibiotic had no effect after the onset of colitis.24 
In HLA-B27 transgenic rats and DSS-treated mice, oral administration of either ciprofloxacin or 
metronidazole could prevent colitis but was less effective in treating established inflammation.13 
The greater efficacy of selective antibiotics for preventing colitis may be explained by different 
roles for various endogenous bacterial species in the different phases of the inflammatory process. 
As proposed by Rath et al, some bacterial species might initiate inflammation while others, 
perhaps including a larger spectrum of intestinal bacteria, perpetuate disease.13 Therefore, it is 
easier to prevent onset of colonic inflammation than to treat established disease. These findings 
are in agreement with the ability of recombinant IL-10 to prevent but not treat experimental 
chronic granulomatous inflammation induced by bacterial cell wall polymers in rats.28 This might 
also explain the relative lack of efficacy by metronidazole and ciprofloxacin in the treatment of 
ileal Crohn’s disease,29 whereas metronidazole or ornidazole could prevent recurrence of Crohn’s 
disease in the neoterminal ileum after ileal resection and primary ileocolonic anastomosis.30-31 
A unique feature of our study is the observation that selective antibiotics showed regional 
differences in treating established colitis in IL-10-/- mice. Ciprofloxacin was most beneficial in the 
cecum, but did not treat colonic inflammation, whereas metronidazole was more effective in the 
colon. On the other hand, broad spectrum antibiotics vancomycin-imipenem were superior to 
ciprofloxacin or metronidazole alone and successfully treated both intestinal regions. Regional 
specificity of antibiotics is seen in human Crohn’s disease in which metronidazole, either alone or 
in combination with ciprofloxacin, is more effective in colonic versus ileal Crohn's disease,27,29,32 
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although in a small study ciprofloxacin did treat Crohn’s ileitis.33 In two other studies efficacy of 
ciprofloxacin in relation to disease localization was not mentioned.34-35 In our study cytokine 
production by colonic explants, normalized for tissue weight, was significantly reduced by 
metronidazole but not by ciprofloxacin, demonstrating the specificity of ciprofloxacin for the 
cecal region rather than the colon. 
Treatment with vancomycin-imipenem correlated with a 1-2 log decrease of total luminal 
bacteria, while other treatments did not significantly decrease total luminal bacterial 
concentrations. Similar effects on total cecal bacterial load by this antibiotic combination have 
been reported in HLA-B27 transgenic rats13 as well as by metronidazole plus ciprofloxacin 
treatment in the SAMP/Yit mouse model,23 most likely due to emergence of resistant bacterial 
species. Our results confirm the importance of luminal antigenic bacterial load in the perpetuation 
of chronic colitis, since the broad spectrum antibiotic combination almost totally eliminated 
disease. When all treatment groups were merged, there was a significant correlation between 
direct microscopic bacterial counts and histology scores in both the cecum and colon. However, 
reduction of bacterial load is not the only mechanism involved in response to treatment, because 
1) selective antibiotics have selective therapeutic effects in different large intestinal regions, 
despite the lack of effect on direct microscopic bacterial counts in IL-10-/- mice, 2) vancomycin-
imipenem was more effective than ciprofloxacin in reducing cecal inflammation, but did not 
decrease the total aerobic count, 3) decreased luminal E. coli and E. faecalis concentrations, but 
not the total aerobic counts, correlated with reduced cecal inflammation. Therefore, our results 
suggest that not only reduced bacterial load but also specific subsets of aerobic bacteria like E. 
coli, might preferentially perpetuate cecal inflammation, while anaerobic bacteria, including 
Bacteroides, cause colitis. This hypothesis is consistent with the selective effects of ciprofloxacin 
in the cecum and metronidazole in the colon. Ciprofloxacin is most effective against enteric 
aerobic Gram-negative organisms, and in our study it significantly reduced total cecal and colonic 
aerobic bacteria, with undetectable E. coli and a significantly reduced amount of luminal 
Enterococci spp. Interestingly, in preliminary studies, IL-10-/- mice monoassociated with E. coli 
preferentially develop cecal inflammation.36 E. coli could therefore play a role in the (induction 
and) perpetuation of cecal inflammation in specific pathogen-free IL-10-/- mice. Despite elevated 
amounts of cecal E. coli in HLA-B27 transgenic rats with severe chronic colitis,37 
monoassociation of these rats with E. coli did not induce colitis in these rats,38 indicating that the 
ability of E. coli to induce and perpetuate chronic colitis is host-dependent. The potential role of 
E. coli in chronic intestinal inflammation was further emphasized by the observation that ileal 
mucosa from Crohn’s patients with postoperative recurrence contained more 
enteroadherent/invasive E. coli strains than healthy controls.39 In addition, IBD patients have 
increased serum and mucosal antibody responses to E. coli.40-41 Monoassociation of IL-10-/- mice 
with E. faecalis induces a distal colitis with slow onset of disease, starting at 12 weeks of 
colonization.36,42-43 Although ciprofloxacin reduced cecal inflammation and luminal 
concentrations of E. faecalis in our study, the regional localization (distal colon versus cecum) 
and the slow onset of disease in monoassociated IL-10-/- mice make it unlikely that E. faecalis 
plays an important role in cecal inflammation. Additionally, it also appears unlikely that E. 
faecalis perpetuates established distal colitis in IL-10-/- mice colonized with specific pathogen-free 
bacteria for four to six weeks, since metronidazole, which selectively decreased colonic 
inflammation, had no effect on E. faecalis concentrations. 
Metronidazole is selectively active against anaerobic bacteria, including colonic Gram-
negative Bacteroides spp.44 Metronidazole effectively treated colonic inflammation in our IL-10-/- 
mice, significantly reduced luminal anaerobic bacteria and eliminated Bacteroides spp, in both the 
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cecum and colon, suggesting that differences in local luminal concentrations of these organisms 
could not explain the regional variation of colonic inflammation. Thus, anaerobic bacteria appear 
to have little effect in cecal inflammation in this model, but could play an important role in 
colonic inflammation. In selective colonization studies, a cocktail of six enteric bacteria, including 
B. vulgatus, induced minimal colitis in gnotobiotic IL-10-/- mice,5 although monoassociation with 
B. vulgatus induced colitis in carrageenan-fed guinea pigs and HLA-B27 transgenic rats.38,45 
Additionally, Mann et al demonstrated that different Bacteroides spp show variability in 
pathogenic capacity, with B. vulgatus and Bacteroides thetaiotamicron but not Bacteroides 
distasonis inducing colitis in monoassociated HLA B27 transgenic rats.46 In our study, host-
specificity and pathogenic variability of anaerobic species might determine which organisms 
mediate colonic inflammation. Thus, it appears likely that metronidazole eliminates other 
anaerobic intestinal organisms than B. vulgatus, which could mediate established colitis but not 
cecal inflammation in IL-10-/- mice.  
Administration of several Lactobacillus spp can both prevent and treat colitis in IL-10-/- 
mice.47-48 However, our FISH analysis demonstrated that both vancomycin-imipenem and 
ciprofloxacin treatment eliminated Lactobacilli spp, whereas metronidazole did not affect 
endogenous luminal Lactobacilli spp. Therefore, the beneficial effects of antibiotics are not 
mediated by increased Lactobacilli spp levels. 
In conclusion, selective antibiotics and broad spectrum combination antibiotics can 
prevent development of inflammation in both the cecum and colon of IL-10-/- mice after 
colonization with specific pathogen-free bacteria. In contrast, treatment of established colitis is 
more selective in its regional therapeutic response. Ciprofloxacin is most effective in cecal 
inflammation and reduces aerobic organisms, including E. coli and E. faecalis, whereas 
metronidazole is preferentially active in the colon and selectively decreases anaerobic bacteria and 
Bacteroides spp. Vancomycin-imipenem treats both regions very effectively, reduces total luminal 
bacteria and eliminates specific aerobic and anaerobic organisms. These results suggest that 
specific subsets of aerobic and anaerobic intestinal bacteria selectively perpetuate colitis in the 
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Probiotics in experimental colitis 
Abstract 
Background and aims 
B. vulgatus induces colitis in gnotobiotic HLA-B27 transgenic rats, while broad spectrum 
antibiotics prevent and treat colitis in specific pathogen-free transgenic rats, although disease 
recurs after treatment ends. Lactobacilli treat human pouchitis and experimental colitis. We 
investigated if Lactobacillus GG can prevent colitis in transgenic rats monoassociated with B. 
vulgatus and if Lactobacillus GG or Lactobacillus plantarum can treat established colitis in 
specific pathogen-free transgenic rats and prevent recurrent disease after antibiotics were stopped. 
 
Methods 
1. Germ-free HLA-B27 transgenic rats were monoassociated with B. vulgatus for four 
weeks following two weeks colonization with Lactobacillus GG or no bacteria. 2. Specific 
pathogen-free B27 transgenic rats received oral vancomycin-imipenem for two weeks, or water 
alone, followed by four weeks treatment with either oral Lactobacillus GG, Lactobacillus 
plantarum or water only. Disease activity was quantified by blinded gross and histologic scores, 
cecal MPO, IL-1β, TNF, TGF-β and IL-10. 
 
Results 
Lactobacillus GG did not prevent colitis in B. vulgatus-coassociated transgenic rats nor 
treated established disease in specific pathogen-free rats. However, Lactobacillus GG but not 
Lactobacillus plantarum prevented colitis relapse in antibiotic-treated rats with reduced gross and 
histologic scores, cecal MPO, IL-1β and TNF, whereas cecal IL-10 was increased. 
 
Conclusions 
Lactobacillus GG did not prevent colitis in gnotobiotic transgenic rats nor treated 
established disease in specific pathogen-free rats, but was superior to Lactobacillus plantarum in 
prevention of recurrent colitis. These studies suggest that antibiotics and probiotic agents provide 
synergistic therapeutic effects, perhaps mediated by altered immunomodulation with selective 




The role of intestinal bacteria in the pathogenesis of human IBD, particularly Crohn's 
disease, is well-recognized.1-2 These diseases typically occur at sites with the highest 
concentrations of intestinal bacteria, such as the colon and terminal ileum. Antibiotics and fecal 
diversion are effective treatment modalities for Crohn's disease,1-3 whereas re-establishing 
continuity of the bypassed distal bowel or infusion of intestinal contents into the excluded ileum 
leads to disease recurrence.4 
The role of intestinal bacteria in the initiation and perpetuation of chronic intestinal 
inflammation is most convincingly demonstrated in experimental models of chronic intestinal 
inflammation in which genetically susceptible hosts develop spontaneous colitis in the presence of 
commensal intestinal organisms, whereas no disease occurs in the germ-free state.5, 6-8 
HLA-B27 transgenic rats develop colitis, gastritis, and systemic inflammation in an 
specific pathogen-free environment.9 However, germ-free transgenic rats and non-transgenic rats 
colonized with specific pathogen-free bacteria show no evidence of colitis, gastritis, and 
arthritis.5,10 Colitis and gastroduodenal inflammation in transgenic rats is attenuated by 
metronidazole therapy and can be prevented and treated with broad spectrum antibiotics.11 
Moreover, cecal bacterial overgrowth within an experimental blind loop exacerbates colitis, 
whereas a bypass of the cecum attenuates disease in this model, which correlates with the 
concentrations of luminal Bacteroides species.12 B. vulgatus preferentially induces colitis in 
transgenic rats after monoassociation for 4 weeks, whereas monoassociation with E. coli does not 
cause disease.13 These findings indicate that not all bacteria are equal in their capacity to induce 
colitis. 
Probiotics are defined as living commensal micro-organisms that are important to the 
health and well-being of the host.14 Lactobacilli, although not predominant enteric organisms, are 
present throughout the GI tract of healthy humans and rodents. Several Lactobacillus strains, such 
as Lactobacillus plantarum, Lactobacillus acidophilus, Lactobacillus fermentum and 
Lactobacillus GG are able to colonize the human GI tract.15 Several human clinical trials have 
shown efficacy of several species of probiotics in viral-, and bacterial-induced infectious colitis as 
well as in antibiotic-associated diarrhea.14,16-17 Rectal administration of native murine 
Lactobacillus reuteri prevented colitis in IL-10-/- mice and a similar effect was shown by the oral 
prebiotic lactulose, which stimulated the growth of endogenous Lactobacilli spp.18 Continuous 
oral treatment of Lactobacillus plantarum in germ-free IL-10-/- mice colonized with specific 
pathogen-free flora could attenuate established colitis.19. A probiotic preparation including four 
species of Lactobacilli, three Bifidobacteria and one Streptococcus salivarius (VSL# 3) 
maintained remission of refractory pouchitis after transient antibiotic therapy.20 This probiotic 
cocktail VSL#3 was also beneficial in the treatment of colitis in IL-10-/- mice.21 
The first aim of our study was to investigate if the probiotic species Lactobacillus GG can 
prevent colitis in HLA-B27 transgenic rats monoassociated with the disease-inducing B. vulgatus. 
Secondly, we determined if Lactobacillus GG or Lactobacillus plantarum could treat established 
colitis in specific pathogen-free HLA-B27 transgenic rats or prevent recurrent disease after broad 
spectrum antibiotics were stopped. Thirdly, we studied the protective mechanisms of probiotics in 




Probiotics in experimental colitis 
Materials and methods 
Rats 
Transgenic rats of the 33-3 line on an inbred F344 background, bearing several copies of 
the genes for HLA-B27 and human β2 microglobulin, 9 and their non-transgenic littermates were 
originally obtained from Dr. Joel Taurog, Southwestern Medical School, Dallas, TX. After 
Caesarian section they were housed in Trexler isolators in germ-free conditions at the Gnotobiotic 
Core facility at the College of Veterinary Medicine at Raleigh, NC. Specific pathogen-free 
transgenic rats and their non-transgenic littermates were born and maintained in filter-top cages in 
a specific pathogen-free environment. 
 
Bacteria 
Freeze-dried cultures of Lactobacillus GG, which was Lactobacillus rhamnosus strain 
GG, and Lactobacillus plantarum strain 299v were kindly provided by ConAgra, Omaha, NE. 
Before administration Lactobacilli strains were grown aerobically overnight at 37°C in MRS 
broth. The next day the bacteria were harvested by centrifugation. After washes bacteria were 
resuspended in sterile PBS and added to the drinking water. Quantification and purity of bacterial 
suspensions as bacterial CFU was performed in serial dilutions of the drinking water on 
Lactobacillus MRS-Vancomycin plates. B. vulgatus was kindly provided by Dr. A.B. Onderdonk, 
(Harvard University, Cambridge, MA) and was originally derived from guinea pigs with 
carrageenan-induced colitis.22 This strain has been used to induce colitis in monoassociated 





In the first part of the study germ-free transgenic rats and their non-transgenic littermates 
were divided into three groups of six rats each at the age of two months. The first two groups were 
monoassociated with either B. vulgatus or Lactobacillus GG for four weeks, the third group was 
selectively colonized with B. vulgatus for four weeks, but was colonized with Lactobacillus GG 
for two weeks before co-colonization with B. vulgatus. Colonization with B. vulgatus was 
performed by oral and rectal swabbing using stool from other B vulgatus-monoassociated rats. 
Lactobacillus GG or Lactobacillus plantarum was administered once in the drinking water at 1010 
CFU per rat per day after overnight culture at 37°C in MRS broth. The amount of bacteria 
consumed by each rat per day was calculated by measured consumption of 30 ml of water per day 
times 3.3x108 CFU/ml = 1010 CFU. Successful colonization was assessed after one week by 
plating stool suspensions on BBE and MRS plates for Bacteroides spp and Lactobacillus 
respectively for a two days anaerobic culture, as well as by performing Gram stains. No 
contaminating organisms were discovered. Rats were killed after four weeks of B. vulgatus or 
Lactobacillus GG colonization. At necropsy ceca and colons were fixed in 10% buffered formalin 
for histological evaluations. Ceca were also snap-frozen for subsequent MPO and cytokine 
analysis. The cecal contents were collected for microbiological analysis as described below. 
 
Prevention of relapse study 
At 10 weeks of age specific pathogen-free HLA-B27 transgenic rats were divided into the 
following four treatment groups, each consisting of six rats; group one received only drinking 
water ad libitum for six weeks, group two received 50 mg/kg each of vancomycin-imipenem in 
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their drinking water for two weeks, followed by four weeks of water, group three received 50 
mg/kg each of vancomycin-imipenem for two weeks, followed by daily administration of 
Lactobacillus GG or Lactobacillus plantarum in the drinking water at 1010 CFU/rat/day during 
four weeks, group four received two weeks of water, followed by four weeks of 1010 CFU/rat/day 
Lactobacillus GG or Lactobacillus plantarum in their drinking water. All rats were killed six 
weeks after the start of treatment. Ceca and colons were collected for histology and snap frozen 




Tissues were prepared as previously described.10 A validated histological inflammatory 
scoring ranging from 0-4 was used for blinded evaluation of colonic and cecal inflammation.10 
 
Cecal cytokine analysis 
Frozen cecal tissues were thawed and lysed in PBS containing a cocktail of protease 
inhibitors (antipain, aprotinin, leupeptin, pepstatin A, all at 1 µg/ml and 1 mM PMSF (Sigma, St 
Louis, MO).23 Tissue was then homogenized, after which the homogenate was assayed for IL-1β, 
TNF, IL-10 and TGF-β. Concentrations of interleukin-1β were measured by a rat IL-1β ELISA 
developed by S. Poole, as described.10 Cecal TNF and IL-10 concentrations were determined by 
rat cytokine-specific ELISAs. TGF-β1 concentrations were measured after acidification and 




Homogenized ceca were assayed for MPO activity (units per gram of tissue) as described 
previously.24 
 
Determination of cecal bacterial concentrations 
Cecal contents were removed aseptically, immediately placed into an anaerobic chamber 
and dissolved in sterile pre-reduced PBS. Serial 100-fold dilutions were plated and cultured 
anaerobically for two days on Lactobacilli spp MRS-vancomycin agar for quantification of 
Lactobacillus, on BBE agar plates for Bacteroides spp, and on Brucella agar (Remel, Lenexa, KS) 
for total anaerobic bacteria. Morphology was determined by Gram staining. Results were 
expressed as CFU per gram cecal contents dry weight. 
 
Inhibition of in vitro adherence to IEC-6 cells 
The rat epithelial cell line IEC-6 cells (ATCC # CRL 1592, Rockville, MD) were grown 
to confluence in a 12-well tissue culture plate in antibiotic-free DMEM containing 5% heat-
inactivated newborn bovine serum and 10 IU (International Units)/ml insulin (Life Technologies, 
Burlington, ON, Canada). 
Intestinal epithelial adherence assay was performed according to Mack et al.25 Briefly, 
after removal of non-adherent cells, an adherent IEC-6 monolayer was incubated at 37°C with 109 
CFU B. vulgatus in the presence or absence of 109, 108 or 107 CFU Lactobacillus GG per well in 2 
ml of antibiotic-free complete medium under aerobic conditions. After 3 hours incubation non-
adherent bacteria were removed by washing three times with warm PBS, IEC-6 cells plus 
adherent bacteria were collected by trypsinization. Collected cells and adherent bacteria were then 
86 
Probiotics in experimental colitis 
serially diluted and plated anaerobically on BHI plates for 48 hours. Bacteria were counted by 
colony identification, confirmed by Gram staining. 
 
Statistical analysis 
Statistics were performed using the Student t test or Mann-Whitney test for comparison 






Monoassociation of transgenic rats with B. vulgatus resulted in mild cecal and colonic 
inflammation (histology score cecum 1.5 ± 0.1 and colon 1.2 ± 0.1). However, pretreatment of 
germ-free transgenic with Lactobacillus GG followed after two weeks by co-association with B. 
vulgatus did not prevent the development of mild colitis induced by B. vulgatus (histology scores 
cecum 1.6 ± 0.2 and colon 1.1 ± 0.2). However, monoassociation of gnotobiotic transgenic rats 
with Lactobacillus GG did not induce colitis (cecal and colonic scores both 0.2 ± 0.1). Similarly, 
gnotobiotic non-transgenic rats colonized with B. vulgatus, Lactobacillus GG or both did not 
develop colitis (histology score cecum or colon 0.2 ± 0.1). 
Cecal IL-1β concentrations from B. vulgatus-monoassociated transgenic rats (12 ± 3 
pg/mg cecal wet weight) were not significantly different from those obtained from B. vulgatus- 
and Lactobacillus GG -co-associated transgenic rats (11 ± 2 pg/mg). Cecal IL-1β concentrations 
from Lactobacillus GG-monoassociated transgenic rats (5 ± 2 ng/g) were similar to those from 
gnotobiotic non-transgenic littermates colonized with B. vulgatus, Lactobacillus GG or both (2 ± 
1 pg/mg). 
The concentration of Bacteroides spp in the cecal content of transgenic rats co-associated 
with B. vulgatus and Lactobacillus GG did not significantly differ from B. vulgatus-
monoassociated transgenic rats (61 ± 8x109 versus 47 ± 4x109 CFU/g cecal content in B. vulgatus 
and B. vulgatus plus Lactobacillus GG-associated transgenic rats respectively). The concentration 
of cecal Lactobacillus GG (0.45 ± 0.04x109 CFU/g) in the B. vulgatus plus Lactobacillus GG-co-
associated rats was 100 fold lower than the B. vulgatus concentrations, but did not significantly 
differ from the concentration of cecal Lactobacillus GG in Lactobacillus GG-monoassociated 
transgenic rats (0.49 ± 0.10 x109 CFU/g). Gram staining, aerobic and anaerobic culture of cecal 
contents from the gnotobiotic rats excluded contamination with other organisms. 
 
Prevention of colitis relapse in specific pathogen-free HLA-B27 transgenic rats 
Oral administration of broad spectrum antibiotics (oral imipenem-vancomycin) for two 
weeks to specific pathogen-free HLA-B27 transgenic rats followed by cessation of this treatment 
resulted in relapse of colitis after four weeks. The cecal gross gut scores (1.7 ± 0.2) as well as total 
colonic histology scores (1.7 ± 0.2) of antibiotic-water treated rats four weeks after stopping 
antibiotics did not differ from untreated control transgenic animals (cecal gross score 1.7 ± 0.2, 
total colonic histology score 1.7 ± 0.1) (figures 1-3). Also Lactobacillus GG administration alone 
could not effectively treat disease (cecal gross score 1.3 ± 0.3, total colonic histology score 1.8 ± 
0.2). However, if the antibiotic treatment was followed by daily oral administration of 
Lactobacillus GG, relapse of colitis could be partially prevented, as shown by a significant 
decrease of cecal gross score (0.6 ± 0.1) and total colonic histologic inflammatory score (1.1 ± 
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0.3) of this treatment group (figures 1-3). In contrast to Lactobacillus GG treatment, oral 
administration of Lactobacillus plantarum alone or after antibiotic treatment had no effect; neither 
cecal gross scores (data not shown) nor colonic histology scores (figure 3) differed significantly 
















Figure 1. Gross gut scores (GGS) (0-4) of ceca from specific pathogen-free transgenic rats treated with 
vancomycin-imipenem (Abs) or water followed by oral Lactobacillus GG or water administration. GGS from 
untreated specific pathogen-free transgenic rats are also given. Each group consisted of six rats. Data are 




Figure 2. Blinded total colonic inflammatory scores in specific pathogen-free transgenic rats treated with two 
weeks oral broad spectrum antibiotics (Abs) or water followed by four weeks Lactobacillus GG, Lactobacillus 
plantarum (L. pl) or water. Also histology scores from specific pathogen-free transgenic untreated rats were 
given. Values represent mean ± SEM of total histology scores (0-4). Vancomycin-imipenem followed by daily 
oral Lactobacillus GG administration significantly decreased total colonic histology scores versus other 
treatment groups. *p< 0.05 versus other treatment groups. Each group consisted of six specific pathogen-free 
transgenic rats. 
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Figure 3. Representative photomicrographs of tissue sections (x40) from ceca of 16 weeks old specific 
pathogen-free transgenic rats which were treated with (A) water (B) two weeks oral vancomycin-imipenem 
followed by four weeks of water, (C) two weeks oral vancomycin-imipenem, followed by daily administration of 
Lactobacillus GG during four weeks (D) two weeks water, followed by four weeks oral Lactobacillus GG. Note 
the extensive mucosal and some submucosal inflammation as well as significant crypt hyperplasia in ceca in 
figures 2A-B and D. Only mild to modest mucosal inflammation was seen in transgenic rats treated with the 
combination of broad spectrum antibiotics followed by Lactobacillus GG (2C). 
 
Cecal MPO values reflected the gross and histologic scores; only transgenic rats treated 
with antibiotics followed by Lactobacillus GG showed a significant reduction of cecal MPO (5.6 
± 1.0 U/g tissue) versus all other treatment groups, whereas MPO in cecal homogenates from 
transgenic rats treated with antibiotics alone (20.3 ± 5.6 U/g) or with Lactobacillus GG alone 
(10.2 ± 1.4 U/g) did not differ from untreated transgenic controls (13.3 ± 3.7 U/g) (figure 4). 
Cecal MPO from transgenic rats that had been fed Lactobacillus plantarum with or without 
antibiotic pre-treatment did not differ significantly from other treatment groups (data not shown). 
 
Mucosal cytokines 
Cecal homogenates from specific pathogen-free transgenic rats treated with antibiotics 
and/or Lactobacillus GG contained significantly less IL-1β than the other treatment groups (figure 
5A). A similar pattern was shown for cecal TNF, although TNF concentrations were about 10-fold 
less than cecal IL-1β (figure 5B). Interestingly, IL-10 concentrations were significantly increased 
in cecal homogenates from antibiotics-Lactobacillus GG treated transgenic rats versus other 
























Figure 4. Cecal MPO concentrations in specific pathogen-free transgenic treated with two weeks oral broad 
spectrum antibiotics (Abs) or water followed by four weeks Lactobacillus GG or water. Values from untreated 
transgenic control rats are also given. Data represent mean MPO levels in Units per gram cecum. Error bars 
represent SEM.  *p< 0.05 versus untreated controls.  
 
Bacteriology of cecal contents 
No differences were found in total bacterial counts of cecal contents between the 
antibiotic and/or Lactobacillus GG treatment groups in specific pathogen-free transgenic rats. 
Also concentrations of cecal anaerobic and aerobic bacteria as determined by culture on Brucella 
and SBA plates respectively were not significantly different (data not shown). Oral administration 
of Lactobacillus GG resulted in a 10-fold increase of Lactobacillus spp in cecal contents (1.0 ± 
0.5x107 CFU/g with antibiotics alone versus 12 ± 3x107 CFU/g cecal content in antibiotics-
Lactobacillus GG-treated rats). However, cecal Bacteroides spp did not differ significantly among 
the treatment groups (2.0 ± 1.4 x1010 with antibiotics alone versus 2.7 ± 0.3 x1010 CFU/g cecal 
content in the antibiotics-Lactobacillus GG -treated group). 
 
In vitro inhibition of bacterial adherence 
B. vulgatus was able to adhere to IEC-6 cells after an incubation of 3 hours. However, co-
culture of 109 B. vulgatus and 109 Lactobacillus GG per well significantly reduced the amount of 
adherent B. vulgatus. No effect was noted with concentrations of 108/well (figure 6) or 107/well 
Lactobacillus GG (data not shown). 
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Figure 5. Cecal IL-1β (A) or TNF, IL-10 or TGF-β (B) concentrations (in pg/mg) from transgenic rats treated 
with two weeks oral broad spectrum antibiotics (Abs) or water followed by four weeks Lactobacillus GG or 
water as well as from untreated controls. Error bars indicate SEM. *p< 0.05 versus untreated controls. 
Combination of antibiotics followed by Lactobacillus GG significantly decreases cecal IL-1β and TNF, but also 




Figure 6. Dose-dependent inhibition of in vitro adherence of 109 CFU B. vulgatus/2 ml well to IEC-6 cells by 
Lactobacillus GG. Data represent concentrations (x 103 CFU) of adherent B. vulgatus after three hours 
incubation with IEC-6 monolayers in the presence or absence of 108 or 109 CFU Lactobacillus GG /2 ml well. 




Broad spectrum antibiotics can prevent as well as treat established colitis in specific 
pathogen-free HLA-B27 transgenic rats.11 Similar results were obtained in other experimental 
colitis models in rats and mice, emphasizing the important role of intestinal bacteria for the 
induction and perpetuation of chronic intestinal inflammation.11,26-27 Oral vancomycin-imipenem 
treatment resulted in undetectable levels of Bacteroides spp, which are capable of selectively 
inducing colitis in HLA-B27 transgenic rats.10,13 
We found that colitis relapsed within four weeks of stopping vancomycin-imipenem 
treatment of established colitis in specific pathogen-free transgenic rats, resulting in disease 
relapse within four weeks with gross and histologic scores, MPO and proinflammatory cytokine 
levels nearly identical with untreated controls. This finding correlated with the re-appearance of 
luminal Bacteroides spp, since cecal Bacteroides concentrations were not significantly different in 
antibiotic-treated rats versus untreated transgenic controls. These findings are in agreement with 
clinical observations in Crohn's disease, which recurs after stopping antibiotic treatment.28 These 
observations can be explained by the reappearance of disease-inducing intestinal bacteria in 
genetically susceptible hosts. 
A clinically relevant finding of our study was that oral Lactobacillus GG treatment 
partially prevented relapse of colitis after antibiotic treatment, whereas Lactobacillus GG 
administration alone failed to show a beneficial effect. This conclusion was supported by 
significantly decreased gross cecal inflammation and colonic histology scores, as well as a 
significant decrease of nonspecific inflammatory markers and cytokines, such as cecal MPO, IL-1 
and TNF in antibiotic-Lactobacillus GG-treated specific pathogen-free transgenic rats versus 
other treatment groups. This is the first report of an interactive effect of antibiotic and probiotic 
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therapy in experimental colitis. These results are in agreement with Gionchetti et al, in which 
relapsing pouchitis was prevented in 85% of refractory pouchitis with an oral probiotic cocktail 
VSL#3, which includes four strains of Lactobacilli, three Bifidobacteria species and 
Streptococcus salivarius subsp. thermophilus after the broad spectrum antibiotic rifaximin was 
stopped.20 Similarly, prospective treatment with rifaximin followed by VSL#3 could also prevent 
endoscopic post-operative recurrence of Crohn's disease.29 
Another major finding in our study was the specificity of prevention of relapsing colitis by 
various Lactobacillus species as demonstrated by the lack of efficacy of Lactobacillus plantarum 
in preventing colitis relapse in specific pathogen-free transgenic rats after antibiotic treatment. 
However, this result is in contrast with our previous reports that oral Lactobacillus plantarum 
attenuated colitis in IL-10-/- mice,20 whereas Lactobacillus GG had no effect.30 A preventive effect 
of Lactobacillus plantarum was also shown in methotrexate-induced enterocolitis in rats.31 These 
contrasting responses suggest that different Lactobacilli may have variable host specificity or 
different efficacy in various inflammatory conditions, indicating that not all probiotics are equally 
protective in chronic experimental colitis. The concept of selective dependency of beneficial 
effects of a probiotic bacterial species on the species and genetic background of the host is similar 
to that of disease-inducing bacteria.10, 13, 32-33 
Other studies have reported primary beneficial effects of probiotics in the treatment or 
prevention of human or experimental intestinal inflammation. VSL#3 was able to treat established 
colitis in IL-10-/- mice.25 The same cocktail has also shown efficacy in an open-labeled study on 
the maintenance therapy of ulcerative colitis.34 Lactobacillus GG can prevent relapsing 
Clostridium difficile diarrhea,19 traveler's diarrhea35 and rotavirus infections in children.36 The 
non-pathogenic E. coli strain Nissle was shown to be as effective as low dose mesalamine in 
maintaining remission of ulcerative colitis.37-38 
The protective mechanisms of probiotic bacteria are still relatively unknown, with 
postulated effects on luminal microecology, mucosal barrier function and immunoregulation. In 
our study there was no decrease in the number of luminal Bacteroides spp, raising the possibility 
that some of the protective effects of antibiotics-Lactobacillus GG could be explained by 
immunomodulation. Not only does this therapy result in decreased cecal proinflammatory 
cytokines IL-1β and TNF, but it also increased mucosal IL-10. The lack of stimulation of mucosal 
IL-10 by Lactobacillus GG or antibiotics alone indicate that neither treatment is responsible for 
induction of IL-10. It is possible that combination antibiotics and probiotics alters the balance of 
enteric bacterial components, leading to altered mucosal cytokine profiles. IL-10 is an 
immunoregulatory cytokine, mainly produced by macrophages, dendritic cells and TR1 
lymphocytes. However, we recently reported that in cecal bacterial lysate-stimulated mesenteric 
lymph node cells of HLA-B27 transgenic rats as well as their non-transgenic littermates IL-10 is 
primarily produced by B cells.39 In vitro, lysates of VSL#3 stimulates IL-10 production and 
diminishes TNF secretion by rat splenocytes stimulated with cecal bacteria.40 In preliminary data, 
it was demonstrated that DNA extracts of VSL#3 induce IL-10 and exert protective immune 
responses.41 IL-10 can inhibit antigen-specific proliferation and cytokine secretion by TH1 
lymphocytes and has downregulatory effects on macrophages and dendritic cells, such as 
suppression of activation and IL-12 production.42-43 IL-10 can also prevent IFN-γ-induced 
disruption of colonic epithelial barriers.44 Defective in vivo production of IL-10 results in 
spontaneous colitis in IL-10-/- mice in the presence of normal intestinal bacteria.7,45 Furthermore, 
oral administration of Lactococcus lactis, engineered to produce high colonic IL-10 levels, 
prevents the onset of colitis in IL-10-/- mice as well as in DSS-induced colitis.46 Thus, stimulation 
of colonic IL-10 production by the combination of antibiotics use and Lactobacillus GG 
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colonization could have a variety of beneficial effects on mucosal immunoregulation and barrier 
function. 
Increased mucosal IL-10 production and decreased levels of the proinflammatory 
cytokines IL-1β and TNF by the combination of antibiotics and Lactobacillus GG in our study are 
in agreement with findings of Ulisse et al, who showed increased IL-10 as well as decreased TNF 
and IFN-γ in pouch biopsies of refractory pouchitis patients treated with VSL#3 after antibiotic 
pretreatment.47 Similar to our findings, these authors found that tissue IL-10 levels were 
unchanged in inflamed pouches and were not affected by prior antibiotic treatment.47 However, in 
IL-10-/- mice the probiotic cocktail VSL#3 treated colitis with a concomitant decrease of mucosal 
IFN-γ and TNF secretion,21 indicating that beneficial effects of probiotics in colitis can be 
mediated by factors other than IL-10 induction. 
Several non-immune protective mechanisms have been described for probiotic bacterial 
species. These organisms can exert growth inhibitory and bactericidal activities on 
enterotoxigenic E. coli.48 However, in our study cecal concentrations of the disease-inducing 
Bacteroides spp were not significantly decreased. Another potential protective non-immune 
mechanism involves inhibition of epithelial adherence of disease-inducing organisms. Intestinal 
bacteria compete with other organisms for a limited number of epithelial receptors. Increased 
amounts of colonic mucosal-associated bacteria were found in IL-10-/- mice28 well as in mucosal 
biopsies from IBD patients.49 Madsen et al also reported a relative lack of adherent Lactobacilli in 
IL-10-/- and a restoration to normal levels after probiotic treatment.19, 21 Our in vitro co-culture 
studies demonstrate that Lactobacillus GG only at high concentrations of 109 CFU/ml decreased 
adherence of B. vulgatus to rat IEC-6 cells, with no effects at lower doses. This result is in 
agreement with in vitro studies by Madsen21 and Mack25 in which probiotic bacteria prevented the 
epithelial adherence of Salmonella dublin or enteropathogenic E. coli. However, in our study in 
vivo co-association of B. vulgatus and Lactobacillus GG did not prevent colitis in gnotobiotic 
transgenic rats. This lack of effect by Lactobacillus GG in the dual association model could be 
explained by the overwhelming colonization capacity of the disease-inducing B. vulgatus versus 
Lactobacillus GG, which were 100 fold more frequent than Lactobacillus GG. We suspect that the 
lack of effect by Lactobacillus GG in the dual association model could be explained by the 
overwhelming colonization capacity of the disease-inducing B. vulgatus versus Lactobacillus GG, 
which were 100 fold more frequent than Lactobacillus GG. It is possible that at this relatively low 
in vivo luminal concentration Lactobacillus GG would not be able to mediate protection by 
inhibiting epithelial adherence of B. vulgatus, since equal concentrations of Lactobacillus GG 
were required to interfere with B. vulgatus epithelial adherence. Based on these findings we 
postulate that protective effects by probiotics in specific pathogen-free transgenic rats could only 
be achieved by pretreatment of the rats with vancomycin-imipenem, which would result in a 
significant decrease of B. vulgatus before Lactobacillus GG treatment.11 However, despite the 
prevention of colitis relapse by the combination treatment of vancomycin-imipenem followed by 
Lactobacillus GG this treatment did not significantly reduce luminal Bacteroides spp, even 
though increased cecal Lactobacilli spp was shown by cecal culture. Taken together, reduction of 
luminal Bacteroides spp could not explain the protective effects of broad spectrum antibiotics 
followed by Lactobacillus GG. Prevention of colitis relapse as well as immunomodulatory effects 
were shown only with the combination treatment of vancomycin-imipenem followed by 
Lactobacillus GG. It is possible that the combination treatment promoted synergistic interaction 
of Lactobacillus GG with other endogenous probiotic species, resulting in disease protection. The 
absence of these potential beneficial interactions with other intestinal protective bacteria in 
gnotobiotic transgenic rats co-associated with Lactobacillus GG and B. vulgatus could also 
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explain the lack of efficacy of Lactobacillus GG in prevention of colitis. Alternatively, lack of 
exposure to lactic acid bacteria early in life in these gnotobiotic rats may prevent stimulation of 
protective responses by Lactobacillus GG at an older age. 
In summary, oral Lactobacillus GG can prevent relapse of colitis in specific pathogen-free 
B27 transgenic rats after antibiotics are stopped, whereas oral administration of Lactobacillus 
plantarum did not have any effect, demonstrating the selective protective effects of two 
Lactobacillus species. The beneficial in vivo effects of Lactobacillus GG following antibiotics are 
possibly the result of enhanced IL-10 production. This is the first study in experimental colitis in 
which antibiotics and probiotics display synergistic in vivo effects. Restoring the microbial 
balance between detrimental and protective luminal bacteria by combining antibiotic and 
probiotic approaches may be the most physiologic approach to treat IBD and may alter the natural 
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Abstract 
Introduction and aims 
HLA-B27 transgenic rats develop spontaneous colitis when housed under specific 
pathogen-free conditions but germ-free rats remain disease-free, emphasizing a role for intestinal 
bacteria in the pathogenesis of the disease. Prebiotics are nutrients that affect the host by 
stimulating growth and/or activity of potentially health promoting (probiotic) bacteria. The aims 
of this study were to investigate whether prebiotics can prevent colitis in specific pathogen-free 
HLA-B27 rats, and secondly, to explore mechanisms of protection. 
 
Methods 
Specific pathogen-free HLA-B27 transgenic rats received orally the prebiotic combination 
inulin/oligofructose, or not, prior to the development of clinically detectable colitis. After seven 
weeks, the rats were killed, and cecal and colonic tissues were collected for gross cecal scores, 
histological inflammatory scores (scale 0-4), and mucosal cytokine measurement. Cecal and 
colonic contents were collected for PCR-DGGE analysis of the gut microbiota, and enumeration 
of selected bacterial populations by FISH. 
 
Results 
Prebiotic treatment significantly decreased gross cecal scores and inflammatory 
histological scores in the cecum and colon. Prebiotic treatment also decreased cecal IL-1β, but 
increased cecal TGF-β concentrations. Inulin/oligofructose altered the cecal and colonic PCR-
DGGE profiles, and FISH analysis showed significant increases in cecal Lactobacillus and 
Bifidobacterium populations after prebiotic treatment compared to water-treated rats. 
 
Conclusions 
The prebiotic combination inulin/oligofructose partially prevented colitis in HLA-B27 
transgenic rats, which was associated with alterations to the gut microbiota, decreased tissue 
proinflammatory cytokines and increased immunomodulatory molecules. These results show 





The role of the gut microbiota in the pathogenesis of IBD is well recognized.1,2 These 
diseases typically occur at sites with the highest concentrations of intestinal bacteria, such as the 
colon and terminal ileum. The role of intestinal bacteria and the genetic background of the host in 
the initiation and perpetuation of chronic intestinal inflammation are most convincingly 
demonstrated in rodent models of chronic intestinal inflammation.3 In these models, genetically 
susceptible hosts develop spontaneous colitis in the presence of intestinal bacteria, but not in the 
germ-free state.3 
One example of a well-characterized model of intestinal inflammation is the HLA-B27 
transgenic rat, which develops colitis, gastritis, and arthritis in a specific pathogen-free 
environment.4 However, germ-free transgenic rats, as well as non-transgenic rats colonized with 
specific pathogen-free bacteria, do not show evidence of colitis, gastritis, and arthritis.5 Colitis 
and gastroduodenal inflammation in transgenic rats can be prevented with broad spectrum as well 
as selective antibiotics.6 Moreover, cecal bacterial overgrowth within an experimental blind loops 
exacerbates colitis, whereas bypass of the cecum attenuates disease in this model.7 B. vulgatus 
preferentially induces colitis in transgenic rats after monoassociation for four weeks, whereas 
monoassociation with E. coli does not cause disease.8 These findings indicate that although 
bacteria are crucial in the pathogenesis of colitis, not all bacteria are equal in their capacity to 
induce intestinal inflammation. 
Probiotics are “defined, live microorganisms administered in adequate amounts which 
confer a beneficial physiological effect on the host.” 9 We and others have shown that certain 
probiotic bacteria such as Lactobacillus species have protective activities in several experimental 
models of chronic intestinal inflammation, including specific pathogen-free HLA-B27 transgenic 
rats and specific pathogen-free IL-10-/- mice.10,11 Probiotic cocktails have also proven efficacy in 
ulcerative colitis12 and refractory pouchitis.13 
Prebiotics are non-digestible polysaccharides or oligosaccharides that affect the host by 
selectively stimulating growth and/or activity of a limited number of potentially health promoting 
(probiotic) bacteria.14 Previous studies have demonstrated that the prebiotics inulin and 
oligofructose selectively stimulate the growth of endogenous Bifidobacteria or Lactobacilli.15,16 
To date, the efficacy of prebiotics as monotherapy has been limited to induced models of 
colitis.17,18 However, as probiotics were effective in specific pathogen-free HLA-B27 transgenic 
rats11 we designed this study to determine if prebiotics would have a similar degree of protection 
in this model. In addition, the role of immune factors, cecal and colonic SCFA, and the 
composition of the intestinal microbiota were studied as possible mechanisms of protection. In 
this study, we demonstrate that the combination of inulin and oligofructose partially prevented 
colitis. This beneficial effect was associated with alterations to the gut microbiota, a decrease in 
cecal proinflammatory cytokines, and increased immunoregulatory cytokines. These results show 




Materials and methods 
Animals 
HLA-B27 transgenic rats (the 33-3 line on the F344 background) and their non-transgenic 
littermates were originally obtained from Dr. Joel D. Taurog, University of Texas Southwestern 
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Medical Center. Rats were born and maintained in specific pathogen-free housing conditions at 
the University of North Carolina, Chapel Hill. Presence or absence of the HLA-B27 transgene 
was determined by PCR using DNA isolated from tail clippings as described previously.19 All 
studies were approved by University of North Carolina at Chapel Hill Institutional Animal Care 
and Use Committee. 
 
Experimental design 
Seven week old specific pathogen-free HLA-B27 transgenic rats, prior to the development 
of histologic inflammation, were divided into two groups of six rats each. The first group was 
administered a combination of chicory inulin and oligofructose in a mixture of 1:1 (Raftilose 
Synergy1, Orafti, Tienen, Belgium) in their drinking water at a dose of 7.5 g/kg bodyweight, 
whereas the control group received no addition. The amount of prebiotics consumed by each rat 
per day was calculated by measured consumption of 30 ml of water per day. Rats were killed after 
seven weeks. At necropsy cecal and colonic tissue and content were snap-frozen for subsequent 
cytokine analysis and microbiological and SCFA assessment. Mesenteric lymph node cells were 
collected for cell cultures. 
 
Gross cecal scores 
The cecum and colon were inspected grossly in a blinded fashion for evidence of intestinal 
wall thickness and scored on a scale ranging from 0 to 4, using a previously validated system.11,20 
 
Histology 
Colons and ceca were fixed and stained as previously described.11,20 A validated histologic 
inflammatory score ranging from 0 to 4 was used for blinded evaluation of cecal and colonic 
inflammation.20 
 
Preparation of cecal bacterial lysates 
Cecal bacterial lysates were prepared as described previously.19 Briefly, cecal contents 
from several specific pathogen-free HLA-B27 non-transgenic rats were homogenized and the 
supernatant was filtered through a 0.45 µm syringe filter. Sterility was confirmed by aerobic and 
anaerobic culture. 
 
Mesenteric lymph node cell cultures 
Mesenteric lymph nodes were removed from water- and prebiotic-treated HLA-B27 
transgenic rats, and single cell suspensions were prepared by gentle teasing, as previously 
described.19 Mesenteric lymph node cells were washed twice and 4x105 cells were cultured in 96 
well flat bottom microplates (Costar 3595), in 0.2 ml complete medium, as described previously.19 
Cells were stimulated with the optimal concentration of 50 µg/ml cecal bacterial lysate, as 
described previously.19 Culture supernatants were collected after three days and stored at -20°C. 
 
Cytokine measurements in mesenteric lymph node cell cultures 
Cytokines in cell culture supernatants were measured by ELISA using unlabeled capture 
antibodies and biotin-labeled detection antibodies, followed by horse-radish peroxidase labeled 
Streptavidin.19 The concentration of each cytokine was determined by comparison to a standard 
curve generated using recombinant proteins. For IFN-γ, we used unlabeled polyclonal anti-IFN-γ 
antibody and biotin-labeled monoclonal anti-IFN-γ antibody (clone DB-1) (Biosource 
International, Camarillo, CA). For IL-10 we used unlabeled monoclonal anti-rat IL-10 antibody 
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(clone A5-7) and biotin-labeled monoclonal anti-rat IL-10 antibody (clone A5-6) (BD Biosciences 
Pharmingen, San Diego, CA). 
 
Cecal cytokine analysis 
Cecal cytokines were measured as described previously.11 Briefly, frozen cecal tissues 
were thawed and lysed in PBS containing a cocktail of protease inhibitors.21 Tissue was then 
homogenized after which the homogenate was assayed for IL-1β, IL-10 and TGF-β, as 
described.11 IL-1β was measured by ELISA according to the manufacturer’s instructions (National 
Institute for Biological Standards and Controls, South Mimms, UK). IL-10 was measured as 
described in the previous paragraph. TGF-β concentrations were measured after acidification and 
neutralization according to the manufacturer’s instructions using a TGF-β specific ELISA 
(Promega, Madison, WI, USA). 
 
SCFA analysis in cecal contents 
Cecal or colonic content (100 mg portions) was combined with 400 µl water and 100 µl of 
25% phosphoric acid in a 2 mL microcentrifuge tube, mixed thoroughly, and immediately frozen. 
At the time of analysis, samples were thawed and 100 µl of internal standard (4-methyl-n-valeric 
acid at 50 µmol/ml) was added. The samples were centrifuged to obtain a clear supernatant that 
was placed into 1.8 mL GC vials for analysis. SCFA separation was performed using a Varian 
3400 gas chromatograph equipped with a Varian 8200CX autosampler. Approximately 1 µl was 
injected onto a Stabilwax-DA GC capillary column (30m x 0.53mm ID: Restek Corp., Bellefonte 
PA) with an injector split ratio of 20:1. Injector and detector temperatures are set at 170°C and 
190°C, respectively. Column temperature was increased from 120°C to 170°C at 10°C/min and 
held for 5 minutes. Data acquisition and integration were performed using an Schmadzu Class-VP 
Chromatography Laboratory Automated Software System. 
 
PCR-DGGE from cecal and colonic contents 
In order to detect changes in the composition of the large bowel microbiota of rats, we 
utilized PCR-DGGE. DNA was extracted from cecal and colonic samples by preparing a 1/10 
(wt/vol) homogenate in PBS (pH 7.0). Samples were vortexed and stored at -80°C until further 
use. DNA extraction followed a previously described method.22 Amplification of total bacterial 
community DNA was carried out by targeting 16S rDNA sequences using universal bacterial 
primers HDA1-GC and HDA-2 and using a procedure described previously.22 The PCR products 
were checked by electrophoresis through a 2% agarose gel, stained with ethidium bromide (5 
µg/ml) and viewed by UV transillumination. PCR amplicons were analyzed by DGGE. This was 
performed with a DCode apparatus (Bio-Rad, Hercules, CA), using a 6% polyacrylamide gel with 
a 30 to 55% gradient of 7.0 M urea and 40% (vol/vol) formamide that increased in the direction of 
the electrophoresis. Electrophoresis was carried out in 1× TAE buffer at 130 V and 60°C for 4 
hours. Gels were stained with ethidium bromide solution (5 µg/ml) for 20 min, washed with 
deionised water for 20 min, and viewed by UV transillumination. DNA fragments of interest were 
cut from the polyacrylamide gel using a sterile scalpel blade after the stained gel had been 
photographed. DNA was eluted from the gel, cloned and sequenced as described previously.23 
Sequences were compared to those in the GenBank database using the BLASTn algorithm in 
order to identify the bacterial species from which the DNA sequence originated.24 
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Fluorescent in-situ hybridization 
FISH was carried out as described previously.  Briefly, 100 mg of cecal or colonic 
content was diluted, homogenized, fixed overnight in paraformaldehyde at 4ºC, and then stored at 
-80ºC until analysis. Total cell numbers were counted by DAPI staining, while probe Erec482 was 
used for the detection of cells from the Clostridium-group XIVa,  probe BAC303 for the 
detection of the Bacteroides/Prevotella genera,  probe Bif164 for the detection of the genus 
Bifidobacterium  and probe Lab158 to detect Lactobacilli and Enterococci.  The samples 
hybridized overnight at 50ºC in a dark humid chamber.  After hybridization, the slides were 
washed, air dried, mounted, and the fluorescent cells in the samples were counted automatically 
with a Leica DMRXA epifluorescence microscope (Leica, Wetzlar, Germany).  However, when 
the cell number was lower than 4x10  cells/g wet weight, the cells were counted visually using an 
Olympus BH2 epifluorescence microscope.  All results are stated as bacterial counts/g luminal 
content, thus normalized for the weight of luminal contents used during FISH analysis. 











Statistics were performed using the non-paired Student’s t test for comparison between 





Gross cecal scores and histology 
Daily water consumption did not differ significantly between the experimental groups 
(data not shown). Oral administration of the prebiotic combination inulin and oligofructose to 
HLA-B27 transgenic rats partially prevented the development of colitis. Gross cecal scores were 
significantly decreased in prebiotic-treated rats (figure 1), whereas water-treated animals showed 
severe cecal macroscopic inflammation (P < 0.005). This beneficial effect of prebiotic treatment 
was also reflected by significantly lower histological scores for cecum (P < 0.01) and colon (P < 
0.005) (figure 2) in prebiotic-treated versus untreated transgenic rats. Severe mucosal and 
submucosal inflammation with significant crypt hyperplasia was seen in untreated transgenic rats 
(figure 3A), whereas prebiotic treatment resulted in only modest mucosal inflammation (figure 
3B). Interestingly, all water-treated rats developed arthritis in one or more joints, whereas only 
one out six rats in the prebiotic group showed arthritis (data not shown). 
 
Mucosal cytokine profile 
Cecal IL-1β concentrations were decreased after prebiotic treatment (P < 0.05 versus 
water controls; figure 4A). In contrast, prebiotics increased cecal TGF-β secretion (P < 0.05 
versus water controls; figure 4B), whereas cecal IL-10 production did not significantly differ 





















Figure 1. Decreased gross cecal scores (0-4 )after prebiotic treatment. Specific pathogen-free transgenic rats 
were treated for seven weeks with prebiotics inulin and oligofructose (mixture 1:1) or water prior to the 
development of histologic inflammation. Each group consisted of six rats. Values are presented as mean ± SEM, 






















Figure 2. Decreased histologic scores after prebiotic treatment. Blinded microscopic inflammation scores from 
ceca and colons in specific pathogen-free transgenic rats were treated for seven weeks with prebiotics inulin and 
oligofructose (mixture 1:1) or water prior to the development of histologic inflammation. Each group consisted 
of six rats. Values are presented as mean ± SEM, ** P < 0.01, *** P < 0.005 versus untreated transgenic rats. 
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Figure 3. Decreased cecal inflammation in transgenic rats after prebiotic treatment. Representative 
photomicrographs of tissue sections (x40) from ceca of 14 weeks old specific pathogen-free transgenic rats were 
treated for seven weeks with water (A) or the prebiotics inulin and oligofructose (mixture 1:1) (B) prior to the 
development of histologic inflammation. Note the extensive mucosal and submucosal inflammation as well as 
significant crypt hyperplasia in ceca from water-treated transgenic rats (A). Only modest mucosal inflammation 

























Figure 4A. Altered cecal cytokine profile after prebiotic treatment. Cecal IL-1β concentrations (ng/100 mg 
tissue) (A) from transgenic rats treated with either water or oral prebiotics prior to the development of histologic 
inflammation. Each group consisted of six rats. Values are presented as mean ± SEM, * P < 0.05 versus 



























Figure 4B. Altered cecal cytokine profile after prebiotic treatment. TGF-β concentrations (pg/100 mg tissue) (B) 
from transgenic rats treated with either water or oral prebiotics prior to the development of histologic 
inflammation. Each group consisted of six rats. Values are presented as mean ± SEM, * P < 0.05 versus 























Figure 5. Decreased interferon-γ secretion after prebiotic treatment. Specific pathogen-free transgenic rats were 
treated with either water or prebiotics prior to the development of histologic inflammation. After seven weeks, 
rats were killed and mesenteric lymph nodes were collected. Mesenteric lymph node cells were isolated and 
cultured in the presence of cecal bacterial lysate at 50 µg/ml protein concentration. Interferon-γ concentrations 
(ng/ml) were measured in the triplicate supernatants by ELISA. Each group consisted of six rats. Values are 
presented as mean ± SEM, ** P < 0.01 versus untreated transgenic rats. 
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Mesenteric lymph node cell cytokine responses 
Stimulation with cecal bacterial lysate induced higher interferon-γ responses in mesenteric 
lymph node cells from untreated transgenic rats compared to prebiotic-treated animals (P < 0.01; 
figure 5). No differences in IL-10 production were found for cecal bacterial lysate-stimulated 
mesenteric lymph node cells from prebiotic- versus untreated transgenic rats (data not shown). 
 
PCR-DGGE profiles and FISH enumeration of cecal and colonic bacteria 
A relatively simple microbiota profile was detected in cecal and colonic contents of the 
HLA-B27 rats that had been administered the prebiotic preparation (figure 6). Most strikingly, the 
profiles of untreated transgenic rats lacked a DNA fragment originating from Bifidobacterium 




Figure 6. Altered PCR-DGGE profiles result from prebiotic treatment. Specific pathogen-free transgenic rats 
were treated for seven weeks with either water or prebiotics prior to the development of histologic inflammation. 
At necropsy bacterial DNA was extracted from cecal and colonic contents and PCR-DGGE was performed as 
described in the materials and methods section. The gel shows microbiota profiles generated from cecal contents 
derived from water-treated transgenic rats and inulin/oligofructose treated rats. Each lane represents a single 
sample. Arrows indicate 16S rRNA gene fragments originating from Bifidobacterium animalis (>97% identity).  
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12.3 ± 3.4 6.2 ± 1.9 8.2 ± 2.6 88.9 ± 32.8a 24 ± 0.6a 
 
        
 
Table 1. Quantitative bacteriology of cecal contents of HLA-B27 transgenic rats by FISH seven weeks after 
treatment with either water or inulin/oligofructose prior to the development of histologic inflammation. Values 
represent mean ± SEM bacterial counts per gram cecal stool. a P < 0.05 versus untreated group 
 
This suggested that the bifidobacterial population had been influenced by prebiotic 
consumption. This was confirmed by enumeration of Bifidobacteria by FISH (table 1). 
Additionally, FISH analysis showed an increase in Lactobacillus numbers in animals administered 
the prebiotic preparation (table 1). The microbiota profile in colonic contents did not differ from 
that of the cecum (data not shown). 
 
Cecal SCFA concentrations 
Analysis for the SCFA concentrations in the luminal contents of the cecum indicate that 
there were no significant differences between untreated and prebiotic-treated transgenic rats. Total 
cecal SCFA concentrations were 92 ± 17.3 (untreated) and 102 ± 37.7 (prebiotics) µmol/g, and 
consisted primarily of acetate (76 ± 4.9 untreated versus 82 ± 7.6% prebiotics), propionate (15 ± 
3.6 untreated versus 11 ± 5.8% prebiotics), and butyrate (7 ± 1.1 untreated versus 8 ± 3.1% 




Members of the gut microbiota do not induce disease in the normal host, whereas chronic 
intestinal inflammation can develop in the genetically susceptible host in response to the same 
intestinal bacteria.3 Manipulating the gut microbiota might be of importance in order to change 
the natural course of colitis. For example, in several models of experimental colitis, antibiotic 
treatment decreased the amounts of intestinal disease-inducing bacteria and prevented 
inflammation,6,25,32 whereas increased amounts or the addition of certain strains of colonic 
probiotic bacteria could prevent disease.10,11,33 
We showed in the present study that a combination of inulin and oligofructose partially 
prevented intestinal inflammation in specific pathogen-free HLA-B27 transgenic rats. This is the 
first study in which prebiotics were used as primary therapy in genetically susceptible rodents. 
The results are in agreement with findings by Schultz et al in a recent study, which reported that a 
probiotic preparation that also contained inulin attenuated colitis development HLA-B27 rats.34 
Our results also confirmed previous studies in induced models of colitis, in which prebiotic 
treatment resulted in attenuation of colitis. In rats, oral inulin decreased distal colonic lesions in 
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DSS-induced colitis,17 and oral fructo-oligosaccharides decreased TNBS-induced colitis, although 
its effects were apparent only after 14 days of feeding.18 No effects were seen after oral 
administration of trans-galacto-oligosaccharide started before or during TNBS-colitis induction,35 
indicating that not all prebiotic preparations are equally effective in preventing disease. In patients 
with mild to moderate ulcerative colitis, prebiotics such as germinated barley food extracts 
decreased clinical and endoscopic evidence of inflammation in both a small placebo-controlled 
trial as well as in an open-label study.36,37 Inulin administration to ulcerative colitis patients with 
pouchitis after colectomy led to a reduction of inflammation in the pouch mucosa.38 
Changes in the gut microbiota composition, especially growth promotion of beneficial 
bacteria induced by prebiotics, may contribute to colitis prevention.16 In this study we analyzed 
intestinal microbiota changes using molecular techniques such as PCR-DGGE and FISH. Analysis 
of the cecal and colonic microbiota using PCR-DGGE showed alterations to the microbiota 
profile induced by prebiotic treatment in HLA-B27 transgenic rats. Prebiotic administration to 
transgenic rats resulted in the detection of a 16S rRNA gene fragment that was absent in untreated 
transgenic rats. Sequence analysis revealed that this band represented Bifidobacterium animalis. A 
similar microbiotic spectrum in cecal contents of transgenic rats was found by PCR-DGGE after 
feeding probiotics plus inulin.34 Interestingly, in the latter study added probiotic bacteria could not 
be detected, indicating that prebiotic inulin mediated the changes in cecal microflora. Quantitative 
analysis of the cecal and colonic content by FISH in our study confirmed that the prebiotic 
combination significantly increased cecal and colonic Bifidobacteria, but it also showed an 
increased amount of intestinal Lactobacilli, as shown in table 1. Increasing concentrations of 
intestinal probiotic bacteria by oral administration has been effective in experimental colitis as 
well as human IBD.11,13,33 Oral administration of Lactobacilli and Bifidobacteria decreased colitis 
in TNBS-induced colitis and caused similar changes in cecal microbiota composition as those 
induced by fructo-oligosaccharides. Adding Lactobacilli and Bifidobacteria to topical butyrate 
solutions in rats with TNBS-induced colitis was necessary to induce a similar disease 
improvement as shown by oral fructo-oligosaccharides administration, suggesting that the 
increase of protective bacteria mediated the clinical efficacy of prebiotics.18 Feeding germinated 
barley foodstuff to humans also stimulated growth of Bifidobacteria as well as Eubacterium 
species and increased the production of butyrate and other SCFA.39 Thus, increased probiotic 
intestinal bacteria are associated with prevention of colitis in the present study, and might 
(partially) mediate the beneficial effects of prebiotic administration. 
B. vulgatus and possibly other anaerobic bacteria play a pathogenic role in colitis 
development in transgenic rats and in human IBD. This was demonstrated by the induction of 
colitis in transgenic rats.8,20 Moreover, metronidazole attenuated colitis in this model and is an 
effective adjunct therapy in Crohn’s colitis.6,32 Probiotic bacteria are reported to suppress the 
growth of pathogenic intestinal bacteria. For example, Bifidobacterium infantis suppressed growth 
of B. vulgatus.40 Similarly, Bifidobacteria-fermented milk decreased fecal B. vulgatus 
concentrations in ulcerative colitis.41 Inulin and oligofructose also reduced luminal Clostridium 
difficile populations in healthy volunteers, which was associated with a bifidogenic effect.42 
Despite a trend towards a decreased intestinal population of Bacteroides/Prevotella relative to the 
total amount of luminal bacteria after feeding inulin/oligofructose in transgenic rats, this trend did 
not reach statistical significance. We also did not observe any significant differences in the 
amounts of cecal Clostridia-group XIVa between the experimental groups. Taken together, this 
would suggest that prebiotics and/or probiotic Bifidobacteria and Lactobacilli did not mediate 
protection by suppressing the growth of Bacteroides species in transgenic rats. 
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Prebiotics that escape digestion in the upper intestine are important sources of energy for 
cecocolonic bacteria. The end-products of prebiotic fermentation by these organisms lead to the 
production of lactate and SCFA, such as acetate, propionate and butyrate. Changes in SCFA 
production, especially increased luminal butyrate concentrations, can also contribute to down-
regulation of proinflammatory cascades in models of experimental colitis and human 
IBD.17,36,39,43-47 However, we did not detect significant differences in luminal SCFA 
concentrations in prebiotic- versus untreated transgenic rats, indicating that prebiotics did not 
mediate protection by changes in luminal SCFA concentrations. 
A widely accepted hypothesis for the pathogenesis of chronic intestinal inflammation, 
such as IBD, is an overly aggressive TH1 mediated cytokine response to commensal bacteria. We 
recently showed that cecal bacteria induce a proinflammatory cytokine response in colitis-
susceptible transgenic rats, whereas the same bacteria induce anti-inflammatory cytokines, such as 
an increase of IL-10 and TGF-β, in mesenteric lymph nodes and cecal mucosa of disease-tolerant 
non-transgenic littermates.11,19 In our current study we report that cecal bacterial lysate-stimulated 
mesenteric lymph node cells derived from prebiotic-treated transgenic rats produced less IFN-γ 
than those from untreated transgenic rats. Prebiotic treatment also significantly decreased cecal 
IL-1β production, which correlated with less cecal and colonic inflammation. Decreased 
production of mucosal proinflammatory cytokines is in agreement with probiotic treatment studies 
in experimental colitis10,11,33 and refractory pouchitis after colectomy for ulcerative colitis.13 
Of major interest, we report for the first time that prebiotic treatment of transgenic rats 
significantly increased cecal TGF-β. This finding indicates that prebiotics can exert 
immunomodulatory effects, either directly or secondarily through increase of intestinal probiotic 
bacteria. Indeed, probiotics administered to pregnant and lactating mothers increased the amount 
of TGF-β in the breast milk.48 The importance of TGF-β  in immune homeostasis is demonstrated 
by the fact that TGF-β deficient mice die within five weeks of severe multiple organ 
inflammation.49 TGF-β  is also important for the regulation of intestinal inflammation. Colitis 
develops in SCID mice restored with a mixture of CD45RBhi CD4 and CD45RBlow CD4 cells that 
were treated with anti-TGF-β mAb.50 Furthermore, intranasal administration of a TGF-β-
containing plasmid prevented TNBS induced colitis.51 Therefore, increased cecal TGF-β  could 
mediate some of the beneficial effects of prebiotics. 
In conclusion, we showed in HLA-B27 transgenic rats that oral administration of the 
prebiotic combination inulin and oligofructose partially prevents colitis. Protection induced by 
these prebiotics correlated not only with changes in intestinal microbiota towards an increase of 
luminal Bifidobacteria and Lactobacilli, but was also associated with immunomodulatory effects. 
Although prebiotics can mediate protective effects through Bifidobacteria and Lactobacilli, it is 
also possible that prebiotics are beneficial by direct immunosuppressive or immunomodulatory 
effects on the host. These studies suggest that prebiotics may have potential as adjuvant 
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Cytokine profiles in HLA-B27 rats 
Abstract 
Introduction and aims 
Germ-free HLA-B27 transgenic rats do not develop colitis, but colonization with specific 
pathogen-free bacteria induces colitis accompanied by immune activation. To study host-
dependent immune responses to commensal cecal bacteria we investigated cytokine profiles in 
mesenteric lymph node cells from HLA-B27 transgenic versus non-transgenic littermates after in 
vitro stimulation with cecal bacterial lysates. 
 
Methods 
Supernatants from cecal bacterial lysate-stimulated unseparated and T or B cell-depleted 
mesenteric lymph node cells from HLA-B27 transgenic and non-transgenic littermates were 
analyzed for IFN-γ, IL-12, TNF, IL-10 and TGF-β production. 
 
Results 
Our results show that unfractionated transgenic mesenteric lymph node cells stimulated 
with cecal bacterial lysate produced more IFN-γ, IL-12, and TNF than did non-transgenic 
mesenteric lymph node cells. In contrast, cecal bacterial lysate-stimulated non-transgenic 
mesenteric lymph node cells produced more IL-10 and TGF-β. T cell depletion abolished IFN-γ 
and decreased IL-12 production, but did not affect IL-10 and TGF-β production. Conversely, 
neither IL-10 nor TGF-β was produced in cultures of B cell-depleted mesenteric lymph nodes. In 
addition, CD4+ T cells enriched from mesenteric lymph nodes of HLA-B27 transgenic but not 
from non-transgenic rats produced IFN-γ when co-cultured with cecal bacterial lysate-pulsed 
antigen presenting cells from non-transgenic rats. Interestingly, IL-10 and TGF-β, but not IFN-γ, 
IL-12, and TNF were produced by mesenteric lymph node cells from germ-free transgenic rats. 
 
Conclusions 
These results indicate that the colitis that develops in specific pathogen-free HLA-B27 
transgenic rats is accompanied by activation of IFN-γ-producing CD4+ T cells that respond to 
commensal bacteria. However, B cell cytokine production in response to components of 




In recent years several studies have emphasized the role of commensal intestinal bacteria 
in the pathogenesis of experimental chronic immune-mediated intestinal inflammation and human 
IBD. This is most clearly demonstrated in a wide variety of genetically engineered and induced 
rodent models in which the susceptible host develops spontaneous colitis in the presence of non-
pathogenic resident intestinal organisms.1 In most rodent models chronic intestinal inflammation 
is mediated by the TH1 cytokines IL-12 and IFN-γ, while suppression of inflammation is mediated 
by the regulatory cytokines IL-10 and TGF-β. The influence of resident flora on the initiation and 
perpetuation of spontaneous colitis, gastritis and arthritis has been well characterized in HLA-
B27/β2 microglobulin transgenic rats, which develop disease by three months of age when raised 
under specific pathogen-free conditions.2 When raised in a germ-free environment these rats fail 
to develop gastritis, colitis and arthritis.3,4 However, these animals develop colitis and gastritis 
within one month after transfer to a specific pathogen-free environment.3 In this model B. 
vulgatus preferentially induces colitis after monoassociation for one month, with no inflammation 
resulting from E. coli monoassociation.5 The importance of host genetic susceptibility was 
illustrated by the lack of colitis or activation of immune responses in wild-type non-transgenic 
littermates colonized with the same specific pathogen-free bacteria or B. vulgatus.3,5 The role of 
resident intestinal flora in the pathogenesis of colitis in transgenic rats is further emphasized by an 
increase of cecal inflammation after the creation of a blind cecal loop which results in an 
increased bacterial load, including Bacteroides species,6 and studies showing that broad spectrum 
antibiotics can prevent as well as treat colitis.7 In other experimental models of colitis, similar 
findings have been reported.8-9 
Although these observations suggest a central role for normal luminal bacteria in the 
induction and perpetuation of immune-mediated colitis in this model, the mechanisms by which 
bacteria activate immune cells responsible for the development of colitis remain unclear. The aim 
of our study was to investigate cytokine responses induced in HLA-B27 transgenic rats and their 
non-transgenic littermates by commensal enteric bacteria and their products. We show that lysates 
of cecal contents induce mesenteric lymph node cells to produce an array of cytokines. Mesenteric 
lymph node CD4+ cells from transgenic rats, but not from non-transgenic rats, produce IFN-γ, 
which is dependent on in vivo bacterial colonization. Both transgenic and non-transgenic 
mesenteric lymph node B cells produce IL-10 and TGF-β. The production of these two regulatory 
cytokines is independent of prior bacterial colonization. 
 
 
Materials and methods 
Animals 
HLA-B27 transgenic rats (the 33-3 line on the F344 background) and their non-transgenic 
littermates, originally obtained from Dr. Joel D. Taurog, University of Texas Southwestern 
Medical Center, were maintained in specific pathogen-free housing conditions at the University of 
North Carolina, Chapel Hill or in germ-free conditions in the Gnotobiotic Animal Core of the 
Center for Gastrointestinal Biology and Disease at the College of Veterinary Medicine, NC State 
University in Raleigh, NC. Presence or absence of the HLA-B27 transgene was determined by 
PCR using DNA isolated from tail clippings. Rats between the ages of four and six months were 
used for our studies. All studies were approved by University of North Carolina at Chapel Hill 
Institutional Animal Care and Use Committee. 
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Histology 
Colons and ceca were fixed and stained as previously described.3 A validated histologic 
inflammatory score ranging from 0 to 4 was used for blinded evaluation.3 
 
Preparation of mesenteric lymph node cells and enrichment of lymphoid cell 
subpopulations 
Mesenteric lymph nodes were removed from HLA-B27 transgenic and non-transgenic 
rats, and single cell suspensions were prepared by gentle teasing. Magnetic bead separation, using 
antibody coated microbeads and columns designed for cell depletion (Miltenyi Biotec, Auburn, 
CA) was performed according to the manufacturer's instructions using the following reagents: LD 
columns; Rat Pan T Cell Microbeads, clone OX-52, for T cell depletion; Rat CD45RA, clone OX-
33, for B cell depletion; Rat CD4 Microbeads, clone OX-38, for CD4+ cell depletion; Rat CD8a 
Microbeads, clone G38, for CD8+ cell depletion; and Rat CD45RA plus Rat CD8a Microbeads to 
enrich CD4+ cells. 
 
Preparation of cecal bacterial lysates 
Cecal bacterial lysates were prepared as described by Cong et al.10 Briefly, cecal contents 
from several non-transgenic or transgenic rats were solubilized by vortexing in RPMI, and 
incubated with 10 µg/ml DNA-ase, 0.01 M magnesium chloride and then homogenized for 3 
minutes using 0.1 mm glass beads in a Mini-Bead Beater (Biospec Products, Bartlesville, OK). 
After centrifuging at 10,000g for 10 min the supernatant was filtered through a 0.45 µm syringe 
filter. Sterility was confirmed by aerobic and anaerobic culture. 
 
Mesenteric lymph node cell cultures 
Either unseparated mesenteric lymph node cells, or cell subpopulations obtained after 
antibody-coated magnetic bead depletion, were washed and 4x105 cells were cultured in 96 well 
flat bottom microplates (Costar 3595), in 0.2 ml complete medium (RPMI 1640 plus 5% heat 
inactivated fetal calf serum, 2 mM L-glutamine, 1 mM sodium pyruvate, 5x10-5 M 2-
mecaptoethanol, and 50 µg/ml gentamicin) for three days, which we found to be optimal for 
detection of all of the cytokines measured with the exception of TGF-β. Similar relative 
differences in cytokines produced by transgenic versus non-transgenic mesenteric lymph node 
cells were present at each time point between 12 hours and six days. For analysis of TGF-β 
production, 8x105 cells were cultured for five days in serum-free RPMI which was supplemented 
with 1% Nutridoma-SP (Roche Molecular Biochemicals, Mannheim, Germany). Higher levels of 
TGF-β were consistently found in supernatants of day five compared to day three cultures. Cells 
were stimulated with different concentrations of cecal bacterial lysate as indicated for each 
experiment. Culture supernatants were collected and stored at –20°C. 
 
Preparation of antigen-presenting cells and co-cultures with CD4+ cells 
We used T-cell depleted mesenteric lymph node cells from non-transgenic rats for 
antigen-presenting cells. T cells were lysed using IgM anti-rat CD3 (clone 1F4, Pharmingen, San 
Diego, CA), followed by incubation with rabbit complement (normal rabbit serum prepared in this 
laboratory). The cells remaining after complement-mediated lysis of CD3+ cells were >95% 
surface Ig positive, <2% CD4 positive and <2% CD8 positive. The cells were pulsed overnight 
with cecal bacterial lysate from non-transgenic rats (100 µg/ml) or with unrelated protein antigen 
keyhole limpet hemocyanin (KLH; Pierce, Rockford, IL) in complete medium. The pulsed 
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antigen-presenting cells were then washed to remove excess antigens and other bacterial products. 
Magnetic bead-enriched CD4+ cells, 2x105 per well, were stimulated with antigen-pulsed antigen-
presenting cells, 3x105 per well. Supernatants were harvested after 3 days and stored at -20°C. 
 
Flow cytometry 
Mesenteric lymph node cells before and after magnetic bead separation were evaluated by 
flow cytometry using the following fluorochrome labeled or unlabeled reagents. For detection of 
HLA-B27-expressing cells, we used culture supernatant from the murine hybridoma, designated 
ME-1, obtained from ATCC (Rockville, MD), followed by FITC labeled goat anti-mouse IgG (γ 
chain specific) antibody (Southern Biotechnology, Birmingham, AL). For surface 
immunoglobulin positive B cells, we used FITC labeled goat anti-rat IgG (H + L) antibody 
(Kirkegaard & Perry Laboratories, Gaithersburg, MD). For CD4+ and CD8+ cells we used PE-
anti-CD4 monoclonal antibody (clone W3/25) and FITC anti-CD8 monoclonal antibody (clone 
OX-8), (Caltag, Burlingame, CA) respectively. 
 
Cytokine and PGE2 measurements 
Cytokines in cell culture supernatants were measured by ELISA using unlabeled capture 
antibodies and biotin-labeled detection antibodies, followed by horse-radish peroxidase labeled 
Streptavidin. The concentration of each cytokine was determined by comparison to a standard 
curve generated using recombinant proteins. For IFN-γ, we used unlabeled polyclonal anti-IFN-γ 
antibody and biotin-labeled monoclonal anti-IFN-γ antibody (clone DB-1) (Biosource 
International, Camarillo, CA). For IL-10 we used unlabeled monoclonal anti-rat IL-10 antibody 
(clone A5-7) and biotin-labeled monoclonal anti-rat IL-10 antibody (clone A5-6) (BD Biosciences 
Pharmingen, San Diego, CA). For IL-12 we used a rat IL-12 p40 CytoSet (Biosource 
International). For TNF we used a rat TNF BD OptEIA ELISA Set (BD Biosciences Pharmingen). 
TGF-β concentrations were measured after acidification and neutralization according to the 
manufacturer using a TGF-β1 specific ELISA (Promega, Madison, WI). PGE2 was measured 
using a competitive immunoassay Correlate-EIA (Assay Designs Inc., Ann Arbor MI). 
 
Cytokine mRNA expression in cecal tissues 
Total RNA was extracted from cecal tissue using a standard technique as described 
previously.11 One microgram of RNA isolated from each sample was reverse transcribed, and the 
cDNA (1 - 2 µg) was then amplified using primers specific for rat cytokines.11-16 Negative 
controls without cDNA were included in each experiment. Aliquots of all samples were analyzed 
by electrophoresis on 2% agarose gel containing GelStar (BioWhittaker). The size of the PCR 
product was compared to the predicted size using a 100 bp DNA ladder (Gibco BRL, Grand 
Island, NY). The DNA products were visualized by ultraviolet fluorescence and photographed 
(Polaroid 665, Polaroid Corp, Cambridge, MA). The cytokine mRNA was quantified by 
densitometry, and the ratio to β-actin mRNA was calculated.  
 
Statistical analysis 
Cytokine levels are expressed as mean ± standard deviation of triplicate measurements. A 
non-paired Student t-test or alternate Welch t-test was used, in which a two-tailed p value of < 
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Results 
Evaluation of colitis and of lymphoid cell subpopulations in mesenteric lymph 
nodes of specific pathogen-free and of germ-free transgenic and non-transgenic 
rats 
Transgenic rats housed in specific pathogen-free conditions showed significant gross and 
histologic evidence of colitis of the entire colon and cecum, with over 95% of the transgenic rats 
demonstrating histology scores higher than 3.0 on a 0-4 scale. In contrast, their non-transgenic 
littermates exposed to the same microflora did not develop colitis, nor did germ-free transgenic or 
non-transgenic rats exhibit any disease (figure 1). 
Specific pathogen-free transgenic rats with colitis had larger mesenteric lymph nodes, 
containing over 3-fold more cells, than did mesenteric lymph nodes of their non-transgenic 
littermates (table 1). Mesenteric lymph nodes from specific pathogen-free transgenic rats 
contained a significantly higher percentage and total number of CD4+ T cells than non-transgenic 
mesenteric lymph node (table 1). The percentage of CD8+ T cells and of B cells was lower in 
transgenic versus non-transgenic mesenteric lymph nodes. However, due to the higher number of 
total mesenteric lymph node cells, transgenic mesenteric lymph nodes contained significantly 
more CD8+ cells and B cells than did mesenteric lymph nodes of non-transgenic littermates. 
Mesenteric lymph nodes of germ-free rats were small and contained much lower cell 
numbers than mesenteric lymph nodes of specific pathogen-free rats. The total number of 
mesenteric lymph node cells was not significantly different between germ-free transgenic and 
germ-free non-transgenic rats. Mesenteric lymph nodes from germ-free transgenic rats contained 
higher proportions and higher total numbers of CD4+ cells but lower proportions and fewer total 
numbers of B cells compared to mesenteric lymph nodes of non-transgenic littermates, whereas 
the percentages and numbers of CD8+  cells were similar (table 1). All animals identified as HLA-
B27 transgenic by PCR analysis of tail DNA also expressed HLA-B27 on mesenteric lymph node 






Figure 1. Representative photomicrographs of tissue sections (x40) from ceca of five to six month old (A) germ-
free non-transgenic; (B) germ-free transgenic; (C) specific pathogen-free non-transgenic; (D) specific pathogen-
free transgenic rats. Note the extensive mucosal and submucosal inflammation as well as significant crypt 
hyperplasia in the cecum from a specific pathogen-free transgenic rat (D), whereas no colitis was present in cecal 
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  Specific Pathogen-Free Germ-Free  
  Non-Transgenic Transgenic Non-Transgenic Transgenic  
  n=15 n=15 n=16 n=12  
 Total Cells 
(x 106) 87.6 ± 6.2 279.8 ± 22.7 a 41.8 ± 4.8 41.7 ± 5.5 
 
      
 Percent     
 CD4+ 40.3 ± 0.9 56.2 ± 1.1a 28.1 ± 1.4 42.2 ± 1.9a  
 CD8+ 16.7 ± 0.6 13.4 ± 0.5c 11.9 ± 0.8 13.5 ± 0.6  
 Surface Ig 36.4 ± 1.8 24.9 ± 1.2a 51.3 ± 2.7 38.7 ± 2.1b  
      
 Cells x 106     
 CD4+ 35.5 ± 2.9 155.6 ± 11.9a 11.4 ± 1.1 17.7 ± 2.7b  
 CD8+ 14.7 ± 1.2 37.6 ± 3.5a 5.0 ± 0.7 5.8 ± 1.0  
 Surface Ig 31.9 ± 2.7 70.3 ± 6.8a 22.2 ± 3.4 16.0 ± 2.1  
     
 
Table 1. Cell numbers and cell subpopulations in mesenteric lymph nodes of specific pathogen-free and germ-
free HLA-B27 transgenic rats and their non-transgenic littermates. Values represent mean ± SEM of cell 
numbers or of percentages of the different lymphoid cell subpopulations. a p<0.001, b p <0.01, c p <0.05 versus 
non-transgenic littermates.  
 
Cytokine production in unseparated mesenteric lymph node cells from specific 
pathogen-free transgenic versus non-transgenic rats 
Unseparated transgenic mesenteric lymph node cells, stimulated in vitro with 100 µg/ml 
cecal bacterial lysate produced significantly more IFN-γ, IL-12, and TNF compared to mesenteric 
lymph node cells from non-transgenic rats (figures 2A, B, and C). In contrast, non-transgenic 
mesenteric lymph node cells stimulated with 10 µg/ml cecal bacterial lysate produced 
significantly more IL-10 than transgenic mesenteric lymph node cells (figure 2D). TGF-β 
production by mesenteric lymph node cells followed the same trend as IL-10 after 10 µg/ml and 
also 100 µg/ml cecal bacterial lysate stimulation; non-transgenic unseparated mesenteric lymph 
node cells produced significantly more TGF-β than those from transgenic littermates (figure 2E). 
PGE2 concentrations did not differ significantly in cecal bacterial lysate stimulated mesenteric 
lymph node cell cultures from transgenic versus non-transgenic rats (data not shown). 
Stimulation with cecal bacterial lysate obtained from either transgenic rats or from non-
transgenic rats showed the same pattern; both lysates induce more IFN-γ, IL-12, and TNF, and 
less IL-10 and TGF-β in mesenteric lymph node cell cultures of transgenic compared to non-
transgenic rats (data not shown). In five separate experiments, we did not observe consistent 
differences in cytokine levels induced by bacterial lysates from either transgenic or from non-
transgenic rats. Therefore, we chose to use cecal bacterial lysate from non-transgenic rats for the 
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Figure 2. Cytokine levels in supernatants of unseparated mesenteric lymph node cell cultures from five month 
old specific pathogen-free non-transgenic or transgenic rats after stimulation with various concentrations of cecal 
bacterial lysate (in µg/ml) from non-transgenic rats. (A) IFN-γ; (B) IL-12 (p40); (C) TNF; (D) IL-10; (E) TGF-β. 
Data shown are from a representative experiment out of two to seven separate experiments. Cytokines levels are 
expressed in ng/ml. Values represent the mean and standard deviations of each cytokine detected in triplicate 
supernatants.   ** p< 0.01 versus non-transgenic mesenteric lymph node cell supernatants, * p< 0.05 versus non-
transgenic mesenteric lymph node cell supernatants. Non-TG, non-transgenic; TG, transgenic. 
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Cecal cytokine mRNA expression in specific pathogen-free transgenic versus non-
transgenic rats 
The mRNA expression of proinflammatory cytokines was significantly higher in cecal 
tissues from transgenic compared to non-transgenic rats (figure 3). The cytokine/β-actin ratios for 
IL-1β, IFN-γ as well as for IL-12 were significantly higher in transgenic rats compared to non-
transgenic littermates. Consistent with results from cecal bacterial lysate-stimulated unseparated 
mesenteric lymph node cell cultures, cecal IL-10 mRNA expression was significantly higher in 
non-transgenic versus transgenic rats. However, cecal mRNA expression for TGF-β did not differ 































Figure 3. Expression of IFN-γ, IL-12, IL-10, TGF-β and IL-1β mRNA in cecal tissues from specific pathogen-
free transgenic rats and their non-transgenic littermates. Total RNA was reverse transcribed and amplified for 
various cycles by the polymerase chain reaction. Cytokine and β-actin mRNA expression was evaluated in eight 
non-transgenic and six transgenic rats. Tissue from each individual animal was analyzed separately. The results 
shown represent the averages of the ratios of specific cytokine versus β-actin mRNA obtained in two to three 
separate experiments.  
** p< 0.01 versus non-transgenic cecal tissue, * p< 0.05 versus non-transgenic cecal tissue. 
Non-TG, non-transgenic; TG, transgenic. 
 
Cytokine production in mesenteric lymph node cells from germ-free transgenic 
versus non-transgenic rats 
 Cecal bacterial lysate stimulation of mesenteric lymph node cells from germ-free rats did 
not induce IFN-γ, IL-12 or TNF production compared to unstimulated levels (data not shown), 
indicating that production of these cytokines in transgenic rats depends on in vivo exposure to 
commensal bacteria and their products. In contrast, mesenteric lymph node cells from both 
transgenic and non-transgenic germ-free rats produced IL-10 and TGF-β after stimulation with 
bacterial lysate (figure 4), indicating that these two cytokines can be produced by naive cells 
independent of in vivo exposure to commensal intestinal microorganisms.  
 As in specific pathogen-free rats, IL-10 detected in the supernatants of mesenteric lymph 
node cell cultures from germ-free non-transgenic rats was significantly more than that from germ-
free transgenic rats after stimulation with 1 µg/ml and with 10 µg/ml cecal lysate (figure 4A). 
After stimulation with the optimal dose of 100 µg/ml, germ-free non-transgenic mesenteric lymph 
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node cells produced almost twice as much TGF-β compared to germ-free transgenic mesenteric 
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Figure 4. Cytokine levels in supernatants of unseparated mesenteric lymph node cell cultures from four to five 
month old germ-free non-transgenic or transgenic rats after stimulation with various concentrations of cecal 
bacterial lysates (in µg/ml) from non-transgenic rats. (A) IL-10; (B) TGF-β. Data shown are from a 
representative experiment out of five (IL-10) or two (TGF-β) separate experiments. Cytokines levels are 
expressed in ng/ml. Values represent the mean and standard deviations of each cytokine detected in triplicate 
supernatants. ** p< 0.01 versus non-transgenic mesenteric lymph node cell supernatants, * p< 0.05 versus non-
transgenic mesenteric lymph node cell supernatants. 
 
Cytokine production in mesenteric lymph node cells after T cell or B cell 
depletion or in co-cultures of CD4 cells plus antigen-pulsed antigen-presenting 
cells 
To determine which cell type(s) are critical to the production of the cytokines that we 
evaluated, we carried out negative selection to deplete T cells or B cells from mesenteric lymph 
node cell preparations. After T cell depletion less than 2.5% of the total remaining cells were 
CD4+/CD8+, as determined by flow cytometry. Approximately 97% of the T cell-depleted 
mesenteric lymph node cells were positive for surface Ig, which is characteristic of B cells. In 
response to 100 µg/ml of cecal bacterial lysate, T cell-depleted mesenteric lymph node cells from 
transgenic rats did not produce IFN-γ (figure 5A). IFN-γ production was dramatically reduced but 
not absent in cultures of B cell-depleted mesenteric lymph node cells. CD4+ cell depletion of 
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mesenteric lymph node cells, with less than 0.5 % remaining CD4+ cells, significantly reduced 
IFN-γ production to the same degree as T cell depletion (figure 5B). In contrast, CD8+ cell 
depletion of mesenteric lymph node cells, with less than 0.5% CD8+ cells, had no effect on IFN-γ 
production after bacterial lysate stimulation (figure 5B). 
IL-12 production was significantly reduced after T cell depletion in transgenic mesenteric 
lymph node cells in response to 100 µg/ml cecal bacterial lysate (figure 5C). Supernatants of B 
cell-depleted mesenteric lymph node cell cultures contained slightly more IL-12 than did 
supernatants of unseparated mesenteric lymph node cell cultures. 
To more precisely evaluate CD4+ T cell responses to cecal bacterial lysate, we co-cultured 
CD4-enriched mesenteric lymph node cells with cecal bacterial lysate pulsed antigen-presenting 
cells. As shown in figure 6, CD4+ cells from transgenic but not from non-transgenic mesenteric 
lymph nodes produced high amounts of IFN-γ in co-culture with cecal bacterial lysate pulsed 
antigen-presenting cells. Interestingly, the in vitro response is not dependent on antigen 
presentation via the HLA-B27 molecule because CD4+ cells from transgenic rats respond to 
antigen-pulsed non-transgenic antigen-presenting cells. Further studies focusing on the potential 
differences between antigen-presenting cells from transgenic and from non-transgenic rats to 
present bacterial antigens are in progress. 
In contrast to IFN-γ and IL-12, supernatants of cecal bacterial lysate stimulated T cell-
depleted mesenteric lymph node cells contained equivalent or greater amounts of IL-10 and TGF-
β compared to supernatants of unseparated mesenteric lymph node cells, indicating that these two 
cytokines are not produced by T cells (figure 7). Moreover, the levels of IL-10 and TGF-β in 
supernatants of B cell depleted mesenteric lymph node were even lower than amounts in 
supernatants of unstimulated cells, indicating that B cells either produce the majority of the IL-10 
and TGF-β or that B cells are essential to their production (figure 7). 
As also shown in figure 7, IL-10 and TGF-β levels were lower in supernatants of T cell-
depleted transgenic compared to non-transgenic mesenteric lymph node cells after cecal bacterial 
lysate stimulation. In a total of seven separate experiments, there is a trend towards production of 
lower amounts of IL-10 by T cell-depleted transgenic mesenteric lymph node cells compared to 
non-transgenic cells (ratio IL-10 transgenic:IL-10 non-transgenic = 0.78 ± 0.06). These results 
suggest that there is only a marginal difference between the abilities of transgenic and non-
transgenic mesenteric lymph node cells to produce IL-10 in response to commensal bacteria and 
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Figure 5. Cytokine levels in mesenteric lymph node cell cultures from four to five month old specific pathogen-
free transgenic rats. (A, B) IFN-γ and (C) IL-12 production by transgenic mesenteric lymph node cells which 
were either unseparated, T cell depleted, CD4+ cell depleted, CD8+ cell depleted or B cell depleted, then 
stimulated with 100 µg/ml cecal bacterial lysate from non-transgenic rats. Cytokine levels are expressed in 
ng/ml. Values represent the mean and standard deviations of each cytokine detected in triplicate supernatants and 
are representative of three separate experiments. **p< 0.01 versus unseparated mesenteric lymph node cell 
supernatants. 
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Figure 6. IFN-γ production by CD4+ mesenteric lymph node T cells in co-culture with cecal bacterial lysate-
pulsed antigen-presenting cells. CD4+ T cells were enriched from mesenteric lymph nodes of specific pathogen-
free transgenic or non-transgenic rats and stimulated for three days with either cecal bacterial lysate-pulsed or 
KLH-pulsed antigen-presenting cells prepared from mesenteric lymph nodes of non-transgenic rats as described 
in Materials and Methods. Cecal bacterial lysate-pulsed antigen-presenting cells alone do not produce detectable 
amounts of IFN-γ. Values represent the mean and standard deviation of IFN-γ in triplicate culture supernatants 
and are representative of six separate experiments. ***p<0.005 versus IFN-γ in supernatants of transgenic CD4+ 
mesenteric lymph node cells in co-culture with KLH-pulsed antigen-presenting cells and versus IFN-γ in 
supernatants of non-transgenic CD4+ mesenteric lymph node cells in co-culture with cecal bacterial lysate-pulsed 




We evaluated in vitro responses of mesenteric lymph node cells to physiologically 
relevant components of luminal contents, since mesenteric lymph nodes drain the diseased 
cecum and proximal colon in specific pathogen-free HLA-B27 transgenic rats. For these 
studies, we prepared lysates of cecal contents as described by Cong et al,10 rather than 
attempting to culture intestinal bacteria for the following reasons: 1) the lysates contain 
bacterial products that are present at the site of maximal inflammation, 2) not all enteric 
bacteria can be cultured, and 3) culturing can change bacterial antigen expression. 
 We showed that cecal bacterial lysate can stimulate significantly higher amounts of 
those cytokines generally associated with TH1 responses including IFN-γ, IL-12 and TNF 
from unseparated mesenteric lymph node cells collected from specific pathogen-free 
transgenic rats than from non-transgenic littermates. These results correlated with cecal 
mRNA expression of the same cytokines in colitic specific pathogen-free transgenic rats, 
which is in agreement with and extends a previous report by Rath et al.3 We therefore 
conclude that in vitro production of proinflammatory cytokines by draining mesenteric lymph 
node cells stimulated with commensal cecal bacterial lysates correlates with mucosal cytokine 
responses in the diseased cecum. These results, and our failure to detect IFN-γ, IL-12 or TNF 
in cultures of mesenteric lymph node cells from germ-free transgenic rats, indicate that cecal 
bacteria and their products can induce these proinflammatory cytokines in mesenteric lymph 






Figure 7. Cytokine levels in mesenteric lymph node cell cultures from four to five month old specific pathogen-
free non-transgenic and transgenic rats. (A) IL-10 and (B) TGF-β production by mesenteric lymph node cells 
which were either unseparated, T cell depleted, or B cell depleted, then stimulated with 10 µg/ml of cecal 
bacterial lysate from non-transgenic rats. Cytokine levels are expressed in ng/ml. Values represent the mean and 
standard deviations of each cytokine detected in triplicate supernatants and are representative of seven (IL-10) or 
three (TGF-β) separate experiments. ** p< 0.01 versus unseparated mesenteric lymph node cell supernatants. 
Non-TG, non-transgenic; TG, transgenic. 
 
T cell-depletion in our studies resulted in complete loss of IFN-γ responses by mesenteric 
lymph node cells from transgenic rats. Furthermore, CD4 T cell depletion of transgenic 
mesenteric lymph node cells abrogated IFN-γ production, whereas CD8+ cell depletion had no 
effect. In addition, CD4+-enriched mesenteric lymph node cells from transgenic but not from non-
transgenic rats produced IFN-γ after stimulation with cecal bacterial lysate pulsed antigen-
presenting cells. Combined, these results indicate that cecal bacteria and their products stimulate 
mesenteric lymph node-derived CD4 T cells to produce IFN-γ in specific pathogen-free transgenic 
rats. The disease-inducing capacity of these CD4 T cells was demonstrated by the ability of lymph 
node-derived CD4+ cells from colitic specific pathogen-free transgenic donor rats to transfer 
colitis into specific pathogen-free nude transgenic recipients, which do not develop disease in the 
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Cytokine profiles in HLA-B27 rats 
CD8+, not CD4+ T cells. However, CD8+ T cells were not essential to the pathogenesis of colitis 
in HLA-B27 transgenic rats.18  
 While the role of the HLA-B27 molecule in development of inflammatory diseases has 
not been identified, a variety of plausible explanations have been proposed, based on the ability of 
HLA-B27 to activate CD4+ T cells. Recent reports described CD4+ T cells that recognized 
unusual forms of HLA-B27, such as heterodimers that lack an associated peptide, altered three 
dimensional structure of HLA-B27, or HLA-B27 homodimers.19 HLA-B27 homodimers that are 
capable of binding peptide and thus taking on MHC class II-like conformation have been 
identified.20 Moreover, MHC class I-restricted CD4+ T cells derived from MHC class II–deficient 
mice induced colitis in congenic immunodeficient mice.21 Any or all of the proposed mechanisms 
could explain the link between HLA-B27 expression and development of inflammatory disease in 
the transgenic rat model that we have employed. 
Interestingly, in our studies, IFN-γ production by transgenic mesenteric lymph node cells 
was significantly reduced after B cell depletion, indicating either that B cells provide help for 
IFN-γ production by mesenteric lymph node-derived CD4 T cells through antigen-presenting cell 
activity or, less likely, that these cells produce IFN-γ. In a comprehensive analysis reported by 
Harris et al, B cells, like T cells, could be divided into subsets (designated Be1 and Be2).22 Be1 
cells, but not Be2 cells produce IFN-γ. In addition, different B cell subsets have the capacity to 
influence cytokine production by CD4+ T cell subsets.22 Furthermore, lower levels of IFN-γ were 
detected in spleen cell cultures of LCMV-infected B cell deficient mice compared to B cell replete 
mice after in vitro antigen stimulation.23 
IL-12 production in response to the optimal concentration of cecal bacterial lysate was 
reduced by 80% in T cell-depleted mesenteric lymph node cell cultures, indicating that IL-12 
production is T cell-dependent. Although IL-12 is mainly produced by antigen-presenting cells 
such as macrophages and dendritic cells, activated T cells can stimulate IL-12 production by 
antigen-presenting cells.24 
IFN-γ, IL-12 and TNF were produced by cecal bacterial lysate-stimulated transgenic 
mesenteric lymph node cells, but not by non-transgenic mesenteric lymph node cells. In addition, 
N-γ, IL-12 and TNF were not detected in supernatants of lysate-stimulated mesenteric lymph 
d 
-β relative to their transgenic littermates, whereas the 
production of another immunoregulatory molecule, PGE2, was not significantly different in 
superna
IF
node cell cultures from germ-free rats. Thus, the production of these three cytokines is dependent 
both on the genetic susceptibility of the host and on prior in vivo stimulation by commensal 
intestinal bacteria or the presence of colonic inflammation. 
Of potential relevance to immunoregulation, we observed that cecal bacterial lysate-
stimulated unseparated mesenteric lymph node cells from non-transgenic rats produce
significantly more IL-10 and TGF
tants from lysate-stimulated transgenic and non-transgenic mesenteric lymph node cells. 
IL-10 is an immunoregulatory cytokine, produced by TR1 and also by B cells and dendritic cells, 
with the ability to prevent the development of colitis. IL-10 inhibits antigen-specific proliferation 
and cytokine production by TH1 lymphocytes and has downregulatory effects on antigen-
presenting cells such as suppression of macrophage activation and IL-12 production.25-27 The 
important anti-inflammatory effect of IL-10 is demonstrated by the observation that severe 
inflammatory disease develops in IL-10-/- mice. The role of commensal bacteria in this model is 
underscored by the observation that germ-free IL-10-/- mice do not develop colitis.28-29 IL-12 and 
IFN-γ production in response to in vitro LPS stimulation is elevated in spleen cells from IL-10-/- 
compared to wild-type control mice.30 Several in vivo studies have shown that parenteral 
administration of IL-10 or IL-10-producing T cells could prevent colitis in models of chronic 
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intestinal inflammation.31-35 However, parenterally administered recombinant IL-10 appeared to 
have limited capacity to reverse
lo ucosal delivery of IL-10 by genetically engineered Lactococcus lactis or by adenoviral 
vectors encoding IL-10 was able to reverse colitis in IL-10-/- mice and DSS-induced colitis.37-38 
TGF-β is another immunoregulatory molecule, which is produced by antigen-presenting 
cells and by TH3/TR1 lymphocytes, whereas TGF-β receptors are expressed on a variety of cells.39 
Of significant interest, we show here that cecal bacterial lysate-stimulated B cells, but not T cells, 
produce IL-10 and TGF-β. The importance of TGF-β in immune homeostasis is demonstrated by 
the fact that TGF-β deficient mice die within five weeks of severe multiple organ inflammation.40 
CD4+ CD25+ T cells exert immunosuppression by a cell-cell interaction involving cell surface 
TGF-β.41 TGF-β is important for the regulation of intestinal inflammation. Intranasal 
administration of a TGF-β-containing plasmid pre
 established experimental colitis11 or human Crohn’s disease.36 A 
cal m
vented TNBS-induced colitis.42 
cells. Also, transfer of B cells from IL-10/TCRα double 
deficien
enic rats, housed in either specific pathogen-free or germ-free 
conditio
oduction in our studies are not defined 
but are 
Our results show that the levels of IL-10 and TGF-β in supernatants of unseparated 
mesenteric lymph node cell cultures from either germ-free or specific pathogen-free rats 
correlated with the percentage of B cells, and that neither IL-10 nor TGF-β were detected in B 
cell-depleted mesenteric lymph node cell cultures. B cells display several immune functions, such 
as production of immunoglobulins and cytokines, presentation of antigens, and potentiation of T 
cell responses.19,43 B cells also have immunoregulatory functions,44-46 and murine B-1 B cells have 
been shown to produce IL-10 after LPS stimulation.47 Mizoguchi et al48 demonstrated that IL-10-
producing B cells are protective, since B cell/TCRα double deficient mice had more colitis than 
TCRα deficient mice with competent B 
t mice was unable to suppress chronic intestinal inflammation in B cell/TCRα double 
deficient mice.48 Similarly, specific pathogen-free Gαi2-/- mice that develop colitis lack IL-10 
producing B cells.49 IL-10-producing B cells can also prevent arthritis.50 
In our study mesenteric lymph node-derived B cells also produce TGF-β in both 
transgenic and non-transg
ns. Earlier studies have shown that normal B cells can produce TGF-β, which limits their 
own clonal expansion and differentiation.51 An immunoregulatory function of TGF-β-producing B 
cells was shown by Tian et al in a murine model of autoimmune diabetes in which activated B 
cells produced TGF-β.52 These B cells induced apoptosis of lymphocytes and prevented the 
development of autoimmune responses after co-transfer of B cells with disease-inducing T cells. 
The bacterial components that stimulate cytokine pr
likely to be extremely heterogeneous, including LPS and PG-PS complexes that stimulate 
polyclonal responses by T cells and B cells as well as bacterial antigens that induce antigen-
specific responses. While we have not identified the nature of the components that induce the 
responses evaluated here, we predict that bacterial products activate B cells in a polyclonal 
fashion via TLR as has been demonstrated.53 In support of this view, we have found that LPS 
induces IL-10 and TGF-β, but not IFN-γ, in mesenteric lymph node cell cultures from transgenic 
and non-transgenic rats (data not shown). In addition, we propose that bacterial antigens, 
presented by antigen-presenting cells in vitro, restimulate T cells that have previously responded, 
in vivo, to the same bacterial antigens. A future direction of these studies is to further identify the 
effects of the different components of bacterial lysates. 
In summary, our study indicates that mesenteric lymph node cells produce an array of 
cytokines in response to in vitro stimulation with normal, physiologically relevant cecal bacteria 
and their products. CD4+ mesenteric lymph node cells from colitis-susceptible HLA-B27 
transgenic rats, maintained in specific pathogen-free conditions, produce cytokines that are found 
in association with TH1 immune responses. B cells, from both HLA-B27 transgenic rats and their 
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non-transgenic littermates, maintained in specific pathogen-free or germ-free conditions, produce 
IL-10 and TGF-β, cytokines that are often associated with protective immune response. Thus, our 
results reveal the diversity of responses of T cells and of B cells that can be activated by 
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B. vulgatus-induced colitis in HLA-B27 rats 
Abstract 
Introduction and aims 
HLA-B27/β2 microglobulin transgenic rats develop spontaneous colitis when raised under 
specific pathogen-free conditions, whereas transgenic rats maintained under germ-free housing 
conditions fail to develop intestinal inflammation. Specific pathogen-free HLA-B27 transgenic 
rnu/rnu rats, which are congenitally athymic, remain disease-free in the absence of T 
lymphocytes. Taken together these results indicate that commensal intestinal bacteria and T cells 
are pivotal for the development of colitis in transgenic rats. Gnotobiotic transgenic rats 
monoassociated with B. vulgatus develop colitis. However, it is not known if T cells are also 
required in the induction of colitis by a single bacterial strain, such as B. vulgatus. The aim of this 
study was therefore to investigate the role of T cells in the development of colitis in B. vulgatus-
monoassociated HLA-B27 transgenic rats. 
 
Methods 
HLA-B27 transgenic rnu/rnu and rnu/+ rats where monoassociated with B. vulgatus for 8-
12 weeks. CD4+ T cells from mesenteric lymph nodes of B. vulgatus monoassociated rnu/+ 
transgenic donor rats were transferred into B. vulgatus monoassociated rnu/rnu transgenic 
recipients. Mesenteric lymph node cells were collected and stimulated in vitro with B. vulgatus. 
Cecal and colonic tissue was collected for histology, MPO and cytokine analysis. 
 
Results 
B. vulgatus monoassociated rnu/+ rats showed higher histologic inflammatory scores and 
elevated cecal and colonic IFN-γ mRNA, MPO, and cecal IL-1β levels, compared to rnu/rnu 
transgenic rats which did not contain T cells. After transfer of CD4+ cells from colitic B. vulgatus 
monoassociated rnu/+ transgenic donor rats into B. vulgatus monoassociated rnu/rnu transgenic 
recipients, colitis developed that was accompanied by B. vulgatus-induced IFN-γ responses by 
mesenteric lymph node cells and inflammatory parameters similar to rnu/+ transgenic rats. 
 
Conclusions 
These results show that T cells are required, and CD4+ cells are sufficient, for the 
development of colitis in HLA-B27 transgenic rats monoassociated with the non-pathogenic 




f commensal intestinal bacteria in the pathogenesis of experimental 
colitis 
fail to develop intestinal inflammation and arthritis 
whereas colitis and gastritis develop within one month after transfer to a specific pathogen-free 
t.4,5 Although the results of numerous studies have been reported, the mechanisms 
underly
nu/+ transgenic 
littermates coincides with development of colitis under specific pathogen-free conditions.6 The 
le for T cells in inducing intestinal inflammation in this model was further emphasized 
by the 
m our 
laboratory have previously shown that monoassociation of HLA-B27 transgenic rats with B. 
-negative non-pathogenic microorganism, leads to induction and perpetuation of 
colitis i
. coli isolated from a Crohn's disease patient.7 The ability of B. 
vulgatus to induce colitis was first described using carrageenan-fed guinea pigs as the model 
system.8 Furthermore, Bacteroides species were identified among the bacteria that preferentially 
expanded in HLA-B27 transgenic rats after the creation of a blind cecal loop, which resulted in 
development of severe cecal inflammation.9 To study the role of T cells in the chronic 
inflammation induced by B. vulgatus, we compared gnotobiotic HLA-B27 transgenic rnu/rnu and 
rnu/+ rats after monoassociation with this single bacterial strain. 
In the present study, we showed that B. vulgatus induced colitis in previously germ-free 
transgenic rnu/+ but not in rnu/rnu transgenic rats. Furthermore, disease developed in rnu/rnu 
transgenic recipients after transfer of activated CD4+ T cells from B vulgatus monoassociated 
rnu/+ transgenic rats. These data provide clear evidence that T cells are required for the induction 
of colitis by B. vulgatus in rnu/rnu transgenic rats. Moreover, the results show that CD4+ cells 
alone can generate the responses we observed; CD8+ cells are not required. 
oduction 
The important role o
and human IBD has been emphasized by numerous recent studies. This has been 
demonstrated in several animal models of experimental colitis, in which the susceptible host 
develops spontaneous colitis in the presence of non-pathogenic intestinal organisms.1 In a well 
characterized animal model of inflammation, HLA-B27/β2 microglobulin transgenic rats 
expressing high copy numbers of the human HLA-B27 gene  develop spontaneous colitis, gastritis 
and arthritis by three months of age when raised under specific pathogen-free conditions.2 
Commensal bacteria of the intestine tract have been extensively implicated in development of 
disease. Treatment of transgenic rats with broad spectrum antibiotics is effective for preventing 
the onset and also for ameliorating established disease.3 In addition, when HLA-B27 rats are 
raised in a germ-free environment they 
environmen
ing intestinal inflammation in HLA-B27 rats remain unclear. Disease does not develop in 
transgenic rnu/rnu rats, which are congenitally athymic and therefore lack conventional T 
lymphocytes, thus providing direct evidence that T cells are required for development of colitis in 
this model. Even if rnu/rnu transgenic rats carry the disease-prone B27 transgenic locus they are 
protected from disease, whereas the presence of T cells in their heterozygous r
critical ro
development of colitis by after T cells had been transplanted into specific pathogen-free 
rnu/rnu HLA-B27 transgenic recipients, with CD4+ T cells being more efficient than CD8+ T cells 
in transferring disease.6 
Most studies in HLA-B27 transgenic rats are carried out under specific pathogen-free 
conditions. However, monoassociation of HLA-B27 rats would provide a model to efficiently 
explore the role of T cells in the induction of colitis by a single bacterial strain. Studies fro
vulgatus, a Gram
n the genetically susceptible host. In HLA-B27 transgenic rats, B. vulgatus preferentially 
induces colitis within one month after monoassociation,7 however, no inflammation results after 
monoassociation with an E
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Materials a
Anima
atus monoassociation was confirmed by anaerobic and aerobic cultures, 
as well
cribed.5,14 A validated histologic 
inflamm
lter.13 A single colony 
of murine E. coli, isolated from specific pathogen-free normal C57BL/6 mice was cultured in 
Brain-Heart Infusion broth for 48 hours and the resulting bacteria were used to prepare a lysate 
nd methods 
ls 
We used germ-free HLA-B27 transgenic rats (of the 33-3 line)2,10 and their non-transgenic 
littermates that were either homozygous or heterozygous for the nu allele (rnu/rnu, or rnu/+ 
respectively).11,12 Rnu/rnu rats are athymic, whereas heterozygous rnu/+ rats are euthymic and 
have normal T cell function.6 All germ-free animals were monoassociated with B. vulgatus in the 
Gnotobiotic Animal Core of the Center for Gastrointestinal Biology and Disease at the College of 
Veterinary Medicine, NC State University in Raleigh, NC. Rats used for these experiments were 
four to eight months old, and animals were monoassociated with B. vulgatus for 8-12 weeks. 
Presence or absence of the HLA-B27 transgene was determined by PCR using DNA isolated from 
tail clippings, as described previously. All studies were approved by University of North Carolina 
at Chapel Hill Institutional Animal Care and Use Committee. 
 
Experimental design 
Germ-free rnu/rnu and rnu/+ HLA-B27 transgenic rats were monoassociated for 8–12 
weeks with B. vulgatus by oral and rectal swabbing with a slurry of fecal material from B. 
vulgatus monoassociated rats. In separate experiments, we transferred 107 mesenteric lymph node 
CD4+ T cells derived from rnu/+ HLA-B27 transgenic rats monoassociated with B. vulgatus 
intraperitoneally into B. vulgatus monoassociated rnu/rnu transgenic recipients, as described 
below. After seven to nine weeks, the rats were killed and mesenteric lymph node cells were 
collected for flow cytometry and cell cultures. Cecal and colonic tissue was collected for MPO, 
cecal cytokines, and histology, as described below. B. vulgatus derived from a guinea pig with 
carrageenan-induced colitis was a kind gift from Dr. A. B. Onderdonk, Harvard University, 
Cambridge, MA. B. vulg
 as by Gram staining. 
 
CD4+ T cell transfer 
Donor cells were isolated from mesenteric lymph nodes from rnu/+ HLA-B27 transgenic 
rats monoassociated with B. vulgatus for at least four weeks. Mesenteric lymph node cells were 
isolated by gentle teasing, washed twice, and then CD4+ T cells were obtained by negative 
selection using anti-rat CD45RA and anti-rat CD8a antibody coated microbeads and columns 
designed for cell depletion according to the manufacturer's instructions (Miltenyi Biotec, Auburn, 
CA), as described previously.13 Subsequently, 107 CD4+ T cells were transferred intraperitoneally 
into rnu/rnu transgenic recipients monoassociated with B. vulgatus. At the time of transfer, 
recipients had been monoassociated for at least two weeks. 
 
Histology 
Colons and ceca were fixed and stained as previously des
atory score ranging from 0 to 4 was used for blinded evaluation.5,14 
 
Preparation of bacterial lysates 
Bacterial lysates were prepared as described previously.13,15 Briefly, cecal contents, pooled 
from several B. vulgatus monoassociated non-transgenic rats, were disrupted using glass beads to 
lyse the bacteria. The lysate was then filtered through a 0.22 µm syringe fi
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preparation as described above. Sterility of lys
bacterial culture. 
Mesen
esenteric lymph node cells were evaluated by flow cytometry using the following 
r unlabeled reagents: ME-1 (anti-HLA-B27) hybridoma culture 
superna
nal anti-IFN-γ antibody (clone DB-1) (Biosource International, 
Camarillo, CA), unlabeled monoclonal anti-rat IL-10 antibody (clone A5-7) and biotin-labeled 
 antibody (clone A5-6) (BD Biosciences Pharmingen, San Diego, CA), 
and ho
). Fluorescence staining was captured 
using an Alpha Imager 2000 (AlphaInnotech, San Leandro, CA). The IFN-γ mRNA was 
 densitometry, and the ratio to β-actin mRNA was calculated. 
or measurement of cecal IL-1β, tissue from the distal cecum was homogenized in the 
1β was determined in the supernatant according to the 
manufa
ates was confirmed by aerobic and anaerobic 
 
teric lymph node cell cultures 
Mesenteric lymph nodes were removed from the rnu/rnu and rnu/+ transgenic rats, and 
single cell suspensions were prepared by gentle teasing. Unseparated mesenteric lymph node cells 
were washed twice and 4x105 cells were cultured in 96 well flat bottom microplates (Costar 
3595), in 0.2 ml complete medium (RPMI 1640 plus 5% heat inactivated fetal calf serum, 2 mM 
L-glutamine, 1 mM sodium pyruvate, 5x10-5 M 2-mecaptoethanol, and 50 µg/ml gentamicin) for 
three days. Cells were stimulated with different concentrations of B. vulgatus or E. coli lysate, as 





tant (ATCC Rockville, MD); FITC labeled goat anti-mouse IgG (γ-chain specific) 
antibody (Southern Biotechnology, Birmingham, AL) to detect binding of the unlabeled ME-1; 
FITC labeled goat anti-rat IgG (H + L) antibody (Kirkegaard & Perry Laboratories, Gaithersburg, 
MD) to identify B cells; PE-anti-rat CD4 (clone W3/25), and FITC anti-rat CD8 (clone OX-8), 
(Caltag, Burlingame, CA); and FITC anti-rat TCRαβ (clone R73) (BD Biosciences Pharmingen) 
to identify T cell subpopulations. 
 
Cytokine measurements 
We used the following commercially available ELISA reagents, as previously described, 
to measure IFN-γ and IL-10 in culture supernatants.13 Unlabeled polyclonal anti-IFN-γ antibody 
and biotin-labeled monoclo
monoclonal anti-rat IL-10
rseradish peroxidase labeled Streptavidin (BD Biosciences Pharmingen). Standard curves 
were generated using recombinant cytokines (BD Biosciences Pharmingen). 
 
Cytokine mRNA expression in cecal tissues 
RNA was isolated from snap frozen cecal tissue using TRIzol (Invitrogen, Carlsbad, CA), 
reverse transcribed (1 µg RNA), and amplified using primers specific for rat IFN-γ as described 
previously.13,16 The PCR products (7 µl) were subjected to electrophoresis on 2% agarose gels 
containing gel Star fluorescent dye (FMC, Philadelphia, PA
quantified by
 
Cecal IL-1β analysis 
F
presence of protease inhibitors.17 IL-
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MPO assay 
Ceca were homogenized as described in the previous section. Subsequently, MPO activity 
(units per gram of cecal tissue) was quantified, as described previously.14,18 
Statist
Results 
tus monoassociated transgenic rats 
 to that observed in the intestinal tract of transgenic rnu/+ rats 
monoassociated with B. vulgatus (figures 1C and 2). 
Identi
 those from rnu/rnu 
transgenic rats. 




Concentrations of the various cytokines are expressed as mean ± standard error as 
measured in triplicate culture supernatants. Data were analyzed using the paired Student's t-test, 
and a P value of < 0.05 was considered statistically significant. 
 
 
Colitis in B. vulga
Transgenic rnu/+ rats monoassociated with B. vulgatus for 8-12 weeks demonstrated a 
mild histologic colitis in both cecum and colon (figures 1A, 2). This inflammation is characterized 
by mononuclear cell infiltration of the intestinal mucosa with crypt hyperplasia. In contrast, 
transgenic rnu/rnu rats housed under identical conditions did not show microscopic signs of 
colitis (figures 1B, 2). When CD4+ T cells derived from colitic B. vulgatus monoassociated rnu/+ 
transgenic rats were transferred into B. vulgatus monoassociated rnu/rnu transgenic rats, the 
recipients developed mild colitis in the cecum and colon. This inflammation was very similar in 
appearance and severity compared
 
fication of mesenteric lymph node cell populations 
Mesenteric lymph nodes from B. vulgatus monoassociated transgenic rnu/+ rats with 
colitis were larger and contained over 5-fold more cells than those from transgenic rnu/rnu rats 
without disease (table 1). Mesenteric lymph nodes from transgenic rnu/+ rats contained 5-fold 
more CD4+ T cells than CD8+ T cells (table 1). Most of the transgenic rnu/rnu mesenteric lymph 
node cells expressed immunoglobulin, a surface marker of B cells, whereas transgenic rnu/+ 
mesenteric lymph node cells contained 2-3 fold fewer B cells compared to
Donor mesenteric lymph node cells, enriche
ata not shown). After adoptive transfer of CD4+ T cells, the total number of unseparated 
mesenteric lymph node cells as well as the proportion of CD4+ cells was significantly higher, 
while the proportion of surface Ig expressing cells was lower in rnu/rnu transgenic recipients 
compared to rnu/rnu transgenic rats that did not receive CD4+ T cells. All animals identified as 





igure 1. Representative photomicrographs of tissue sections (x10) from cecal tissue of six to eight month old 






(A) B. vulgatus monoassociated transgenic rnu/+ rats; (B) B. vulgatus monoassociated transgenic rnu/rnu rats; 
(C) B. vulgatus monoassociated transgenic rnu/rnu rats after CD4+ T cell transfer. 
 
 




















transgenic rnu/rnu rats, and B. vulgatus monoassociated transgenic rnu/rnu rats after CD4+ T cell transfer. 
Monoassociated rats were killed 8-12 weeks after B. vulgatus monoassociation. Values represent mean ± SEM of 
cecal or colonic histology scores (0-4). Each group consisted of six or seven rats. *P < 0.001 versus transgenic 
rnu/rnu rats. 
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  B. vulgatus monoassociated HLA- B27 transgenic rats   
   rnu/rnu rnu/+ rnu/rnu CD4 T cells  
   n=7 n=7 n=6  
 Total Cells (x 106) 19 ± 2 100 ± 8a 48 ± 6b  
      
 Percent     
 TCRαβ 1.9 ± 0.6 63.0 ± 3.0a 9.7 ± 1.4b  
 CD4 2.8 ± 0.3 51.1 ± 1.9a 9.6 ± 1.4b  
 CD8 1.5 ± 0.1 10.2 ± 0.7a 1.3 ± 0.2  
 Surface Ig 93.5 ± 0.7 36.4 ± 3.2a 81.7 ± 1.2a  
 HLA-B27 97.3 ± 0.7 98.1 ± 0.1 96.5 ± 0.7  
      
 
Table 1. Cell numbers and cell subpopulations in mesenteric lymph nodes of B. vulgatus monoassociated 
rnu/rnu, rnu/+, and rnu/rnu recipients of CD4 T cells from rnu/+ HLA-B27 B. vulgatus monoassociated 
transgenic rats. Values represent mean ± SEM of total cells or of percentages of lymphoid cell subpopulations.  
a p<0.001, b p <0.01 versus rnu/rnu transgenic rats. 
 
Mucosal cytokine and MPO production 
IL-1β levels in cecal homogenates reflected the severity of cecal inflammation in rnu/+ 
transgenic rats. Compared to B vulgatus monoassociated rnu/rnu transgenic rats, cecal tissue from 
rnu/+ rats and from rnu/rnu CD4+ T cell recipients contained significantly more IL-1β (figure 
3A), with the latter group producing higher levels of cecal IL-1β than rnu/+ rats (P < 0.05). 
Cecal MPO showed the same pattern as cecal IL-1β with approximately 2-fold more MPO 
 
Cecal and colonic IFN-γ mRNA expression 
The IFN-γ/β actin mRNA ratio was significantly higher in colons from transgenic rnu/+ 
rats and from rnu/rnu recipients of CD4 T cells compared to transgenic rnu/rnu rats (P < 0.05, 
figure 4A and 4B). The cecal IFN-γ/β actin mRNA ratio in rnu/rnu recipients of CD4 T cells was 
also significantly higher than ratio for cecal tissue from rnu/rnu animals. 
 
Mesenteric lymph node cell cytokine production 
Mesenteric lymph node cells isolated from either transgenic rnu/rnu or from transgenic 
rnu/+ rats did not produce detectable levels of IFN-γ after stimulation with cecal lysates prepared 
from B. vulgatus monoassociated rats (figure 5A). Interestingly, when CD4+ T cells were 
transferred into rnu/rnu transgenic recipients monoassociated with B. vulgatus, mesenteric lymph 
node cells stimulated with B. vulgatus lysate secreted significant amounts of IFN-γ (figure 5A). 
However, when mesenteric lymph node cells in all three groups were stimulated with E. coli 
lysates, no IFN-γ was detected (data not shown), suggesting that IFN-γ responses observed are 
in cecal tissue from transgenic rnu/+ rats and CD4+ T rnu/rnu cell recipients compared to 
transgenic rnu/rnu rats, and higher MPO levels in the CD4+ T cell rnu/rnu cell recipients 
ompared to transgenic rnu/+ rats (figure 3B). c
specific for components of B. vulgatus. Mesenteric lymph node cells from all three groups of rats 
produced IL-10 after stimulation with B. vulgatus lysate, indicating that the mesenteric lymph 





























Figure 3. IL-1β (A) and MPO (B) in cecal homogenates from B. vulgatus monoassociated transgenic rnu/+ and 
transgenic rnu/rnu rats, and B. vulgatus monoassociated transgenic rnu/rnu rats after CD4+ T cell transfer. Data 
represent mean ± SEM of values obtained from 6-7 rats per group *P < 0.05 versus transgenic rnu/rnu rats. **P 




B. vulgatus has been incriminated in the induction and perpetuation of colitis. It is an 
anaerobic Gram-negative bacterial strain that resides in the colon in high concentrations. B. 
vulgatus is a non-pathogenic bacterium; it does not induce colitis in wild-type rats. However, 
HLA-B27 transgenic littermates that are genetically susceptible hosts develop intestinal 






















































































































































Figure 4. Expression of IFN-γ mRNA in cecal and colonic tissues from B. vulgatus monoassociated transgenic 
rnu/+ and transgenic rnu/rnu rats, and B. vulgatus monoassociated transgenic rnu/rnu rats after CD4+ T cell 
transfer. (A) Results are expressed as the ratio of IFN-γ mRNA versus β-actin. * P < 0.05 versus transgenic 
rnu/rnu rats. (B) IFN-γ PCR products from cecal and colonic samples of one representative rat from each group. 


































Figure 5. IFN-γ and IL-10 production in mesenteric lymph node cell cultures from B. vulgatus monoassociated 
transgenic rnu/+ and transgenic rnu/rnu rats, and B. vulgatus monoassociated transgenic rnu/rnu rats after CD4+ 
T cell transfer. Rats were killed 8-12 weeks after B. vulgatus monoassociation and mesenteric lymph node cells 
were stimulated with cecal bacterial lysate from B. vulgatus monoassociated non-transgenic rnu/+ rats. IFN-γ 
(A) and IL-10 (B) were measured in triplicate culture supernatants by ELISA. Values represent mean values 
(pg/ml) ± SEM. *P < 0.005 versus transgenic rnu/rnu rats. 
 
In the present study, we showed for the first time that T cells are required for the induction 
of intestinal inflammation in rnu/rnu transgenic rats monoassociated with non-pathogenic 
commensal B. vulgatus. This was shown by histology scores, cecal MPO and IL-1β, and colonic 
IFN-γ mRNA, that were higher in rnu/+ transgenic rats compared to rnu/rnu transgenic rats. The 
level of histologic inflammation in rnu/+ transgenic rats as detected in our study is similar to the 
histologic scores in transgenic rats that do not carry a nude allele, reported by Rath et al.7 In that 
study, B. vulgatus monoassociated transgenic rats with normal T cell development showed 
average cecal histologic scores of 1.7 ± 0.2, compared to 1.4 ± 0.1 found in our study for rnu/+ 
ansgenic rats. Interestingly, we observed that rnu/+ HLA B27 transgenic rats housed under 
pecific pathogen-free conditions had consistently higher histologic inflammation scores 
 than in B. vulgatus-monoassociated transgenic rats, with 
tr
s
compared to rnu/+ transgenic rats that were monoassociated with B. vulgatus (data not shown). 
The complex intestinal microflora that colonizes the intestinal tract under specific pathogen-free 
conditions provides a strong antigenic stimulus for the genetically susceptible host resulting in a 
more severe intestinal inflammation
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likely synergistic effects between multiple bacterial strains. Monoassociation with B. vulgatus 
induces only mild inflammation, probably due to the lack of other disease-inducing 
microorganisms. 
In the HLA-B27 transgenic rat model, Breban et al previously showed that rnu/rnu HLA-
B27 transgenic rats housed under specific pathogen-free conditions do not develop colitis.6 The 
results of our study extend those findings, confirming that T cells are also one of the critical 
components of the potentially less complex set of factors that are involved in development of 
colitis after colonization with a single microorganism. In several other animal models, T cells 
have been shown to be crucial to the development of inflammation. For example, SCID mice 
develop colitis upon transfer of naive T cells (CD4+ T cells expressing high levels of CD45RB in 
the mouse).19 The equivalent population of naive CD4+ T cells in the rat, cells that express high 
levels of CD45RC, induced inflammation in the stomach and pancreas and also wasting disease in 
athymic rats.20 T cells have also been shown to play a pivotal role in the colitis that develops in 
IL-10-/- mice,21 IL-2-/- mice,22 and CD3ε transgenic mice.23 However, all studies mentioned have 
been performed under specific pathogen-free conditions. The requirement for T cells has not been 
demonstrated in a model of monoassociation with a non-pathogenic bacterial strain, as 
demonstrated in the present study. 
It has been clearly shown that CD4, and not CD8 cells, are crucial for disease-induction in 
HLA-B27 transgenic rats. CD4+ T cells were much more efficient than CD8+ T cells in 
transferring disease into nude HLA-B27 rats.6,24 In the present study, CD4+ T cells were able to 
induce colitis in B. vulgatus monoassociated rnu/rnu transgenic rats that was similar in histologic 
severity to that of B. vulgatus monoassociated rnu/+ transgenic rats. We recently demonstrated 
that IFN-γ is produced by cecal bacterial lysate-stimulated mesenteric lymph node cells derived 
from specific pathogen-free HLA-B27 transgenic rats with severe colitis.13 Depletion of CD4+ 
cells, but not CD8+ cells resulted in complete loss of IFN-γ secretion by mesenteric lymph node 
cells from transgenic rats. In addition, CD4+-enriched mesenteric lymph node cells from 
transgenic but not from non-transgenic rats produced IFN-γ after stimulation with cecal bacterial 
lysate pulsed antigen-presenting cells.13 Combined, these results indicate that cecal bacteria and 
 lymph node cells from recipients did secrete 
IFN-γ. he reason for this discrepancy is unclear. However, a possible explanation comes from 
studies 
their products stimulate mesenteric lymph node-derived CD4+ T cells to produce IFN-γ in specific 
pathogen-free transgenic rats. In the present study, mesenteric lymph node cells from B. vulgatus 
monoassociated rnu/+ transgenic rats stimulated with B. vulgatus lysates did not produce 
detectable IFN-γ in vitro. In contrast, after transfer of CD4+ T cells into B. vulgatus 
monoassociated rnu/rnu transgenic rats, mesenteric
T
of lymphoid cell homeostasis.25 In a variety of model systems in which lymphocytes were 
transferred into lymphopenic hosts such as SCID mice, nude mice, nude rats, or RAG-/- mice, 
responses of the transferred cells were exacerbated compared to responses that would be seen in 
hosts with a normal complement of lymphocytes. One explanation for the apparently heightened 
responses of the transferred cells is that they proliferate until the lymphoid system reaches 
homeostasis, due in part to the lack of competition for cytokines and other factors that the cells 
require.26 As shown in table 1, rnu/rnu rats are indeed lymphopenic. We postulate therefore that 
the lack of homeostatic control of lymphocytes numbers in the mesenteric lymph nodes of the B. 
vulgatus monoassociated rnu/rnu recipient rats allows proliferation and differentiation of the 
transferred rnu/+ CD4+ cells. These B. vulgatus reactive mesenteric lymph node cells then 
produce IFN-γ after in vitro re-stimulation with B. vulgatus components. 
While we did not detect IFN-γ after B. vulgatus lysate stimulation of mesenteric lymph 
node cells from monoassociated rnu/+ rats, colonic tissue isolated from these rats shows 
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expression of IFN-γ mRNA. It is possible that resident intraepithelial lymphocytes, a 
heterogeneous population of cells that have been shown to express IFN-γ  mRNA and to produce 
this cytokine are the source of this activity.27 
In addition, it should be noted that B cells and not T cells are likely to be the source of IL-
10 secr
 addition to the classical heterodimer of the Class I encoded 
heavy c
, Taurog JD, Hammer RE, 
Wilson KH, Sartor RB. Normal luminal bacteria, especially Bacteroides species, mediate chronic 
eted in culture supernatants of B. vulgatus lysate stimulated mesenteric lymph node cells 
(figure 5). In our previous report, we demonstrated that B cell depletion but not T cell depletion 
results in a failure of mesenteric lymph node cells from specific pathogen-free transgenic and non-
transgenic rats to produce IL-10 after cecal bacterial lysate stimulation.13 In the present study, B. 
vulgatus lysate stimulated mesenteric lymph node cells from rnu/rnu transgenic rats, which are 
comprised primarily of B cells, produce IL-10. The lower levels of IL-10 detected in culture 
supernatants of B. vulgatus lysate stimulated mesenteric lymph node cells from rnu/+ transgenic 
rats correlate with the lower proportion of  B cells in the mesenteric lymph nodes of these animals 
(table 1). 
The molecular basis for the development of spondyloarthrophies in human patients that 
carry the HLA-B27 allele and for the occurrence inflammatory conditions in HLA-B27 transgenic 
rats has not yet been determined. However, recent reports implicate the unusual biochemical 
properties of this MHC Class I encoded molecule in disease development. The B27 heavy chain 
can take several different forms in
hain non-covalently associated with β2 microglobulin that presents antigenic peptides to 
CD8+ T cells.28 One of the unusual forms results from homodimerization of two B27 molecules. 
An intriguing possibility that would explain the development of HLA-B27 associated disease was 
recently described by Kollnberger et al.29 The results of their elegant study using tetramers of B27 
homodimers indicate that these molecules are able to activate macrophages to produce TNF and 
nitric oxide, which would then establish a receptive environment for the development of 
inflammatory conditions. 
In conclusion, results of the present study show that T cells are required for development 
of colitis in HLA-B27 transgenic rats monoassociated with the non-pathogenic B. vulgatus. 
Furthermore, disease could be transferred by activated CD4+ T cells into rnu/rnu transgenic 
recipients, indicating that CD4-expressing cells are sufficient to generate the responses we 
measured. Studies in disease-susceptible gnotobiotic rodents monoassociated with disease-
inducing commensal intestinal bacteria will help to unravel the complex microbial-host 
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Cell transfers in HLA-B27 rats 
Abstract 
Introduction and aims 
HLA-B27 transgenic rats develop spontaneous colitis when colonized with intestinal 
bacteria, whereas athymic rnu/rnu HLA-B27 transgenic rats remain disease free. The present 
study was designed to assess the relative contribution of both T cells and non-T cells in 
development of colitis after transfer of mesenteric lymph node cells into rnu/rnu HLA-B27 
recipients lacking T cells. 
 
Methods 
Athymic non-transgenic and HLA-B27 transgenic recipients received either transgenic or 
non-transgenic mesenteric lymph node cells from rnu/+ heterozygous donor rats that contain T 
cells. After eight weeks recipients were euthanized and mesenteric lymph node cells were 
collected for flow cytometry and in vitro stimulation with cecal bacterial lysate. Cecal and colonic 




HLA-B27 transgenic rnu/rnu recipients receiving either non-transgenic or transgenic 
mesenteric lymph node cells developed severe colitis and had higher cecal MPO and IL-1β levels, 
and their mesenteric lymph node cells produced more IFN-γ and less IL-10 after in vitro 
stimulation with cecal bacterial lysate compared to rnu/rnu non-transgenic recipients which 
remain disease free after receiving either transgenic or non-transgenic cells. Interestingly, 
proliferating donor transgenic T cells were detectable one week after adoptive transfer into 
rnu/rnu transgenic recipients but not after transfer into non-transgenic recipients.  
 
Conclusions 
T cells from either non-transgenic or transgenic donors induce colitis in rnu/rnu 
transgenic but not in non-transgenic rats, suggesting that activation of effector T cells by other cell 




ing evidence that IBD occur due to an overly aggressive immune 
respons
d model of experimental colitis is the HLA-B27 transgenic rat model. 
HLA-B27 transgenic rats expressing the human MHC Class I gene, HLA-B27 and β2-
in, develop spontaneous colitis in specific pathogen-free conditions.2,3 Also a single 
strain o
genic rats. 
 cells, and more specifically CD4+ T cells, are required for the development of 
mic HLA-
B27 tra
everal subsets of cells have been proposed to regulate immune responses to commensal 
. Transfer of CD4+ cells expressing high levels of one of the CD45 isoforms 
(design
f CD45RB or 
CD45RC. In addition, IL-10 producing B cells can suppress colitis mediated by CD4+TCRα-β+ T 
cells in TCRα deficient mice.11 Thus, there are several distinct pathways for the regulation of the 
immune responses that mediate chronic intestinal inflammation. 
In the HLA-B27 rat model, little is known about regulation of immune responses. We 
showed previously that B cells from both HLA-B27 transgenic rats and their non-transgenic 
littermates produce IL-10 and TGF-β, which are important regulatory cytokines.7 Therefore, the 
present study was designed to assess whether co-transfer of mesenteric lymph node B cells and T 
cells from either non-transgenic or transgenic rats would induce or prevent intestinal inflammation 
in the rnu/rnu transgenic host. Furthermore, we investigated the role of the non-T cells that 
express HLA-B27 in induction of disease. Our results show that mesenteric lymph node cells 
from either non-transgenic or transgenic donors induce colitis in rnu/rnu HLA-B27 transgenic, 
but not in non-transgenic recipient rats. Furthermore, donor transgenic CD4+ cells did not expand 
after adoptive transfer into rnu/rnu non-transgenic recipients. These findings suggest that 
activation of T cells by HLA-B27-expressing accessory cells, defined as non-T cells that either 
present antigen to T cells or perform co-stimulatory functions, is pivotal to the pathogenesis of 




e to commensal non-pathogenic bacteria in a genetically susceptible host. Many animal 
models of experimental colitis support this concept.1 In these models, the genetically susceptible 
host develops colitis when housed under specific pathogen-free conditions, whereas the germ-free 
state prevents intestinal inflammation. 
A well-characterize
microglobul
f non-pathogenic commensal bacteria, B. vulgatus, is able to induce colitis in this model.4,5 
However, intestinal inflammation does not occur in germ-free animals6 or after monoassociation 
with another commensal intestinal bacterial species, E. coli.4 Moreover, mesenteric lymph node T 
cells produce IFN-γ in response to cecal bacterial lysates.7 Taken together, these results suggest 
that commensal luminal bacteria play a crucial role in the induction and perpetuation of colitis in 
HLA-B27 trans
T
inflammation in HLA-B27 transgenic rats, as shown in cell transfer studies using athy
nsgenic rats. HLA-B27 transgenic rats homozygous for the rnu allele (rnu/rnu) are hairless 
and lack a developed thymus. Rnu/rnu HLA-B27 transgenic rats do not develop disease.8 When 
transgenic CD4+ T cells were transferred into rnu/rnu transgenic rats, intestinal inflammation 
developed.8 We previously showed that activated CD4+ T cells stimulated with cecal bacterial 
lysates are required for production of the TH1 cytokines IFN-γ and IL-12.7 These findings 
underline the importance of T cells, specifically CD4+ cells, in the pathogenesis of colitis in the 
HLA-B27 transgenic model. 
S
luminal bacteria
ated CD45RBhi in the mouse; CD45RChi in the rat) induced colitis in SCID mice9, and 
gastritis, pancreatitis, and wasting disease in athymic rats.10 In both models, the inflammatory 
processes could be attenuated by co-transfer of CD4+ cells that express low levels o
160 
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Materials a
Anima
on.8 Animals were all maintained under specific pathogen-
free ho
ce and 107 unfractionated mesenteric lymph node cells were injected 
intraven
 were washed three times, and 1.5-2x107 cells were injected 
intraven
ssues were fixed and stained as 
previou
red in 96 well flat bottom microplates (Costar 3595), in 0.2 ml complete 
medium (RPMI 1640 plus 5% heat inactivated fetal calf serum, 2 mM L-glutamine, 1 mM sodium 
nd methods 
ls 
We used HLA-B27 transgenic F344 strain rats of the 33-3 line2,12 and their non-transgenic 
littermates that were either homozygous or heterozygous for the rnu allele (rnu/rnu, or rnu/+ 
respectively).13,14 Rnu/rnu rats are athymic and hairless, whereas heterozygous rnu/+ rats are 
euthymic and have normal T cell functi
using conditions at the University of North Carolina, Chapel Hill. Presence or absence of 
the HLA-B27 transgene was determined by PCR using DNA isolated from tail clippings. All 
studies were approved by University of North Carolina at Chapel Hill Institutional Animal Care 
and Use Committee. 
 
Experimental procedure 
Donor cells were obtained from mesenteric lymph nodes from rnu/+ non-transgenic and 
transgenic rats. After obtaining single mesenteric lymph node cell suspensions by gentle teasing, 
the cells were washed twi
ously into the tail vein of four to eight month old rnu/rnu non-transgenic and transgenic 
recipients. After eight weeks, rats were euthanized. Cecal and colonic tissue and mesenteric 
lymph nodes were collected. 
In separate experiments, donor mesenteric lymph node cells from rnu/+ transgenic rats 
were labeled with CFSE (Molecular Probes, Eugene, OR) in order to monitor them after transfer, 
as described previously.15,16 After obtaining single mesenteric lymph node cell suspensions by 
gentle teasing, the cells were washed twice and incubated with CFSE at 5 µM in 1xPBS for 15 
minutes at room temperature. The labeling process was terminated by adding an equal volume of 
fetal calf serum. The cells
ously into rnu/rnu transgenic or rnu/rnu non-transgenic recipients. Rats were euthanized 
on day two or day seven after injection, and flow cytometry was performed on recipient 
mesenteric lymph node and spleen cells, and recipient mesenteric lymph node cells were 
stimulated in vitro as described below. 
 
Histology 
Tissues from different sections of the intestinal tract (proximal, transverse, and distal 
colon, and cecum) were collected from each recipient. The ti
sly described.3,17 Histologic scoring (range from 0-4) was based on well-validated criteria 
and carried out on blinded samples by one evaluator.3,17 
 
Preparation of cecal bacterial lysates 
Cecal bacterial lysates were prepared as described previously.7,18 Briefly, cecal contents 
from several non-transgenic rats were disrupted using glass beads and the lysate was filter-
sterilized (0.22 µm).7 Sterility was confirmed by aerobic and anaerobic bacterial culture. 
 
Mesenteric lymph node cell cultures 
Mesenteric lymph nodes were removed from the rnu/rnu non-transgenic and transgenic 
recipients, and single cell suspensions were prepared, as described previously.7 Unseparated 





pyruvate, 5x10-5 M 2-mercaptoethanol, and 50 µ
Cells were stimulated with concentrations of ceca
n of different cytokines (50 µg/ml for stimulation of IFN-γ production, or 10 µg/ml for 
stimula
) antibody (Southern Biotechnology, Birmingham, AL) or APC labeled rat 
anti-mouse IgG1 (BD Biosciences Pharmingen, San Diego, CA). For surface immunoglobulin 
 labeled goat anti-rat IgG (H + L) antibody (Kirkegaard & Perry 
Labora
ecal cytokines were measured as described previously.17 Briefly, cecal tissues were 
 in PBS containing a cocktail of protease inhibitors,19 after which the homogenate 
was as
omogenized ceca were assayed for MPO activity (units per gram of cecal tissue) as 
n-paired 
Student t-test was used, in which a two-tailed p value of < 0.05 was considered statistically 
g/ml gentamicin) for three days, as described.7 
l bacterial lysate that we found to be optimal for 
the inductio
tion of IL-10 production). Culture supernatants were collected and stored at –20°C. 
 
Flow cytometry 
Mesenteric lymph node cell fractions were evaluated by flow cytometry using the 
following fluorochrome labeled or unlabeled reagents, as previously described.7 For detection of 
HLA-B27-expressing cells, we used culture supernatants from the murine hybridoma, designated 
ME-1, obtained from ATCC (Rockville, MD), followed by either FITC labeled goat anti-mouse 
IgG (γ-chain specific
positive B cells, we used FITC
tories, Gaithersburg, MD). For CD4 and CD8, TCRαβ and CD45RC expressing cells we 
used PE-anti-CD4 monoclonal antibody (clone W3/25), and FITC anti-CD8 monoclonal antibody 
(clone OX-8), (Caltag, Burlingame, CA), FITC or PerCP anti-rat TCRαβ (clone R73), and FITC 
anti-rat CD45RC (clone OX-22) (BD Biosciences Pharmingen) respectively. 
 
Cytokine measurements 
Cytokines in cell culture supernatants were measured by ELISA using unlabeled capture 
antibodies and biotin-labeled detection antibodies, followed by horse-radish peroxidase labeled 
Streptavidin.7 The concentration of each cytokine was determined by comparison to a standard 
curve generated using recombinant proteins. For IFN-γ, we used unlabeled polyclonal anti-IFN-γ 
antibody and biotin-labeled monoclonal anti-IFN-γ antibody (clone DB-1) (Biosource 
International, Camarillo, CA). For IL-10 ELISA we used unlabeled monoclonal anti-rat IL-10 
antibody (clone A5-7) and biotin-labeled monoclonal anti-rat IL-10 antibody (clone A5-6) (BD 
Biosciences Pharmingen, San Diego, CA). 
 
Cecal cytokine analysis 
C
homogenized
sayed for IL-1β according to the manufacturer’s instructions (National Institute for 











Cell transfers in HLA-B27 rats 
Results 
Donor and recipient mesenteric lymph node cell populations before cell transfer 
Unseparated mesenteric lymph node cells from rnu/+ non-transgenic or transgenic rats 
were used as donor cells for adoptive transfer. The transgenic donor rats had moderate colitis as 
 scores of 1.5-2.0 on a 0-4 scale (data not shown). Non-transgenic donor 
mesent
shown by histology
eric lymph node cells contained a higher proportion of B cells and a lower proportion of T 
cells compared to those from their transgenic littermates that developed colitis (table 1). Also, 
both the transgenic and the non-transgenic donor cell preparations contained CD4+ cells that 
express low levels of CD45RC (table 1). B cells were the predominant cell types in mesenteric 
lymph node of rnu/rnu non-transgenic and transgenic recipients (table 1). We evaluated cell 
surface expression of HLA-B27 to confirm the non-transgenic or transgenic status of the donor 
and recipient rats. 
 
  Donor Recipient  
  Non-Transgenic Transgenic Non-Transgenic Transgenic  
  n=6 n=5 n=2 n=2  
 Percent      
 TCRαβ 49.4 ± 1.7 66.6 ± 1.9a 1.1 ± 0.1 1.9 ± 0.5  
 CD4 30.8 ± 1.8 51.8 ± 1.6a 2.3 ± 0.4 2.9 ± 0.1  
 CD45RClow/CD4+ 17.1 ± 1.8 37.3 ± 4.4a 1.8 ± 0.1 2.5 ± 0.3  
 CD8 17.8 ± 0.5 13.7 ± 0.6a 1.4 ± 0.1 1.3 ± 0.1  
 Surface Ig 48.9 ± 1.4 31.7 ± 2.2a 91.0 ± 0.5 93.5 ± 0.5  
 HLA-B27 0.7 ± 0.2 97.9 ± 0.4a 1.1 ± 0.3 98.4 ± 0.1  
       
 
Table 1 ell populations (%) in mesenteric lymph nodes from donor (rnu/+) and recipient (rnu/rnu) HLA-B27 
s before cell transfer. a P < 0.005 versus non-transgenic donor. TG, transgenic; 
mph node cells into rnu/rnu transgenic 
recipients induced severe colitis, as shown in figure 1D. This colitis in characterized by massive 
granulocytes and mononuclear cells of mucosa and submucosa, bowel wall 
thicken
d nsgenic mesenteric lymph node cells remained disease-free, as shown 
in figure 1B. Interestingly, adoptive transfer of non-transgenic mesenteric lymph node cells into 
ipients induced moderate colitis (figure 1C), whereas rnu/rnu non-
transge
nflammation in both cecum and colon in rnu/rnu transgenic recipients receiving 
transgenic mesenteric lymph node cells, and moderate intestinal inflammation in rnu/rnu 
transgenic recipients receiving non-transgenic mesenteric lymph node cells (figure 2A-B). No 
disease was detected in rnu/rnu non-transgenic rats receiving either non-transgenic or transgenic 
mesenteric lymph node cells (P < 0.005 versus transgenic recipients) (figure 2A-B). 
 
. C
non-transgenic and transgenic rat
non-TG, non-transgenic. 
 
Transfer of mesenteric lymph node cells induces inflammation in transgenic but 
not in non-transgenic rnu/rnu recipients 
Adoptive transfer of transgenic mesenteric ly
infiltration of 
ing, crypt abscesses, crypt hyperplasia, and goblet cell depletion. Rnu/rnu non-transgenic 
recipients that receive tra
rnu/rnu transgenic rec
nic recipients receiving non-transgenic mesenteric lymph node cells did not show any 






Figure 1. Cecal inflammation in recipients of mesenteric lymph node cell transfers. Representative sections of 
the cecum of rnu/rnu transgenic and non-transgenic recipient rats, eight weeks after transfer of mesenteric lymph 
node cells from rnu/+ transgenic or non-transgenic donors are shown at 10X magnification. Panels represent 
non-transgenic donor cells transferred into non-transgenic (A) or transgenic (C) recipients, and transgenic donor 




Cell transfers in HLA-B27 rats 
 
Figure 2. Cecal and colonic histologic scores for recipients of mesenteric lymph node cell transfers. Intestinal 
tissue was collected from transgenic and non-transgenic rnu/rnu recipient rats, eight weeks after transfer of 
mesenteric lymph node cells from rnu/+ transgenic or non-transgenic donors. Blinded histology scores for cecal 
(A) and colonic (average of proximal, transverse, and distal colon) (B) tissue are shown. Values represent mean 
± SEM, n=5-8 rats per group. * P < 0.005 for histologic scores of non-transgenic recipient tissue compared to 
transgenic recipient tissue. TG, transgenic; non-TG, non-transgenic. 
 
Flow cytometric analysis of mesenteric lymph node cells in rnu/rnu recipient rats 
after adoptive transfer 
Evaluation of cell subpopulations was carried out on mesenteric lymph node cells 
collected from all recipients, as shown in table 2. Eight weeks after mesenteric lymph node cell 
transfer, cells carrying the HLA-B27 molecule comprised 40% of the total mesenteric lymph node 
cell population in rnu/rnu transgenic recipients receiving non-transgenic mesenteric lymph node 
cells. In contrast, no HLA-B27 positive cells were detected after transfer of transgenic mesenteric 
lymph node cells into rnu/rnu non-transgenic recipients, a consistent finding observed in three 
independent experiments. Of interest, equivalent proportions of CD4+ T cells were present in the 
rnu/rnu transgenic recipients of either transgenic or non-transgenic donor mesenteric lymph node 

















































lymph node cells contained significantly lower proportions of T cells and higher percentages of B 
cells than did rnu/rnu non-transgenic recipients of non-transgenic mesenteric lymph node cells. 
 
 
 Donor Transgenic Non-Transgenic Transgenic Non-Transgenic  
 Recipient Transgenic Transgenic Non-Transgenic Non-Transgenic  
  n=5 n=8 n=6 n=5  
 Total Cells      
 x 106 52 ± 12 83 ± 21 60 ± 7 46 ± 9  
       
 Percent      
 TCRαβ 33.8 ± 3.7b 34.2 ± 2.6b 5.3 ± 1.2b 14.9 ± 1.2  
 CD4 30.8 ± 3.4b 29.6 ± 2.5b 4.1 ± 0.8b 13.2 ± 1.2  
 CD8 1.5 ± 0.2 4.2 ± 0.6 2.8 ± 0.3 2.2 ± 0.3  
 Surface Ig 56.4 ± 5.4b 60.0 ± 3.3b 89.5 ± 1.0a 77.7 ± 2.5  
 HLA-B27 92.5 ± 1.6b 40.6 ± 4.8b 0.4 ± 0.2 0.5 ± 0.1  
       
 
Table 2. Cell numbers and cell populations in mesenteric lymph nodes from rnu/rnu HLA-B27 transgenic rats 
after mesenteric lymph node cell transfer. Values represent mean ± SEM of percentages of the different 
lymphoid cell populations in mesenteric lymph node of recipients analyzed eight weeks after mesenteric lymph 
node cell transfer. TG, transgenic; non-TG, non-transgenic. 
a P < 0.01 versus non-transgenic donor cells transferred into non-transgenic recipients. 
b P < 0.005 versus non-transgenic donor cells transferred into non-transgenic recipients. 
 
Increased cecal MPO and IL-1β in rnu/rnu transgenic recipients 
Inflammation in diseased rats was most severe in the cecum. Therefore, we measured 
myeloperoxidase levels in cecal tissue as a parameter of inflammation, and more specifically, 
granulocyte and macrophage infiltration. Rnu/rnu transgenic recipients receiving transgenic 
mesenteric lymph node cells had higher cecal MPO levels (albeit not statistically significant) and 
 
ric lymph node cell transfer 
Interestingly, the amounts of IFN-γ detectable in the supernatants of the recipient transgenic 
IL-1β levels (P < 0.005) than rnu/rnu transgenic recipients of non-transgenic mesenteric lymph 
node cells as shown in figure 3A and 3B. However, cecal MPO and IL-1β levels were both 
significantly higher in transgenic recipients of non-transgenic mesenteric lymph node cells than 
those found in cecal tissue from rnu/rnu non-transgenic recipients receiving mesenteric lymph 
node cells from either type of donor. 
Cytokine profile in mesenteric lymph node cell cultures from rnu/rnu transgenic 
recipients after mesente
Previously, we have shown that CD4+ T cells are critical for IFN-γ production in HLA-
B27 transgenic rats, whereas B cells are required for IL-10 secretion.7 In the present study, 
mesenteric lymph node cells from recipients were isolated and stimulated in vitro with cecal 
bacterial lysate. IFN-γ secretion in response to stimulation by components of cecal bacteria 
present in the lysate was significantly higher in rnu/rnu transgenic recipients compared to rnu/rnu 
non-transgenic recipients (P < 0.005), as shown in figure 4A. mesenteric lymph node cells 
collected from rnu/rnu transgenic recipients as early as one week after transfer of transgenic 
donor cells produced higher amounts of IFN-γ in response to cecal bacterial lysate compared to 
stimulated mesenteric lymph node cells from rnu/rnu non-transgenic recipients (figure 5). 
166 
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mesenteric lymph node cells collected from rnu/rnu transgenic recipients at this early time point 
after transfer were higher than the amounts produced by cecal bacterial lysate-stimulated 
esenteric lymph node cells from rnu/+ transgenic rats with colitis (figure 5). IL-10 produced in 
sponse to cecal bacterial lysate was significantly higher in cultures of rnu/rnu transgenic 
recipients of non-transgenic mesenteric lymph node cells compared to rnu/rnu transgenic 
re p f transgenic  lymph node cells (P < 0.01, figure 4B). 
 
Figure 3. MPO and IL-1β in cecal tissue of cell transfer recipients. Transgenic and non-transgenic mesenteric 
lymph node cells from rnu/+ rats were transferred into rnu/rnu transgenic and non-transgenic recipients. After 
eight weeks, cecal tissue was collected, homogenized, and MPO (A) and IL-1β (B) were determined in duplicate 
supernatants. Values represent mean ± SEM, n=5-8 rats per group. *P < 0.005 for cecal tissue from non-
transgenic recipients compared to transgenic recipients. TG, transgenic; non-TG, non-transgenic 
m
re










































































































Figure 4. Cytokine production by recipient mesenteric lymph node cells after adoptive mesenteric lymph node 
cell transfer. Mesenteric lymph node cells were collected from transgenic and non-transgenic recipient rats, eight 
weeks after transfer of mesenteric lymph node cells from rnu/+ transgenic or non-transgenic donors and cultured 
in the presence or absence of cecal bacterial lysate. After three days, supernatants were collected and IFN-γ 
stimulated by cecal bacterial lysate at 50 µg/ml (A) and IL-10 stimulated by cecal bacterial lysate at 10 µg/ml 
(B) were measured in triplicate supernatants by ELISA. Values represent mean ± SEM, n=5-8 rats per group. 
IFN-γ levels were significantly lower (*P < 0.005) and IL-10 levels were significantly higher (*P < 0.005) in 
supernatants of cecal bacterial lysate stimulated mesenteric lymph node from non-transgenic recipients 
compared to transgenic recipients. TG, transgenic; non-TG, non-transgenic. 
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recipient recipient no cell transfer
P < 0.05
Figure 5. IFN-γ production by cecal bacterial lysate stimulated mesenteric lymph node cells. Mesenteric lymph 
node cells from rnu/+ transgenic rats were transferred into rnu/rnu non-transgenic or rnu/rnu transgenic 
recipients. After seven days, recipient mesenteric lymph nodes were harvested, and cells were stimulated with 
cecal bacterial lysate at 50 µg/ml or cultured without stimulation (medium). Mesenteric lymph nodes were also 
obtained from rnu/+ transgenic rats (not transplanted) and stimulated with cecal bacterial lysate or cultured with 
medium. Supernatants were collected after three days. IFN-γ was measured in triplicate supernatants by ELISA. 
Values represent mean ± SD of triplicate measurements from mesenteric lymph node cell cultures of individual 
animals. Results are representative of two independent experiments. TG, transgenic; non-TG, non-transgenic. 
 
Transgenic mesenteric lymph node donor cells proliferate and accumulate in 
transgenic but not in non-transgenic recipients 
To obtain a better understanding of the kinetics of donor cell survival and proliferation, 
we evaluated CFSE-labeled transgenic donor cells after transfer into either rnu/rnu non-transgenic 
or rnu/rnu transgenic recipients. CFSE-labeled dividing cells can be easily monitored due to the 
incremental reduction in CFSE fluorescence intensity that occurs with each cell division. On day 
two after transfer, two-fold more CFSE-labeled cells were detectable in the mesenteric lymph 
odes of transgenic recipients compared to non-transgenic recipients (figures 6A-B versus 6E-F). 
Rαβ-expressing cells that had 
divided, as evidenced by their reduced fluorescence intensity (figure 6G-H). It is interesting to 
note that the transferred cells that do not express TCRαβ are not dividing (figure 6H, lower right 
quadrant). We also evaluated spleen cells of the recipients to determine if donor cells were more 
or less abundant outside the mesenteric lymph nodes. More CFSE-labeled donor cells were 
consistently seen in the mesenteric lymph nodes than in the spleen of either transgenic or non-
n
Two populations of TCRαβ-expressing cells are present (figure 6B and 6F). One is CFSE 
positive, identifying donor cells, the other is CFSE-negative. The CFSE-negative cells are either 
donor cells that divided rapidly after transfer and thus lost detectable CFSE, or alternatively, these 
cells could represent the minor population of TCRαβ-expressing cells that are present in the 
mesenteric lymph nodes of rnu/rnu recipients (see table 1). At day seven, mesenteric lymph nodes 
of non-transgenic recipients no longer contain CFSE-labeled cells (figure 6C-D) while mesenteric 
lymph nodes of transgenic recipients contain CFSE-labeled TC
169 
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transgenic recipients (data not shown), excluding the possibility that donor mesenteric lymph 




The results of the present study show that adoptive transfer of mesenteric lymph node 
cells from either transgenic donor rats that develop colitis or from disease-free non-transgenic 
donors into athymic transgenic recipients induces inflammation in the cecum and colon. This 
finding implicates accessory cells that express the HLA-B27 transgene as the activators of 
disease-inducing T cell responses. 
As demonstrated previously, T cells are required for inflammation in HLA-B27 transgenic 
rats, since rnu/rnu transgenic rats remain disease-free.8 Moreover, CD4+ T cells have been shown 
to mediate inflammatory responses in HLA-B27 transgenic rats,8 and they produce large amounts 
of IFN-γ when stimulated with components of commensal bacteria.7 Peptides bound in the peptide 
binding grooves of MHC class I molecules such as HLA-B27 are usually associated with 
activation of CD8+, not CD4+ T cells. However, it has been clearly shown that CD4, and not CD8 
cells, are crucial for disease-induction in HLA-B27 transgenic rats. CD4+ T cells were much more 
efficient than CD8+ T cells in transferring disease into nude HLA-B27 rats.8 Additionally, the 
minor role for CD8+ T cells in disease was shown by the lack of an effect on colitis by either anti-
CD8 treatment or CD8 depletion in HLA-B27 rats.21 In our study, CD8 cells did not proliferate 
and the percentage of CD8+ cells detected by flow cytometry after mesenteric lymph node cell 
transfer is low in all rnu/rnu recipients. 
CD4+ T cell subpopulations with regulatory functions have been identified. In an elegant 
study, Powrie et al showed that transfer of CD4+CD45RBhi T cells from normal mice induced 
+
hi
colitis in SCID mice. This inflammatory process could be prevented by co-transfer of CD4  cells 
that express low levels of CD45RB from normal mice.9 The same principle was shown in athymic 
rats, where transfer of T cells that express high levels of the CD45 isoform, designated CD45RC , 
mediated inflammation in several different organ systems, whereas the severity of inflammation 
was greatly reduced by co-transfer of a CD4+CD45RClow cell population.10 Also B cells and 
intraepithelial lymphocytes have been suggested as regulators of inflammation.11,22 Taken 
together, analysis of these different models of colitis indicates that disease induction as well as 
regulation are complex processes that require interactions among a variety of different cell types. 
In our study, we transferred a mixed cell population of non-transgenic or transgenic 
mesenteric lymph node cells into rnu/rnu athymic HLA-B27 transgenic rats, resulting in moderate 
to severe colitis in the recipients. Donor cells were unfractionated and contained both CD45RClow 
CD4+ and CD45RChi CD4+ cells, as well as B cells and CD8+ cells. We have shown previously 
that mesenteric lymph node-derived rat B cells, but not T cells, produce IL-10 and TGF-β in 
response to components of commensal bacteria.7 Our current findings indicate that CD45RClow 
CD4+cells or B cells, from either transgenic or non-transgenic donors, failed to prevent 
development of inflammation in rnu/rnu transgenic recipients. Conversely, rnu/rnu non-
transgenic recipients that do not express HLA-B27 remain healthy, even after transfer of 
mesenteric lymph node cells from transgenic donors with colitis. 
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Figure 6. CFSE labeled mesenteric lymph node cells from rnu/+ transgenic rats were transferred into rnu/rnu 
non-transgenic (A, B, C, D) or rnu/rnu  transgenic recipients (E, F, G, H). After two (A, B, E, F) and seven days 
(C, D, G, H), recipient mesenteric lymph node cells were collected and analyzed by flow cytometry to enumerate 
CFSE-labeled cells (histograms) and cells that express TCRαβ (dot plots). Values represent percent positive 
cells in the labeled quadrants. 
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Cecal inflammation was more severe and cecal IL-1β levels were higher in rnu/rnu 
transgenic rats after transfer of transgenic mesenteric lymph node cells than non-transgenic 
mesenteric lymph node cells. A number of explanations can be considered, including transfer of 
greater numbers of T cells (table 1) as well as previously activated T cells from transgenic 
compared to non-transgenic donors that are capable of responding rapidly to stimulatory signals. 
IL-10 is an important immunoregulatory molecule.23 For example, IL-10 is produced by 
regulatory T cells and is crucial for the inhibition of colitis in the SCID mouse CD4+CD45RBhi 
cell transfer model.24 In another study, IL-10 producing C3H/HeJBir CD4+ T regulatory cells, 
generated in vitro by sequential stimulation with cecal bacterial antigens in the presence of IL-10, 
prevented onset of colitis in SCID recipients after co-transfer with colitis inducing T cells.25 In 
HLA-B27 transgenic and non-transgenic rats, B cells are the main source of IL-10.7 Although less 
IL-10 is secreted by mesenteric lymph node cells from rnu/rnu transgenic recipients compared to 
those from rnu/rnu non-transgenic recipients, mesenteric lymph node cells of rats from both 
groups were able to produce IL-10. However, the capacity of these cells to produce IL-10 was not 
sufficient to downregulate cecal bacterial lysate-induced IFN-γ secretion by mesenteric lymph 
node cells from rnu/rnu transgenic recipients. In preliminary experiments we have identified 
hyporesponsiveness of transgenic mesenteric lymph node cells to IL-10 that might also explain 
the inability of IL-10 to inhibit development of colitis in transgenic recipients.26 
A major finding in our study is that accessory cells carrying the HLA-B27 molecule 
determine the outcome of effector T cell responses. This is clearly demonstrated by the finding 
that non-transgenic T cells, that do not induce disease in non-transgenic hosts, are capable of 
inducing colitis when transferred to rnu/rnu transgenic recipients. When the same cells are 
transferred to rnu/rnu non-transgenic recipients, no disease develops, indicating that the rnu/rnu 
host expressing transgenic HLA-B27 orchestrates T cell responses to commensal bacteria. The 
importance of HLA-B27 in the activation of T cell responses was further underlined by our 
observation that addition of anti-HLA-B27 antibodies to co-cultures of transgenic CD4+ T cells 
plus cecal bacterial lysate pulsed transgenic antigen presenting cells reduced IFN-γ responses.27 
How can we explain that accessory cells determine disease outcome, but that no disease 
occurs without T cells? There is growing evidence that T cells are not acting in an independent 
fashion, but are influenced by the innate immune system.28 TLR are crucial for innate immune 
responses against microbial products.29 These responses can skew the acquired immune system, 
including T cells, into regulatory or proinflammatory directions. Therefore, dendritic cells and 
macrophages can regulate T cell responses not only by their direct antigen presentation capacities, 
but also indirectly by the production of cytokines that are induced after TLR signaling.30 
If CD4+ T cells, and not CD8+ T cells are required, how does the MHC class I molecule 
HLA-B27 induce development of inflammatory diseases? Although this question has not yet been 
answered definitively, a number of different mechanisms have recently been proposed. Boyle et al 
described several different forms of HLA-B27, such as heterodimers that lack bound peptides. 
These molecules can associate to form either empty or peptide-binding homodimers.31 Support for 
the formation of HLA-B27 homodimers has been reported by Antoniou et al.32 Furthermore, other 
+ 33studies identified human CD4  T cells that recognized unconventional forms of HLA-B27.  
+
 rats3,6 and specific pathogen-free rnu/rnu transgenic rats8 do not 
Although CD4  T cells are considered important for induction of intestinal inflammation in HLA-
B27 transgenic rats, a recent publication showed that mice transgenic for a TCR that recognizes 
B27+ peptide have both CD4 and CD8 cells expressing the transgenic TCR that can see B27.34 
However, HLA-B27 molecules alone are not sufficient to trigger inflammation, since both germ-
free HLA-B27 transgenic
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cells in regulating pathogenic host mucosal immune responses to commensal bacteria. 
 colitis. Taken together, the combination of HLA-B27, CD4+ T cells, and the presence of 
intestinal bacteria, is required for development of disease in HLA-B27 transgenic rats. 
It is unclear what process determines the poor survival of transgenic mesenteric lymph 
node cells in the rnu/rnu non-transgenic recipients. One possibility is that, for this donor recipient 
combination, the donor cells proliferate only minimally, and therefore form a minor population 
relative to the endogenous cell population in the recipients after eight weeks. This is supported by 
the results of our cell transfer experiment using CFSE labeled cells. Multiple cycles of 
proliferation were detected in transgenic recipients but not in non-transgenic recipients on day 
seven after mesenteric lymph node cell transfer. Secondly, transgenic donor cells could be killed 
by NK cells of the non-transgenic host. Cells carrying high copy numbers of HLA-B27 have 
reduced levels of endogenous MHC class I molecules.2 It is possible that this feature makes 
transgenic donor cells prone to NK cell-mediated lysis.35,36 A third possibility is that the donor 
transgenic mesenteric lymph node cells might undergo apoptosis following transfer into rnu/rnu 
non-transgenic recipients, because their activation and subsequent survival depends on 
interactions with HLA-B27-expressing accessory cells. Finally, other organs such as spleen, liver 
or lungs might trap donor cells, thereby preventing these cells from reaching the mesenteric 
lymph node. Although we cannot rule out trapping of donor cells in non-lymphoid tissues, we 
detected a higher percentage of CFSE-labeled donor cells in mesenteric lymph 
of transgenic recipients, supporting the notion that mesenteric lymph nodes constitute an 
important site for activation, proliferation, and survival of the transplanted cells. 
Transfer of non-transgenic donor cells into transgenic recipients can potentially induce 
graft versus host disease, including systemic inflammatory lesions. However, we think that the 
disease we have documented in transgenic recipients of non-transgenic mesenteric lymph node 
cells cannot be explained by a graft versus host reaction. In an extensive description of graft 
versus host disease in the rat, no inflammation of the large intestine was observed, whereas 
moderate to several cecal and colonic inflammation occurred in rnu/rnu transgenic recipients in 
our study.37 Second, the colitis that developed in transgenic recipients following transfer of eithe
nic or non-transgenic cells showed minor differences in severity and were very similar in 
phenotype and histological features (figure 1). Thus, it is unlikely that the inflammation we 
observed following transfer of non-transgenic mesenteric lymph node is the result of a graft 
versus host reaction. 
Several published reports show reduced capacity of accessory cells, such as dendritic 
cells, from HLA-B27 transgenic rats to activate allogenic cells in vitro.38,39 The results of our 
study, while not directly addressing co-stimulatory activity, indicate that cells of
nic recipients are potent stimulators of transferred syngeneic donor mesenteric lymph node 
cells in vivo. The role of accessory cells in determining the nature of the immune response has 
been extensively evaluated, and the results indicate that antigen-presenting cells are crucial for 
both activation and also for subsequent down-regulation of immune responses.40 The results of 
our in vivo transfer study indicate that accessory cells in rnu/rnu transgenic recipients may lack 
the capacity to inhibit the colitis-inducing abilities of CD4+ T cells from donor rats that interact 
with HLA-B27 expressing cells. 
In conclusion, we have shown that colitis develops in rnu/rnu transgenic rats receiving 
transgenic or non-transgenic mesenteric lymph node cells. In contrast, rnu/rnu non-transgenic rats 
remained disease-free after mesenteric lymph node cell transfer, indicating that the accessory cells 
of the nude rats that carry HLA-B27 orchestrate T cell responses to luminal commensal bacteria. 
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Cell signaling in IL-10-/- dendritic cells 
Abstract 
Background and aims 
IL-10-/- mice develop an IL-12 mediated intestinal inflammation in the absence of 
endogenous IL-10. The molecular mechanisms of the dysregulated IL-12 responses in IL-10-/- 
mice are poorly understood. In this study, we investigated the role of NF-κB and STAT3 in LPS-
induced IL-12 p40 gene expression in BMDC isolated from wild-type and IL-10-/- mice. 
 
Methods 
We used LPS-stimulated BMDC from wild-type and IL-10-/- mice. RT-PCR and ELISA 
were used to determine IL-12 p40, TNF, and IL-10 expression, and we performed western blot for 
IkBα degradation/phosphorylation and RelA phosphorylation (S536) and STAT3 
phosphorylation. Immunofluorescence for cRel and FLAG detection was carried out and 
adenoviral gene transfer (Ad5IkBAA, Ad5kBLUC, Ad5STAT3C) and chromatin 
immunoprecipitation (ChIP) for NF-κB binding to the IL-12 p40 promoter were used. 
 
Results 
We report higher IL-12 p40 mRNA accumulation and protein secretion in LPS-stimulated 
BMDC isolated from IL-10-/- compared to wild-type mice. LPS-induced NF-κB signaling is 
similar in IL-10-/- and wild-type BMDC as measured by IκBα phosphorylation and degradation, 
RelA phosphorylation and nuclear translocation, and NF-κB transcriptional activity, with no 
downregulatory effects of exogenous IL-10. ChIP demonstrated enhanced NF-κB (cRel, RelA) 
binding to the IL-12 p40 promoter in IL-10-/- but not wild-type BMDC. Interestingly, LPS induced 
STAT3 phosphorylation in wild-type but not IL-10-/- BMDC, a process blocked by IL-10 receptor 
blocking antibody. Adenoviral gene delivery of a constitutively active STAT3 but not control 




Dysregulated LPS-induced IL-12 p40 gene expression in IL-10-/- mice is due to enhanced 




op spontaneous TH1 mediated colitis when housed under specific 
pathoge
intestinal 
microflora. Dendritic cells are at the interface of innate and adaptive immunity by virtue of their 
crete various cytokines including TNFα, IL-12 p40 and IL-23.6,7 For instance, IL-12 
p40 pro
olecules.10 
Several mechanisms have been proposed for the IL-10 mediated inhibition of LPS-induced 
matory gene expression, including activation of the heme oxygenase/carbon monoxide 
pathwa
develop severe enterocolitis.20 STAT3 deletion in bone marrow cells leads to 
overly activated innate immune responses21 and interferes with the adaptive immune system by 
duction of antigen-specific T cell tolerance.22 Moreover, STAT3 gene inactivation 
leads to
enous IL-10 in 
IL-10-/- mice provides a powerful means to investigate the immunoregulatory mechanisms of this 
cytokine. To date, the intracellular mechanisms of dysregulated IL-12 responses in IL-10-/- mice 
have not been revealed. In this study, we demonstrate that the increased IL-12 p40 gene 
expression in IL-10-/- mice is due to enhanced NF-κB recruitment to the gene promoter caused by 
defective STAT3 activation. This data indicates that STAT3 plays a critical role in the resolution 
of LPS-induced proinflammatory gene expression and may represent a potential target for the 




Cell isolation and stimulation 
Wild-type and IL-10-/- mice (129 SvEv background) between 6 and 10 weeks of age were 
used to isolate bone marrow cells from femur and tibia. Red blood cells were lysed using red 
blood cells lysing buffer (Sigma, St. Louis, MO), and cells were cultured in 24-well low 
adherence plates (Costar, Corning, NY), in complete medium containing RPMI 1640 plus 10% 
oduction 
IL-10-/- mice devel
n-free conditions.1-3 In this experimental model, enhanced IL-12 p40 production by 
immune cells represents a key feature of intestinal inflammation, as demonstrated by the 
prevention and partial treatment of colitis by anti-IL-12 antibodies.4,5 This suggests that in 
absence of IL-10, the host mounts a dysregulated innate response to the commensal 
ability to se
ducing dendritic cells skewed T cell differentiation towards a TH1 profile, a hallmark in 
the IL-10-/- experimental mouse model.8,9 However, the molecular mechanisms of dysregulated 
IL-12 p40 gene expression in IL-10-/- mice following specific pathogen-free transfer are still 
poorly understood. 
IL-10 is a potent immunoregulatory cytokine with numerous effects, such as 
downregulation of proinflammatory cytokines, chemokines, and costimulatory m
proinflam
y,11 inhibition of the NF-κB pathway12-14 and MAP kinase activity,15 mRNA stability,16 
STAT3 activation,17 and induction of Bcl-3.18 However, the molecular mechanisms for 
dysregulated host innate responses in the IL-10-/- mouse model are still unknown. IL-10 mediates 
its inhibitory effects through binding to its receptor complex, which induces activation of the 
cytoplasmic receptor associated JAK1 and Tyk2.10 This is followed by STAT3 phosphorylation, 
homodimerization, and translocation to the nucleus where it binds to STAT-binding elements in 
the promoters of various IL-10 inducible genes, including SOCS3 and Bcl-3.10,18 The pivotal role 
of STAT3 in maintaining host homeostasis is clearly demonstrated by studies using genetic 
deletion. For example, STAT3 deletion is embryogenic lethal19 and myeloid cell-specific STAT3 
deficient mice 
inhibiting the in
 an aggressive and fatal form of enterocolitis, mediated by IL-12.23 These data highlight 
the pivotal role of STAT3 in controlling innate immunity. The absence of endog
180 
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heat inactivated fetal calf serum (HyClone, Logan, UT), 2 mM L-g
pyruvate, 5x10-5 M 2-mecaptoethanol, and 50 µg/ml gentamicin in the
murine
Reage
 phospho-STAT3, STAT3 (Cell Signaling, Beverly, MA), FLAG (Sigma), and 
IκB, RelA, and cRel (Santa Cruz Biotechnology, Santa Cruz, CA) were all used at a 1:1000 
dilution. The specific immunoreactive proteins were detected using the enhanced chemo 
luminescence kit (ECL, Perkin Elmer), as described previously.28 
 
nalysis 
Izol (Invitrogen, Carlsbad, CA), reverse transcribed (1 µg 
RNA), 
lutamine, 1 mM sodium 
 presence of recombinant 
 GM-CSF and IL-4 (both 10 ng/ml, Peprotech, Rockyhill, NJ). Floating cells were gently 
removed and medium was refreshed at day three, and cells were collected at day six. The cells 
were then washed twice and incubated overnight in regular medium without IL-4/GM-CSF. Flow 
cytometry analysis demonstrated a homogenous cell population with >85% CD11c+ cells, and 
<2% T cells. Additionally, MHC class II, CD80, CD86, and OX40-L cell surface expression was 
similar between wild-type and IL-10-/- BMDC, ruling against a possible phenotypic difference 
between the cells (data not shown). For cell stimulation, 1x105 cells (cytokine measurement) or 2-
4x106 cells (proteins, RNA) were plated in a 96-well or 12-well plate, respectively. The cells were 
then stimulated with LPS (5 µg/ml, serotype 055:B5, Sigma, St. Louis, MO) in the presence or 
absence of recombinant murine IL-10 (12h preincubation, 10 ng/ml, Peprotech, Rockyhill, NJ). 
 
nts 
Purified rat anti-mouse IL-10 receptor antibody and purified rat IgG isotype control 
antibody were purchased from BD Pharmingen (San Diego, CA). The JAK2 inhibitor AG490 was 
purchased from Upstate Biotechnology (Lake Placid, NY). 
 
Adenoviral vectors and viral infections 
The constitutively active STAT3 adenovirus (Ad5STAT3C) was engineered by 
substituting the cysteine residues for A661 and N663, allowing STAT3 dimerization and 
activation without phosphorylation at Y705.24 The STAT3C contained an extra 24 base pair DNA 
nucleotides encoding for the flag peptide (DYLDDDDL). The NF-κB super-repressor 
(Ad5IκBAA)25 and the κB-luciferase adenoviral vector (Ad5κBLUC)26 have been characterized 
and described previously. The Ad5GFP virus containing the green fluorescent protein was used as 
a control viral vector throughout the study.27 The optimal multiplicity of infection for maximal 
infection rate was determined by flow cytometry of Ad5GFP infected BMDC, showing an 
infection rate of more than 80 % at an multiplicity of infection of 50 after two days of infection. 
Viability of adenoviral infected BMDC was comparable to uninfected cells as measured by 7-
amino-actinomycin D labeling and flow cytometry analysis. 
 
Western immunoblots 
BMDC were stimulated with LPS (5 µg/ml) at various time points in 12-well plates 
(Costar, Corning, NY), collected, lysed in 1x Laemmli buffer and the protein concentration was 
measured using Bio-rad quantification assay (Bio-Rad Laboratories, Hercules, CA). Protein 
extracts (15 µg) were subjected to electrophoresis on 10% SDS-polyacrylamide gels and 
transferred to nitrocellulose membranes. Antibodies against phospho-IκB, phospho-RelA, 
phospho-p38, p38,
RNA extraction and RT-PCR a
RNA was isolated u ing TRs
and amplified as previously described.28 The PCR products (7 µl) were subjected to 
electrophoresis on 2% agarose gels containing gel Star fluorescent dye (FMC, Philadelphia, PA). 
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Fluorescence staining was captured using an Alpha Imager 2000 (AlphaInnotech, San Leandro, 
CA). Sequences of primers used are described in Table 1. 
 
      
 Primer  Sequence Size (bp)  
      
 IL-12 p40 Sense 5’-GGAAGCACGGCAGCAGAATA-3’ 180  
  Antisense 5’-AACTTGAGGGAGAAGTAGGAATGG-3’   
      
 IL-10 Sense 5’-CTCTTACTGACTGGCATGAGGATC -3’ 475  
  Antisense 5’-CTATGCAGTTGATGAAGATGTCAAATT-3’   
      
 TNFα 
  
Sense 5’-ATGAGCACAGAAAGCATGATC-3’ 175  
Antisense 5’-TACAGGCTTGTCACTCGAATT-3’   
      
 
Table 1. Various sequences of primers used for RT-PCR analysis. 
 
Immunofluorescence 
For FLAG expression, wild-type and IL-10-/- BMDC were infected for 48h with 
Ad5STAT3C or left uninfected. For cRel nuclear translocation, cells were stimulated with LPS (5 
µg/ml) for 30 min. Subsequently, cells were fixed with 100% ice-cold methanol and 
permeabilized with 0.3% saponin for 10 minutes. Cells were blocked with 10% non-immune goat 
serum (NGS; Sigma, St-Louis, MO) for 30 min, then probed with rabbit anti-cRel antibody (Santa 
Cruz Biotechnology, Santa Cruz, CA) diluted 1:200 in 10% NGS for 30 min, followed by 
rhodamine isothiocyanate-conjugated goat anti-rabbit IgG antibody (Jackson ImmunoResearch, 
West Grove, PA) diluted 1:100 in 10% NGS for 30 min. FLAG-expression was detected using 
mouse anti-FLAG Ab (Sigma, St. Louis, MO), 1:250 diluted in 10% NGS for 30 min, followed by 
a FITC-conjugated goat anti-mouse IgG antibody (Jackson Immunoresearch, West Grove, PA) 
diluted 1:100 in 10% NGS for 30 min. 
 
Chromatin immunoprecipitation analysis 
complexes were collected with 
salmon sperm-saturated protein A/G-agarose for two hours and washed twice in high salt buffer 
1% Nonidet P-40, 2 mM EDTA) followed by two 
washes
were reverted by heating for eight hours at 65°C. After proteinase K (100 µg for one pour at 45°C) 
Wild-type and IL-10-/- BMDC were stimulated with LPS (5µg/ml) for zero, four, and eight 
hours, and ChIP assays were performed according to the Upstate protocol. Briefly, proteins/DNA 
were cross linked with 1% formaldehyde for 10 min and then cross linking was blocked with 125 
mM glycine. Cells were then lysed in L1 lysis buffer (50 mM Tris, pH 8.0, 2 mM EDTA, 0.1% 
Nonidet P-40, and 10% glycerol) supplemented with protease inhibitors, and chromatin was 
sheared by sonication (three times for 35 s, 1.0 sec on, 0.8 sec off). The extracts were pre-cleared 
for one hour with salmon sperm-saturated protein A/G-agarose (Upstate Biotechnology, Lake 
Placid, NY). Immunoprecipitation were carried out overnight at 4°C using 3 µg of anti-RelA or 
cRel Ab (Santa Cruz Biotechnology, Santa Cruz, CA). Immune 
(20 mM Tris, pH 8.0, 0.1% SDS, 0.5 M NaCl, 
 with no salt buffer (TE 1x), and two washes in 0.5M LiCL buffer. Samples were rotated 
for five min at 4°C in between every washing step. Immune complexes were extracted two times 
with 250 µl of freshly prepared extraction buffer (1% SDS, 0.1 M NaHCO2). DNA cross-links 
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digestion, DNA was extracted with phenol/chloroform and precipitated in ethanol. DNA isolated 
from an aliquot of the total nuclear extract was used as a loading control for the PCR (input 
control). PCR was performed with total DNA (2 µl, input control) and immunoprecipitated DNA 
(2 l using IL-12 p40 promoter-specific primers as described.29 The PCR products (8 µl) were 
subjected to electrophoresis on 2% agarose gels containing gel Star fluores (FMC, 
Philadelphia, PA). Fluorescent staining was captured using an AlphaImager  2000
Sa  L A)
 
Cytokine measurement 
s were lated f ernatan re collected 
and cytokine leve ea fic r TNFα (R&D 
Sy s, Minneapolis, MN), and IL-12 p40 (Pharmingen/BD Biosciences), to e 
m icate cultur ernatant in 
each separate experiment. 
 
tatistical analysis 
ailed Student’s t-test for paired data. A 
P-value <0.05 was considered statistically significant.  
ompared to wild-type BMDC (figure 1C). This indicates 
that lack of endogenous IL-10 is associated with enhanced IL-12 p40 gene expression in BMDC. 
ulation (figure 1C) in wild-type BMDC. As 
expecte
 µ ) 
cent dye 
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Cell  stimu or 7-24 hours with LPS (5 µg/ml) and sup ts we
ls were m sured using commercially available kits speci fo
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Enhanced IL-12 p40 and TNFα gene expression in LPS-stimulated IL-10-/- 
BMDC 
Since IL-10-/- mice develop spontaneous colitis accompanied by increased IL-12 p40 
production when housed under specific pathogen-free conditions,1,5 we first sought to evaluate the 
profile of TH1 cytokine production in BMDC isolated from both IL-10-/- and wild-type mice. As 
seen in figure 1A-B, LPS induced higher IL-12 p40 and TNFα secretion (approximately 2 fold) in 
LPS-stimulated IL-10-/- compared to wild-type BMDC. Similarly, IL-12 p40 mRNA accumulation 
was higher in LPS-stimulated IL-10-/- c
Interestingly, LPS induced IL-10 mRNA accum
d, IL-10 mRNA remained undetectable in IL-10-/- BMDC (figure 1C). Addition of 
exogenous IL-10 efficiently downregulated LPS-induced IL-12 p40 mRNA accumulation and 
TNFα protein secretion (figure 1A, B and C). This effect was blocked by IL-10 receptor blockade, 
but not by the isotype control IgG Ab (figure 1C). This clearly indicates that lack of IL-10-
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Figure 1. IL-10 mediated inhibition of increased IL-12 p40 and TNFα mRNA accumulation and protein 
secretion in BMDC. BMDC from wild-type and IL-10-/- mice were stimulated with LPS (5 µg/ml) in the 
presence or absence of IL-10 (10 ng/ml). (A) IL-12 p40 secretion at 24h, (B) TNFα secretion at 24h as measured 
in triplicate supernatants by ELISA, data presented as mean ± standard deviation. (C) IL-12 p40 and IL-10 
mRNA levels as determined by RT-PCR in RNA isolated from 12h LPS-stimulated BMDC. In some samples, 
IL-10 receptor antibody or isotype control IgG (30 µg/ml) was used for blockade of the IL-10 receptor. The 
results are representative of 3 independent experiments. 
 
IL-12 p40 secretion in IL-10-/- BMDC is NF-κB mediated 
LPS signals to TLR-4 to activate numerous signaling cascades including the NF-κB 
pathway and its subunits. For example, cRel is important for LPS-induced IL-12 p40 transcription 
in macrophages and in BMDC-derived from cRel-/-p50-/- mice.30,31 However, this subunit is not 
required for IL-12 p40 gene expression in splenic dendritic cells.32 We next determined the role 
and function of cRel in driving LPS-induced IL-12 p40 expression in IL-10-/- BMDC. 
Immunofluorescence analysis demonstrated that cRel distribution is mainly cytoplasmic in 
unstimulated BMDC but clearly translocates to the nucleus in LPS-stimulated cells (figure 2A). 
To investigate the role of NF-κB in LPS-induced IL-12 p40 gene expression, we then utilized 
adenoviral vector mediated gene delivery to selectively block this signaling pathway using the 
IκB super-repressor (Ad5IκBAA). As seen in figure 2, LPS-induced IL-12 p40 mRNA 
accumulation (B) and protein secretion (C) was blocked in Ad5IκBAA- but not control Ad5GFP-
infected IL-10-/- BMDC. Therefore, we conclude that NF-κB activation is essential for LPS-
induced IL-12 p40 gene expression in IL-10-/- BMDC. 
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. IL-12 p40 mRNA accumulation and protein secretion in LPS-stimulated BMDC is NF-κB dependent. 
(A) IL-10-/- BMDC were stimulated with LPS (5 µg/ml) for 30 min, and immunofluorescence detecting cRel was 
performed as described in the materials and methods section. (B) BMDC from IL-10-/- mice were infected with 
the IκB super repressor (Ad5IκBAA) or Ad5GFP (control) and subsequently stimulated with LPS (5 µg/ml). 
Cells were collected, RNA isolated, and IL-12 p40 mRNA was determined by RT-PCR. (C) IL-12 p40 secretion 
by Ad5IκBAA- and Ad5GFP-infected IL-10-/- BMDC, stimulated by LPS (5 µg/ml) for seven hours, as 
measured in triplicate supernatants by ELISA and presented as mean ± standard deviation. All results are 
representative of three independent experiments. **P<0.01. 
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IL-10 has been identified as a negative regulator of NF-κB activities in different cell 
systems.12-14 Thus, we hypothesized that in the absence of endogenous IL-10, NF-κB signaling is 
enhanced and leads to increased LPS-induced IL-12 p40 gene induction. To test this hypothesis, 
we compared NF-κB signaling between wild-type and IL-10-/- BMDC. As shown in figure 3A, 
LPS-induced IκB degradation and phosphorylation were similar between wild-type and IL-10-/- 
BMDC. Interestingly, although exogenous IL-10 blocked LPS-induced IL-12 p40 gene 
expression, no effect was noticed on IκB degradation or phosphorylation (figure 3A). We recently 
showed that LPS-induced RelA phosphorylation at serine residue 536 is critical for IL-6 gene 
expression.26 Similarly, LPS-induced RelA S536 phosphorylation is comparable between wild-
type and IL-10-/- BMDC, and is not inhibited by exogenous IL-10 (figure 3A). Additionally, LPS-
induced κB-luciferase activity is similar between wild-type and IL-10-/- BMDC (data not shown). 
In summary, activation of the proximal NF-κB signaling pathway is similar in wild-type and IL-
10-/- BMDC stimulated with LPS. 
LR-4 activates numerous signaling cascades including the MAP pathways, which also 
ontributes to the regulation of down-stream gene targets.33 Since IL-10 modulates p38-activity 
that impacted gene expression,11,15 we investigated whether other TLR-4 mediated p38 and JNK 
signaling events are affected in IL-10-/- cells. Therefore, we evaluated phosphorylation of the 
MAPK p38 and JNK in LPS-stimulated BMDC. As seen in figure 3B, p38 and JNK 
phosphorylation is induced in LPS-stimulated cells with no difference between wild-type and IL-
10-/- BMDC. IL-10 pre-incubation failed to block LPS-induced p38 and JNK phosphorylation in 
BMDC, showing that this immunosuppressive cytokine is not targeting these MAPK. However, 
blocking p38 activity with SB203580 slightly impaired LPS-induced IL-12 p40 secretion (data not 
shown). Together, these findings suggest that although the MAPK pathway may participate with 
F-κB in regulating IL-12 p40 gene expression, lack of endogenous IL-10 does not lead to 
ysregulated MAPK signaling. Additionally, although NF-κB signaling is critical for LPS–
induced IL-12 p40 gene expression, enhanced IL-12 p40 gene expression is not accompanied by 
increased proximal NF-κB signaling in IL-10-/- BMDC. 
 
Enhanced recruitment of cRel to the IL-12 p40 promoter in IL-10-/- BMDC 
The recruitment of transcription factors as well as duration of binding to various gene 
promoters profoundly affects transcriptional activity.34 cRel played a pivotal role in LPS induced 
IL-12 p40 transcription in macrophages31 and in BMDC derived from cRel-/-p50-/- mice,30 but is 
dispensable in spleen-derived dendritic cells.32 Since we observed enhanced cRel nuclear 
translocation (figure 2A) in LPS-stimulated BMDC, we next compared cRel recruitment to the IL-
12 p40 gene promoter in wild-type and IL-10-/- BMDC. As seen in figure 3C, cRel is strongly 
recruited to the IL-12 p40 promoter in LPS-stimulated IL-10-/- BMDC whereas minimal loading is 
observed in wild-type cells. Moreover, cRel is still loaded on the IL-12 p40 promoter eight hours 






Interestingly, the NF-κB transcriptional subunit RelA is also strongly recruited to the IL-12 p40 
gene promoter in LPS-stimulated IL-10-/- BMDC (figure 3C, middle panel). This suggests that 
enhanced IL-12 p40 gene expression in the absence of endogenous IL-10 is likely due to both 
enhanced binding of NF-κB (cRel/RelA) to the IL-12 p40 promoter as well as a defect in 
terminating gene expression, rather than increased proximal NF-κB signaling. 
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Figure 3. NF-κB signaling and MAP kinase activation in LPS-stimulated BMDC from wild-type and IL-10-/- 
mice. Wild-type and IL-10-/- BMDC were stimulated with LPS (5 µg/ml) in the presence or absence of IL-10 (10 
ng/ml), harvested at 0, 30 and 60 min, and western blot analysis was performed for (A) phospho-IκB and IκB, 
and phospho-RelA and RelA, and (B) phospho-p38, p38, and phospho-JNK. The results are representative of 
four independent experiments. (C) wild-type and IL-10-/- BMDC were stimulated with LPS (5 µg/ml) for zero, 
four, and eight hours. ChIP analysis was performed as described in the materials and methods section. Briefly, 
DNA was immunoprecipitated with cRel or RelA antibody, and PCR was performed with primers specific for 
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STAT3 is activated by LPS-induced IL-10 in wild-type but not in IL-10-/- BMDC 
The lack of suppressive effect of IL-10 on LPS-mediated proximal NF-κB signaling, in 
conjunction with a similar activation profile for various signaling events, suggests that defective 
negative signaling pathways may be associated with enhanced IL-12 p40 gene expression. The 
STAT3 pathway is required for IL-10 mediated down-regulation of LPS-induced gene expression 
in monocytes.35,36 Thus, we investigated STAT3 phosphorylation in LPS stimulated wild-type and 
IL-10-/- BMDC. Interestingly, STAT3 is clearly phosphorylated between 4 and 14h in LPS-
stimulated wild-type, but not in IL-10-/- BMDC (figure 4A). The absence of phospho-STAT3 in 
LPS-stimulated IL-10-/- BMDC is not due to an absence of STAT3 protein, as shown in figure 4A, 
right panel. Moreover, LPS-induced STAT3 phosphorylation in wild-type BMDC is blocked by 
IL-10 receptor Ab but not by control IgG Ab (figure 4B). This suggests that STAT3 activation is 





Figure 4. IL-10 dependent LPS-induced STAT3 activation in wild-type but not IL-10-/- BMDC. BMDC from 
wild-type and IL-10-/- mice were stimulated with LPS (5 µg/ml) in the presence or absence of IL-10 receptor 
antibody (30 µg/ml) or an isotype control Ab (30 µg/ml). Subsequently, cells were harvested at various time 
points and western blot analysis was performed for (A) phospho-STAT3 and STAT3, (B) phospho-STAT3 and 
STAT3 with or without IL-10 receptor blockade. The results are representative of three independent 
experiments. 
 
STAT3 overexpression reduced cRel recruitment to the IL-12 p40 gene promoter 
in IL-10-/- BMDC 
n 75% of Ad5STAT3C-infected, but not in uninfected cells (figure 5B). 
The pattern of staining revealed a partial nuclear STAT3 localization in infected cells (figure 5B). 
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To investigate the impact of STAT3 on LPS-induced IL-12 p40 gene expression in IL-10-/- 
BMDC, we artificially activated this pathway by delivering a constitutively active STAT3 through 
adenoviral vector gene delivery (Ad5STAT3C). This adenoviral vector has been shown to trigger 
STAT3 signaling independently of an exogenous ligand.24 As seen in figure 5A, FLAG-tagged 
STAT3C is highly expressed in Ad5STAT3C infected BMDC compared to uninfected or control 
Ad5GFP-infected cells. Moreover, immunofluorescence staining clearly demonstrated STAT3C 
expression in more tha
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Figure 5. Overexpression of constitutively active STAT3 in IL-10-/- BMDC. IL-10-/- BMDC were infected with 
terestingly, LPS-induced IL-12 p40 mRNA accumulation is strongly blocked in 
 accumulation was unaffected in Ad5STAT3C-infected cells, suggesting a 
selectiv
the constitutively active, FLAG-tagged STAT3 adenovirus (Ad5STAT3C), or Ad5GFP as a negative control. 
(A) After infection, BMDC were collected and protein extracts from these cells were subjected to western blot 
analysis using FLAG antibody. (B) After infection, cells were fixed with 100% methanol and FLAG expression 
was detected by immunofluorescence using FLAG antibody, followed by FITC-conjugated goat anti-mouse IgG 
antibody. The results are representative of three independent experiments. 
 
In
Ad5STAT3C- but not in Ad5GFP-infected IL-10-/- BMDC (figure 6A). Additionally, LPS-
induced TNFα mRNA
e effect of the STAT3 signaling pathway on IL-12 p40 gene expression. Similarly, 
Ad5STAT3C but not control Ad5GFP strongly prevented LPS-induced IL-12 p40 secretion in 
BMDC (figure 6B). Conversely, we used the selective JAK2 inhibitor AG490 to inhibit the 
JAK/STAT pathway in wild-type BMDC. This blockade increased IL-12 p40 secretion by 64 ± 
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Figure 6. Adenoviral delivery of constitutively active STAT3 in IL-10-/- BMDC inhibits IL-12 p40 mRNA 
accumulation and protein secretion. IL-10-/- BMDC were infected with the constitutively active STAT3 
adenovirus (Ad5STAT3C) or the control Ad5GFP, and subsequently stimulated with LPS (5 µg/ml). (A) Cells 
S-induced NF-κB signaling and 
thus IL-12 p40 gene expression. LPS-induced IκB degradation and RelA phosphorylation were 
not blo
ced cRel loading to the IL-12 p40 gene promoter (figure 7B). Altogether, these findings 
indicate that STAT3 controls LPS-induced IL-12 p40 gene expression by inhibiting recruitment of 
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were collected at four hours, RNA was isolated, and IL-12 p40 and TNFα mRNA accumulation was analyzed by 
RT-PCR. (B) BMDC were infected as described above, stimulated with LPS (5 µg/ml) for seven hours, and IL-
12 p40 secretion was measured by ELISA in triplicate supernatants and presented as mean ± standard deviation.  
*** P<0.005. Results are representative of two independent experiments. 
 
We next investigated whether STAT3 interferes with LP
cked in Ad5STAT3C infected cells (figure 7A). This suggests that STAT3 blocks LPS-
induced IL-12 p40 gene expression independently of the proximal NF-κB signaling cascade. 
Because NF-κB recruitment to the IL-12 p40 gene promoter is increased in IL-10-/- BMDC (figure 
3C), we hypothesized that STAT3 signaling interferes with recruitment of cRel to this gene 
promoter. To investigate this possibility, IL-10-/- BMDC cells were infected with Ad5STAT3C or 
Ad5GFP virus, stimulated with LPS for 4h and cRel recruitment to the IL-12 p40 gene promoter 
was analyzed by ChIP assays. As seen in figure 7B, Ad5STAT3C, but not Ad5GFP, blocked cRel 
recruitment to the IL-12 p40 gene promoter (figure 7B). Moreover, IL-10 pre-treatment inhibited 
LPS-indu
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Figure 7. Adenoviral delivery of constitutively active STAT3 in IL-10-/- BMDC inhibits cRel recruitment to the 
IL-12 p40 gene promoter without affecting the NF-κB pathway. IL-10-/- BMDC were infected with either 
d5STAT3C or Ad5GFP, or preincubated with IL-10 (10 ng/ml) for 12 hours, and then stimulated with LPS (5 
Discussion 
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µg/ml) for 1 or 4h. (A) Protein extracts from infected BMDC were collected after one hour, and western blot 
analysis was performed using antibodies for IκB, phospho-RelA, and RelA. (B) Cells were treated for four hours 
as described above and cRel recruitment to the IL-12 p40 promoter was analyzed by ChIP, as described in the 
methods section. The results are representative of two independent experiments. 
 
 
Innate immune responses are induced by the presence of pathogenic and non-pathogenic 
microorganisms and lead to the activation of a complex gene program aimed at re-establishing 
host homeostasis. Although initiation of innate immunity is a critical feature of host homeostasis, 
failure to regulate and/or terminate this response can have deleterious consequences for the host. 
For example, IBD, which include Crohn’s disease and ulcerative colitis, are associated with 
dysregulated innate and adaptive immune responses to luminal non-pathogenic bacteria.37-40 
The immunosuppressive cytokine IL-10 exerts numerous immunoregulatory functions and 
plays a pivotal role in maintaining intestinal homeostasis and controlling innate responses.39 This 
is shown in IL-10-/- mice that develop spontaneous intestinal inflammation when housed under 
specific pathogen-free conditions.1,3 However, these mice remain healthy and disease free when 
born and raised under gnotobiotic conditions, suggesting that IL-10 is involved in regulating 
innate host responses to the luminal intestinal flora.1 Despite numerous a
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mechanisms of IL-10 mediated regulation of innate immune responses have not been clearly 
elucidated. 
In this study, we investigated the molecular mechanism of dysregulated innate responses 
in BMDC isolated from IL-10-/- mice. We report that LPS induced a stronger IL-12 p40 and TNFα 
gene expression in BMDC derived from IL-10-/- compared to wild-type mice. This indicates that 
in the absence of endogenous IL-10, LPS responsiveness is enhanced in BMDC, leading to higher 
IL-12 p40 and TNFα gene expression. Importantly, administration of neutralizing IL-12 antibody 
prevents the early onset of colitis in IL-10-/- mice.5 Thus, our finding that LPS induced higher IL-
12 p40 gene expression in BMDC isolated from IL-10-/- mice correlates with the key role for IL-
12 p40 in this model of experimental colitis. 
LPS-induced IL-12 p40 gene expression is regulated by various signaling cascades and 
transcription factors.31,41,42 Among them, the NF-κB transcriptional system has been shown to play 
a preponderant role in IL-12 p40 gene expression. In an effort to understand the dysregulated IL-
12 p40 gene expression in IL-10-/- BMDC, we carefully investigated LPS signal transduction in 
both wild-type and IL-10-/- mice. We found that LPS-induced IL-12 p40 gene expression is 
strongly inhibited in BMDC expressing an IκB super-repressor, showing the critical role for NF-
κB in regulating this cytokine in BMDC. The negative effect of IL-10 on NF-κB signaling is 
controversial and may reflect cell type specificity. Interestingly, a new report showed that IL-10 
blocked LPS-induced IKK activity and RelA phosphorylation in BMDC.14 Surprisingly, using 
similar dendritic cells, we found that LPS-induced proximal NF-κB signaling is similar between 
wild-type and IL-10-/- BMDC, whereas IL-12 p40 gene expression is stronger in IL-10-/- cells. 
Indeed, levels of IκBα degradation/phosphorylation, RelA phosphorylation and NF-κB 
transcriptional activity were comparable between LPS-stimulated wild-type and IL-10-/- cells in 
our study. Thus, although NF-κB activity is essential for LPS-induced IL-12 p40 gene expression, 
is signaling cascade is not excessively activated in IL-10-/- BMDC. The discrepancy between 
ence of the endogenous 
munoregulatory IL-10 molecule. Also LPS-induced JNK and p38 phosphorylation is similar in 
ild-type and IL-10-/- BMDC, suggesting that LPS induced TLR-4 sign
impaired in either wild-type or IL-10-/- BMDC. 





results in these studies may be related to the supraphysiological dose of IL-10 used (50 ng/ml) by 
Bhattacharyya et al. For example, we found that low amounts of exogenous IL-10 in the 
physiologic range (1 ng/ml, compared to 0.7 ng/ml secreted by LPS-induced BMDC, figure 1B) 
totally blocked LPS-induced IL-12 p40 and TNF secretion without inhibiting NF-κB activity (not 
shown in present study). In addition, our study utilized cells lacking endogenous IL-10, which 
allowed physiological analysis of gene expression in the abs
im
al transduction is not w
tion and IKK activity as well as impaired NF-κB DNA binding activity in LPS-stimulated 
monocyte cell lines.13 Interestingly, we found no evidence of IL-10-mediated inhibition of IκB 
degradation and phosphorylation, suggesting that this immunosuppressive cytokine acts through a 
different mechanism in murine BMDC. This is in agreement with previous studies showing no 
effect of IL-10 on NF-κB activation43 and MAP kinases44 in human macrophages. This data 
suggests that the positive signaling cascade leading to increased IL-12 p40 gene expression 
lated in IL-10-/- BMDC. Thus, impaired activation of inhibitory signaling cascades in IL-
10-/- cells may lead to dysregulated innate host responses in these mice. 
Persistent and sustained recruitment of transcription factors to selective gene promoters is 
responsible for prolonged gene expression. Indeed, kinetics of NF-κB dependent gene 
transcription directly correlates with the extent and duration of recruitment of various subunits to 
gene promoters.34 Of considerable interest, we showed for the first time enhanced recruitment of 
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cRel to the IL-12 p40 promoter in LPS-stimulated IL-10-/- BMDC but not wild-type cells. 
Moreover, cRel was still associated with the IL-12 p40 promoter at eight hours following LPS 
stimula
oxin-stimulated wild-type but not in IL-10-/- BMDC. 
This pr
ingly, STAT3 directly interacted with RelA and 
suppres
odeling and decreased 
recruitm
tion in IL-10-/- BMDC, whereas no such binding was observed in wild-type BMDC. Thus, 
although proximal NF-κB signaling is similar between IL-10-/- and wild-type BMDC, recruitment 
of NF-κB to the IL-12 p40 gene promoter is clearly different. Therefore, both enhanced initial 
binding of cRel and failure to remove NF-κB from the IL-12 p40 promoter rather than excessive 
proximal signaling is responsible for enhanced gene expression. 
Negative regulators of LPS signaling play a pivotal role in controlling innate responses in 
numerous immune cells.39 Interestingly, we found that STAT3, a negative regulator of LPS 
signaling, is strongly phosphorylated in endot
olonged and strong STAT3 phosphorylation in wild-type BMDC is likely due to increased 
IL-10 production. First, LPS induced both IL-10 gene expression and strong STAT3 
phosphorylation in wild-type but not in IL-10-/- BMDC. Second, IL-10 receptor blocking antibody 
prevented LPS-induced STAT3 phosphorylation in wild-type BMDC. Thus, STAT3 
phosphorylation is mediated by LPS-induced IL-10 in wild-type BMDC. The lack of STAT3 
phosphorylation in IL-10-/- cells is functionally linked to enhanced IL-12 p40 gene expression. 
This is clearly illustrated in the experiment where we delivered a constitutively active STAT3 in 
IL-10-/- BMDC using an adenoviral vector. Using this approach, we demonstrated that LPS-
induced IL-12 p40, but not TNFα gene expression is strongly inhibited in IL-10-/- BMDC. 
Conversely, blocking JAK/STAT signaling in wild-type BMDC enhanced LPS-induced IL-12 p40 
protein secretion. Thus, STAT3 has a critical role in down regulating LPS-induced IL-12 p40 
gene expression. This is a selective inhibition, so this mechanism is not responsible for 
suppressing other proinflammatory cytokines induced by LPS, such as TNFα. 
In this study, we provide clear evidence that the STAT3 pathway controlled cRel 
recruitment to the IL-12 p40 gene promoter, thereby providing a mean to selectively terminate 
gene transcription. First, we showed that Ad5STAT3C prevents cRel loading to the IL-12 p40 
gene promoter without interfering with LPS-induced proximal NF-κB signaling. Second, IL-10 
mediated blockade of LPS-induced IL-12 p40 gene expression occurs independently of proximal 
NF-κB signaling but rather involves decreased cRel recruitment to the gene promoter. How can 
STAT3 activation prevent NF-κB recruitment to the IL-12 p40 gene promoter independently of 
proximal signal transduction? One possible scenario is that activated STAT3 migrates to the 
nucleus and interferes with a molecule involved in the regulation of IL-12 p40 gene expression. 
This would be consistent with the partial nuclear localization of activated STAT3 in 
Ad5STAT3C-infected IL-10-/- BMDC. Interest
sed IL-1β and LPS/interferon-γ induced iNOS gene expression in mesangial cells.45 
However, using co-immunoprecipitation analysis, we were unable to detect STAT3/NF-κB 
interaction in wild-type or IL-10-/- BMDC. Another potential mechanism could involve STAT3 
signaling interference with chromatin remodeling through alteration of histone acetylation and/or 
phosphorylation. Nucleosome remodeling of nucleosome 1, which contains the Rel and C/EBP 
cis-elements, is a critical event for signal-induced IL-12 p40 gene expression.46 We have 
previously reported that the TGF-β/Smad pathway blocked LPS-induced histone 
phosphorylation/acetylation in intestinal epithelial cells.26 It is interesting to speculate that IL-10 
activates an event through STAT3 that leads to impaired chromatin rem
ent of essential transcription factors such as cRel and C/EPB. However, Zhou et al 
demonstrated that IL-10 induced only slight changes in chromatin remodeling and C/EPB 
recruitment to the IL-12 p40 promoter in LPS-stimulated peritoneal macrophages.47 Moreover, IL-
10 failed to block LPS-induced histone-3 phosphorylation (ser 10) in the present study (data not 
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shown). Whether other histone modifications are affected by IL-10 is currently under 
investigation. The impact of STAT3 signaling events on chromatin remodeling in BMDC remains 
to be determined. Nevertheless, activation of the IL-10/STAT3 pathway likely controls the initial 
recruitment of transcription factors (cRel, RelA and probably others) and/or stability of 
protein/DNA interaction, which ultimately dictate the amount of IL-12 being transcribed by 
BMDC. 
It is interesting to note that STAT3 blocks LPS-induced IL-12 p40 but not TNFα gene 
expression. Such specific effect has been previously reported for Bcl-3 that is required for 
inhibition of LPS-induced TNFα but not IL-6 secretion in macrophages.18 Moreover, IL-10-
induced NF-κB p50 DNA binding activity is responsible for blockade of TNFα-induced IL-6 and 
MIP2α gene expression in peritoneal macrophages.48 Thus, the molecular mechanism of IL-10-
mediated gene inhibition is diverse and cell type specific. This also indicates that STAT3 
selectively altered a critical component of the transcriptional machinery involved in IL-12 p40 
expression. 
The recently discovered cytokine IL-23 consists of the IL-12 p40 and p19 subunits and is 
secreted by immune cells including dendritic cells.6 This cytokine has the ability to skew T cell 
differentiation towards a TH1 profile. Interestingly, IL-23p19 mRNA levels are increased in 
experimental colitis49 and in Crohn’s disease patients.50 Moreover, mice over expressing IL-23p19 
develop multiple organ failure, systemic inflammation and die before three month of age.51 Since 
LPS-induced IL-12 p40 gene expression is reduced by Ad5STAT3C, the decreased production of 
this subunit may not only impair IL-12 secretion but may also reduce the production of IL-23 in 
BMDC. Further studies will be necessary to understand the impact of STAT3 and IL-23 
expression on inflammatory diseases. 
Our study highlights the complex network of regulatory cascades involved in controlling 
LPS-induced signaling in immune cells. Clearly, malfunction in these regulatory pathways 
impairs host homeostasis. First, tissue-specific disruption of STAT3 in bone marrow cells during 
hematopoeiesis led to overly activated innate immune responses and Crohn’s disease like 
intestinal inflammation.21 The in vivo relevance is shown by the severe intestinal inflammation 
caused by deletion of STAT320,21 or IL-10.2 Conversely, intestinal bacteria52 and regulatory T 
cells,53 engineered to produce IL-10, prevent and treat inflammation in murine models of 
experimental colitis. 
In conclusion, we show that increased LPS-induced IL-12 p40 gene expression in IL-10-/- 
BMDC involves dysregulated recruitment of cRel to the IL-12 p40 promoter due to defective 
STAT3 activation. We propose a model where LPS-induced IL-10 production leads to the 
activation of STAT3 and inhibition of IL-12 p40 gene expression by preventing NF-κB access to 
the gene promoter. This negative feedback mechanism is essential for the attenuation of LPS-
induced innate responses in immune cells. These data provide a potential molecular mechanism 
for inflammation in IL-10-/- mice. Therefore, enhancing STAT3 signaling may represent a 
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manipulating the intestinal flora to influence the onset and course of disease. The implications for 
Introduction 
Genetic susceptibility and environmental factors are required for a host to develop IBD, as 
outlined in the general introduction. Each separate component alone is not sufficient to induce 
disease, whereas the combination of genetic susceptibility and intestinal commensal bacteria 
synergistically determine onset and perpetuation of colitis.  
The animals used in the experiments as described in this thesis, HLA-B27 transgenic rats 
and IL-10-/- mice, allow the study of the immune responses to bacteria in genetically susceptible 
animals. The results from these studies are briefly discussed in the following paragraphs. Animal 
models mimic, but not always accurately reflect the characteristics of human IBD. However, 
many findings from animal models can be translated to IBD patients. Therefore, the discrepancies 
and relevance of our findings for the pathogenesis and treatment of human IBD are emphasized in 
this chapter. Furthermore, some future directions are included, as discussed per chapter. 
 
 
Attenuation of colitis by manipulating 
the intestinal microflora 
Antibiotics 
Compelling data exists that bacteria and their products play a crucial role in the 
pathogenesis of chronic intestinal inflammation in animal models of experimental colitis and 
human IBD.1,2 Crohn’s disease is most commonly found in regions of the gastrointestinal tract 
that harbor high concentrations of enteric microflora, such as the terminal ileum and colon. 
Decreasing the exposure to bacteria by broad spectrum antibiotic therapy, or fecal deviation, 
attenuates colitis. Recurrence of disease can be induced by re-introduction of intestinal contents 
into the bypassed distal intestinal tract. Thus, based on the important role for bacteria in the 
pathogenesis of intestinal inflammation, there is a rationale for the use of antibiotics as primary or 
maintenance therapy in IBD.3 
In Crohn’s disease, metronidazole4,5 and metronidazole in combination with 
ciprofloxacin6-8 are effective in treating colonic inflammation. Also fistulizing Crohn’s disease 
and pouchitis respond to metronidazole.9-12 Although less convincing, there is a role for 
ciprofloxacin in treating Crohn’s disease.13,14 The use of antibiotics in ulcerative colitis is 
currently not justified, based on available studies. 
In this thesis, we concluded in chapter 3 that ciprofloxacin is most effective in treatment 
of cecal inflammation; metronidazole preferentially treats the colon, whereas vancomycin-
imipenem definitively treats both regions. Importantly, these results suggest that subsets of 
aerobic or anaerobic bacteria show regional differences in their capacity to mediate experimental 
colitis in IL-10-/- mice. 
Various studies in animal models indicate that commensal bacterial strains selectively 
induce inflammation in specific parts of the intestinal tract. For example, IL-10-/- mice 
monoassociated with E. coli preferentially develop cecal inflammation with an early onset of 
disease.15 In contrast, monoassociation of IL-10-/- mice with E. faecalis induces distal colitis with 
slow onset of disease, starting at 12 weeks of colonization.15,16 These data support the important 
role of intestinal bacteria for the pathogenesis of IBD and provide therapeutic potential for 
Chapter 10 
IBD patients could be that the composition of the microbiota at the
intestinal tract can determine the phenotype of disease. A better unde
bacteria
tive antibiotics for preventing rather 
than tre
n therapy 
with other therapies that change the bacterial microflora, such as probiotic and prebiotic therapy, 
will be required to prevent these unwanted effects. 
In conclus
treating Crohn’s d
than narrow spectrum antibiotics. The type an
location of disease, species of disease-inducin
The combination with probiotic and prebiotic therapy, with or without antibiotic pretreatment, is 
ption that needs further investigation. 
lammatory disorders. 




 various locations in the 
rstanding of the intestinal 
l profile for individual patients and their regional distribution is required to fully 
investigate this hypothesis. Subsequently, selective antibiotic therapy could reduce disease-
inducing bacteria in affected regions, depending on the phenotype of disease. 
Interestingly, we detected greater efficacy of selec
ating colitis. This may be explained by different roles for various endogenous bacterial 
species in the different phases of the inflammatory process. Some bacterial species might initiate 
inflammation while a larger spectrum of intestinal bacteria perpetuates disease.17 Therefore, it 
seems easier to prevent onset of colonic inflammation than to treat established disease. In human 
IBD, based on the latter hypothesis, antibiotics would be more beneficial as maintenance therapy 
after remission has been established. Disadvantages of the long-term use of antibiotics include 
bacterial resistance to antibiotics as well as bacterial overgrowth. Therefore, combinatio
ion, based on our and other studies, there is a potential role for antibiotics in the 
isease. Our data suggest that broad spectrum agents will be more successful 
d duration of antibiotics can be dependent on the 




Probiotic organisms can potentially interact with or affect three distinct yet interrelated 
components within the intestinal milieu: epithelial cells, enteric flora, and/or mucosal immune 
cells. Conventional therapy for IBD usually targets only one component of disease pathogenesis, 
the mucosal inflammatory response.18 Since the majority of standard treatment regimens are either 
ineffective in completely eradicating disease or are hindered by significant side effects, there is a 
need to identify and characterize novel pharmacologic therapies that will effectively treat and 
maintain remission of these inf
Probiotics are living commensal microorganisms that are important to the health and well 
being of the host.19 The most convincing evidence for the beneficial effect of probiotics in IBD so 
far is derived from a clinical trial with VSL#3. VSL#3 contains 9x1011 viable probiotic organisms, 
including four strains of Lactobacilli, three strains of Bifidobacteria, and one strain of 
Streptococcus salivarius. This probiotic cocktail w
ics-induced remission.20 Preliminary uncontrolled studies suggest that this agent may be 
effective in treating ulcerative colitis patients.21,22 Single probiotic species have also been 
identified and shown to improve disease in ulcerative colitis patients, as shown for the E. coli 
1917 Nissle.23,24 However, Lactobacillus GG failed to induce remission in Crohn’s disease 
patients in a sm
In chapter 4, a clinically relevant finding of our study was that oral Lactobacillus GG 
treatment partially prevented relapse of colitis in HLA-B27 transgenic rats after antibiotic 
treatment, whereas Lactobacillus GG administration alone failed to show a beneficial effect. This 
conclusion was supported by significantly decreased cecal inflammation and colonic histology 
scores, as well as a significant decrease of inflammatory rkers and cytokines in antibiotic-
Lactobacillus GG-treated transgenic rats versus other treatment groups. This is the first report of a 
synergistic effect of antibiotic and probiotic therapy in experimental colitis.  
202 
General discussion 
A possible explanation for the synergistic effects of the combination of antibiotic and 
probiotic treatment is that the combination treatment promoted synergistic interaction of 
Lactobacillus GG with other endogenous probiotic species, resulting in disease protection. The 
absence of these potential beneficial interactions with other intestinal protective bacteria in 
gnotobiotic transgenic rats co-associated with Lactobacillus GG and B. vulgatus could also 
explain
se in transgenic rats after antibiotic treatment. 
Howev
acterial species on the species and genetic 
background of the host is similar to that of disease-inducing bacteria.16,28-30 Extrapolated to human 
gests that not all patients will respond equally to probiotic therapy and that each 
patient 
l effects of the probiotic combination VSL#3 
are med
 shown that probiotic therapy prevents colitis after antibiotic 
treatme
 the lack of efficacy of Lactobacillus GG in prevention of colitis. Another possibility of the 
beneficial effects of the combination treatment in HLA-B27 transgenic rats is the transient 
decrease of competing bacteria by antibiotics, opening an environmental niche for probiotic 
bacteria. Translated to human IBD, restoring the microbial balance between detrimental and 
protective luminal bacteria by combining antibiotic and probiotic approaches may be the most 
physiologic approach to treat IBD and may alter the natural history of these chronic relapsing 
diseases. 
Another major finding in the antibiotic-Lactobacillus GG study was the prevention of 
colitis relapse by specific Lactobacillus species as demonstrated by the lack of efficacy of 
Lactobacillus plantarum in preventing colitis relap
er, this result is in contrast with our previous reports that oral Lactobacillus plantarum 
attenuated colitis in IL-10-/- mice,26 whereas Lactobacillus GG had no effect.27 These contrasting 
responses suggest that different Lactobacilli may have variable host specificity or different 
efficacy in various inflammatory conditions, indicating that not all probiotics are equally 
protective in chronic experimental colitis, and perhaps IBD patients. The concept of selective 
dependency of beneficial effects of a probiotic b
IBD this sug
may respond to a different probiotic preparation. Genetic background, location of disease, 
and the pre-existent microflora profile, could determine optimal protective agents for individual 
patients. This study already identified a group of patients that can benefit from probiotic therapy: 
antibiotic-treated patients. Further identification of subgroups of patients, selected by phenotype 
of disease or genetic background, and possibly intestinal microflora profiles, might be necessary 
to fully utilize the beneficial effects of probiotics in the treatment of IBD. 
Recent studies have shown that the beneficia
iated by TLR-9.31,32 These studies showed the attenuation of experimental colitis by oral 
administration of VSL#3-extracted DNA.31,32 A conclusion from the latter study was that “live 
microorganisms are not required to attenuate experimental colitis.” This conclusion was drawn 
because the administration of DNA or non-viable bacteria also achieved amelioration of colitis in 
murine models of experimental colitis. The implication could be that VSL#3 is not a probiotic, 
since the definition of a probiotic is “the living commensal microorganisms that are important to 
the health and well being of the host.”19 However, the exciting concept of treatment of colitis 
using bacterial DNA rather than live bacteria is based on studies in animal models and needs 
further investigation and confirmation in clinical trials. 
In conclusion, we have
nt. Efficacy of treatment is dependent on the type of probiotic, the genetic background of 
the host, phenotype of disease, presence of endogenous microflora and synergy with additional 
therapies such as antibiotics. In the future, optimal conditions for probiotics as effective therapy 
need to be elucidated. For use in human IBD, details of interest should include the choice of 
probiotic species, synergistic effects with other therapies such as antibiotics, and specification of 





inated barley food extracts decreased clinical and endoscopic inflammation in 
mild-m
. However, it is well 
docume
can also increase the risk of pathogenic 
bacteria
manipulation of the intestinal microflora has clear 
advantages over conventional medications. Changing intestinal microbiota focuses on initial 
tics 
In chapter 5, prebiotics partially prevented colitis in HLA-B27 transgenic rats, which 
correlated with increased endogenous intestinal Bifidobacteria and Lactobacilli as shown by 
PCR-DGGE and FISH. Prebiotic treatment also induced immunomodulatory effects, with 
decreased mucosal proinflammatory IL-1β and increased immunomodulatory molecules such as 
TGF-β. These results provide insight into the protective mechanisms utilized by prebiotics to 
mediate their beneficial effects, and show promise for prebiotics as adjuvant maintenance therapy 
for chronic inflammatory bowel diseases. This approach could be a safe, easy to administer, and 
cost-effective alternative for current treatments in IBD. However, the current clinical support for 
prebiotic use in IBD patients is poor. 
Only few small clinical trials have demonstrated the efficacy for prebiotics in human IBD. 
For example, germ
oderate ulcerative colitis.33,34 Furthermore, inulin administration to ulcerative colitis 
patients with pouchitis after colectomy led to a reduction of inflammation in the pouch mucosa.35 
However, large multicenter clinical trials are required to convincingly support a role for prebiotic 
therapy in IBD. 
This is the first study in which prebiotics were used as primary therapy in genetically 
engineered rodents. The results are in agreement with findings by Schultz et al in a recent study, 
who reported that a probiotic preparation that also contained inulin attenuated colitis development 
in HLA-B27 rats.36 In another study, the application of the probiotic combination of Lactobacillus 
GG and Bifidobacterium lactis, and the prebiotic combination of inulin and oligofructose, or the 
prebiotic- plus probiotic combination was tested in rats.37 The prebiotic combination increased IL-
10 secretion in Peyer’s patches, whereas sIgA secretion was increased by both prebiotic and the 
combination treatment. No significant effect on NK cells activity or spleen and mesenteric lymph 
node cells were detected. Although the different treatments affected immunomodulation, no 
additive or synergistic effects were observed.37 Thus, although there is rationale for the use of 
prebiotics in synergy with probiotics (synbiotics), this concept is not (yet) supported by studies in 
models of experimental colitis. 
The negative side-effects of prebiotics are relatively unknown
nted that prebiotic therapy profoundly changes the intestinal microflora, as shown in 
chapter 5. In addition, not only luminal bacteria, but also the mucosa-associated gut flora is 
affected by the prebiotic combination oligofructose/inulin. This was shown by increased mucosal 
concentrations of Lactobacilli and Bifidobacteria in the proximal and distal colon, when 
endoscopically obtained samples were cultured.38 Of interest, mucosa-associated concentrations of 
cultured anaerobes and Bacteroides spp. were not affected by the prebiotic treatment. The 
potential for prebiotics to stimulate growth of not only beneficial but also pathogenic bacterial 
strains was demonstrated by a study of Salmonella species. Both inulin and fructo-oligosaccharide 
impaired resistance to intestinal Salmonella enterica in rats, which was corrected after calcium 
supplementation.39 This would imply that prebiotics 
l growth in susceptible hosts. Another unwanted effect of prebiotic therapy such as 
lactulose is diarrhea, a common side-effect of this drug. 
As a whole, evidence for the beneficial effects of prebiotic therapy is emerging in animal 
models and clinical trials. The potential advantages of prebiotic therapy (few side-effects, cost-
effective, natural components) justify future mechanistic research and large well-designed clinical 
trials to support the potential use of prebiotics as adjuvant maintenance therapy. 
To summarize part I, therapeutic 
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disease pathogenesis, has fewer side effects, and has the potential to change the natural course of 
disease
biotics, and/or the combination of two or all three of these 
agents,
Bacterial-induced immune responses 
 versus potentially toxic standard therapy. The genetic background of the host can 
determine the choice of therapy, since different bacterial strains have selective activities 
dependent on the genetic background of the host.2 As pointed out in the introduction, future 
identification of susceptibility genes for IBD will allow us to divide patients into different 
subgroups with optimal treatment strategies for each group. For example, if genetic testing 
indicates an expected colonic phenotype of disease, metronidazole might be used for prophylaxis, 
followed by probiotic treatment. It is possible that different bacterial subsets induce disease in 
various intestinal regions in IBD patients, as suggested by monoassociated IL-10-/- mice.15 
Therefore, antibiotics, probiotics, pre
 have great potential of becoming well-accepted therapeutic strategies in the treatment of 
IBD. However, successful use of this approach will require thoughtful identification of patient 
subgroups that will selectively respond to a therapeutic cocktail. 
 
 
in experimental colitis 
Adaptive immune responses 
T lymphocytes 
In Part II, we studied innate and adaptive immune responses to bacteria and their products 
in HLA-B27 transgenic rats and IL-10-/- mice. Using these models of experimental colitis, we first 
explored the cytokine profiles in mesenteric lymph node cells after stimulation with a lysate from 
cecal contents. Transgenic HLA-B27 transgenic rats showed an increased ratio of pro- versus anti-
inflammatory cytokine secretion. 
In chapter 6 we showed that T cells are critical for the production of the proinflammatory 
cytokines IFN-γ and IL-12 in HLA-B27 transgenic rats. In several other genetically engineered 
animal models T cells are crucial to the development of inflammation. This has been 
demonstrated in IL-2-/- mice,40 IL-10-/- mice,41 TCRα-/- mice,42 Tgε26 mice,43 and CD45RBhigh T 
cells transfer into either SCID mice44 or athymic rats.45 However, all of these studies were 
performed in specific pathogen-free conditions. To study the role of T cells in a disease-
susceptible host monoassociated with a single commensal bacterial strain, we monoassociated 
rnu/rnu or rnu/+ transgenic rats with B. vulgatus. B. vulgatus is a non-pathogenic bacterial strain 
that induces mild colitis in HLA-B27 transgenic rats.28 In chapter 7, we used nude athymic HLA-
B27 transgenic rats. Colitis developed in rnu/+ transgenic rats monoassociated with B. vulgatus, 
but rnu/rnu transgenic rats remained disease free in the absence of T cells. In the latter group of 
rats, transfer of CD4+ T cells induced disease, confirming that CD4+ T cells are required for 
induction of colitis.46 Thus, T cells are critical for the development of intestinal inflammation, not 
only in specific pathogen-free conditions, but also in monoassociation with B. vulgatus. 
The question remains whether T cell responses to B. vulgatus in the latter model are 
antigen-specific. This could be addressed in future experiments in rats monoassociated with E. 
coli, which remain disease free. Transfer of CD4+ T cells from B. vulgatus monoassociated rnu/+ 
transgenic rats into E. coli monoassociated rnu/rnu transgenic rats could address this hypothesis. 
If colitis develops in E. coli monoassociated rnu/rnu transgenic recipients, we can reject the 
hypothesis of antigen-specificity. 
205 
Chapter 10 
Bacterial specific T cell responses found in animal models are relevant for human IBD, 
considering that T-cell clones from human mucosal biopsies showed specific responses to 
selective commensal bacteria, including Bacteroides, Bifidobacteria, and E. coli.47,48 Several 
studies have attempted to elucidate the mechanisms of bacterial-specific T cell clones in animal 
models. For example, adoptive transfer of bacterial-antigen-activated CD4+ T cells from colitic 
C3H/HeJBir but not from control C3H/HeJ mice to C3H/HeSnJ SCID recipients induced colitis.49 
In another study,  a model of antigen-specific colitis was developed by transfer of OVA-specific T 
cells from RAG-2-/- TCR transgenic mice into RAG-2-/- recipients whose intestinal tracts were 
colonized with OVA-expressing or control E. coli.50 In this model, transfer of polarized TH1 and 
TH2 subsets induced colitis in recipients colonized with OVA-expressing but not control E. coli, 
and induction of disease was dependent on bacterial-associated OVA. These results indicate the 
role of a specific bacterial antigen in the onset of colitis.50 In a recent study, flagellins, which are 
molecules known to activate innate immunity via TLR-5, were identified as dominant antigens in 
experim ntal colitis by screening an expression library of enteric bacteria for serologic 
responses.51 In this study, multiple strains of colitic mice had elevated serum anti-flagellin IgG2a 
responses and TH1 
induced severe coli
flagellins was elevated in Crohn’s disease patients
controls.51 The latter study identified flagellins as 
 that stimulates pathogenic intestinal immune reactions in 
n together, the data discussed in this paragraph indicate that T 
th the enteric bacterial flora and their products can mediate chronic intestinal 
inflamm





cell subset in this model expressed high levels of CD1d, a 
e
T cell responses to flagellin. In addition, flagellin-specific CD4+ T cells 
tis when adoptively transferred into naive SCID mice. Serum IgG to these 
, but not in patients with ulcerative colitis or in 
a bacterial product that functions not only as an 
adjuvant but also as an antigen
ptible hosts. Takegenetically susce
cells reactive wi
ation. 
However, immunoregulatory responses can also be antigen-specific. For example, 
bacterial-reactive T regulatory cells prevented onset of colitis in C3H/HeSnJ SCID recipients in 
co-transfer with TH1 T cells reactive to intestinal commensal bacteria.52 In another study, H. 
hepaticus induced colitis in IL-10-/-
ce to RAG-/- mice induced colitis, which could be prevented by co-transfer of CD4+ T cells 
from H. hepaticus-infected but not uninfected wild-type mice. This protective effect was mediated 
by IL-10 secretion by CD4+ T cells in a H. hepaticus-antigen-specific manner.53. However, 
regulatory T cells can also exert their protective effects in a non-antigen-specific fashion. CD + T 
cells engineered to secrete IL-10 can home to the gut, and prevented colitis induced by transfer of 
CD45RBhi cells into SCID mice.54,55 Thus, bacterial- and antigen specificity is an important 
feature of the immune system, and antigen-specific T cells have distinct roles in pathogenic or 
regulatory immune responses. Characterization of specific subsets of T cells reactive to specific 
commensal bacteria could be a first step in defining targets for treatment of human IBD. 
 
B lymphocytes 
Generally, regulatory T cells are thought to secrete the majority of IL-10.56,57 Of interest, 
this thesis shows that B cells were the major producers of the regulatory cytokines IL-10 and 
TGF-β in HLA-B27 transgenic rats. However, our findin ells produce rg that B c
es confirmed findings by Mizoguchi et al, who demonstrated that IL-10-producing B cells 
are protective, since B cell/TCRα double deficient mice had more colitis than TCRα deficient 
mice with competent B cells.58,59 The immunoregulatory role of IL-10 producing B cells was 
further demonstrated by the observation that transfer of B cells from IL-10/TCRα double deficient 
mice was unable to suppress chronic intestinal inflammation in B cell/TCRα double deficient 




ed that B cells only play a minor role in the pathogenesis of IBD. One study that 
support
fter establishing the role of T cells in B. vulgatus induced colitis in rnu/rnu HLA-B27 
investigated the role of antigen-presenting cells in controlling T cell function. 
As desc
 of B-1 B cells. Also in mouse spleens, B cells were detected that produce IL-10. These 
B220+CD19+ cells were shown to stimulate naive T cells, and might be involved in activating 
regulatory immune responses.60 A gene that has been shown to be required for the development of 
IL-10-producing B cells is Gαi2.61 Reconstitution of RAG2-/- mice with Gαi2-/- bone marrow 
induced an IBD-like colitis, accompanied by a selective deficit in IL-10 secreting B-1 B cells and 
an increase in B-2 B cells. 
In contrast, B cells also exacerbate inflammation in some models. The transfer of CD4+ T 
cells into SCID mice induces ileitis, whereas co-transfer of mesenteric lymph node B cells from 
SAMP1/YitFc mice increases the severity of ileitis compared to the transfer of CD4+ T cells 
alone.62 The suggested mechanism is the interference of SAMP1/YitFc B cells with the 
suppression of effector T cell proliferation by regulatory αEβ7+CD4+ T cells, thus contributing to 
the development of ileitis in SAMP1/YitFc mice. In another study, B cells were shown to trigger 
intestinal inflammation using transgenic mice expressing CD40 ligand ectopically on B cells 
(CD40L/B).63 CD40L/B transgenic mice developed spontaneous severe transmural intestinal 
inflammation in both colon and ileum, whereas CD40L/B CD40 double-mutant mice did not 
develop colitis, indicating the direct involvement of CD40-CD40L interaction. Furthermore, mice 
transferred with B220+ B cells from diseased CD40L/B transgenic mice and CD4+ T cells from 
wild-type mice also develop colitis.  
Controversy still exists on the role of B cells in the pathogenesis of experimental colitis 
and human IBD. IBD patients have increased serum and mucosal antibody responses to several 
commensal bacteria, including E. coli.64-66 Furthermore, B-1 cells produce IgM or IgA in a T cell–
independent manner, with specificities for common enteric bacterial antigens. However, other 
reports suggest
ed the latter hypothesis showed that the severity of colitis that develops in IL-10-/- mice is 
similar to the colitis that developed in B-/-IL-10-/- mice, implying that B cells were not the primary 
mediator of experimental colitis in this model.41 As described previously in this chapter, the 
distinct effects of B cells per subset are important. Mucosal IFN-γ secreting B-2 cells induce 
proinflammatory effects and IL-10 producing B-1 cells induce anti-inflammatory responses.67 
Furthermore, the location of disease is relevant, since CD45RBhi T cells from IFN-/- mice can 
induce ileitis when transferred into SCID mice only when co-transferred with B cells,68 suggesting 
that the proinflammatory activity of intestinal B cells may be particularly relevant in the ileum. 
Thus, specific subsets of B cells can have either pro or anti-inflammatory capacities, depending on 
their phenotype. These results are relevant to the pathogenesis of IBD and imply that reducing (B-




transgenic rats, we 
ribed in chapter 8, HLA-B27 transgenic rnu/rnu recipients receiving either non-transgenic 
or transgenic cells developed more severe intestinal inflammation compared to rnu/rnu non-
transgenic recipients receiving either transgenic or non-transgenic cells. Therefore, we concluded 
that T cells from either non-transgenic or transgenic donors induce colitis in rnu/rnu transgenic 
but not in non-transgenic recipient rats, suggesting that activation of T cells by antigen presenting 
cells expressing HLA-B27 is pivotal to the pathogenesis of colitis in this model. 
The role of antigen-presenting cells in determining the nature of the immune response has 
been extensively evaluated, and the results indicate that antigen-presenting cells are crucial for 
both activation and also for subsequent down-regulation of immune responses.69 The results of 
207 
Chapter 10 
our in vivo transfer study indicate that accessory cells in rnu/rnu transgenic recipients may lack 
the capacity to inhibit the colitis-inducing abilities of CD4+ T cells from donor rats that interact 
with HLA-B27 expressing cells. Defective stimulation of T cells by antigen-presenting cells in 
HLA-B27 transgenic rats was recently confirmed.70 One of the underlying mechanisms described 
in this study involves a decreased use of the costimulatory molecule CD86 by HLA-B27 dendritic 
cells. Impaired costimulatory function could result in a loss of tolerance toward microbial flora in 
this mo
on. Although the T cells are important tools for the induction 
and pe
imental colitis could 
be attenuated. This was demonstrated using IL-10 producing Lactococcus lactis78 and regulatory 




del. However, activation of T cell responses also plays a role in the HLA-B27 transgenic 
rat model. The importance of HLA-B27 in the activation of T cell responses was underlined by 
our observation that addition of anti-HLA-B27 antibodies to co-cultured transgenic CD4+ T cells 
plus cecal bacterial lysate-pulsed transgenic antigen presenting cells reduced IFN-γ responses.71 
Thus, the activation of antigen-presenting cells by commensal bacterial products can induce both 
overly aggressive immune responses and can also lead to a loss of tolerance in the genetically 
susceptible host. 
The findings of the study presented in chapter 8 emphasize the importance of antigen-
presenting cell function in regulating host immune responses to commensal bacteria in 
experimental colitis, and also indicates that the antigen-presenting cell might be of value as a 
therapeutic target to treat IBD and spondyloarthropathies. Some therapeutic approaches for human 
IBD are directed against T cell functi
rpetuation of colitis, antigen-presenting cells represent a diverse group of cells that can 
determine the outcome of bacterial-induced T cell responses. 
 
Innate immune responses 
Dendritic cells form a small subset of cells that have potent immunoregulatory capacities. 
Mucosal dendritic cells actively process bacterial products and regulate immune responses by 
transporting these antigens to mesenteric lymph nodes and thereby inducing T cell responses. 
Secondly, dendritic cells are present at the interface of innate and adaptive immunity by virtue of 
their ability to secrete various cytokines including TNFα, IL-12 p40 and IL-23.72,73 For instance, 
IL-12 p40 producing dendritic cells skewed T cell differentiation towards a TH1 profile, a 
hallmark in the IL-10-/- experimental mouse model.74,75 Immunoregulatory cytokines, such as IL-
10, can subsequently influence if dendritic cells induce either pro- or anti-inflammatory responses. 
Reported responses to systemic administration of IL-10 have been poor in human Crohn’s 
disease.76,77 One possible explanation for this lack of effect is the absence of high concentrations 
of IL-10 at the relevant sites, such as the intestinal mucosa and mesenteric lymph nodes. Indeed, 
when high amounts of IL-10 were delivered at the site of inflammation, exper
T cells,54 engineered to pro
 that the local delivery of IL-10 prevented and treated intestinal inflammation in murine 
models of experimental colitis. Alternatively, understanding of the mechanisms of IL-10 mediated 
effects are required to determine alternative strategies for recombinant IL-10 treatment. 
In chapter 9, we report mechanisms of IL-10-mediated innate immune responses and 
showed that IL-10-induced STAT3 interfered with the recruitment of transcription factors to the 
gene promoter of the proinflammatory cytokine IL-12 p40. Previously, the importance for IL-10-
induced STAT3 signaling for host homeostasis was shown by deletion of STAT3, that was 
embryologically lethal.79 Moreover, myeloid cell-specific STAT3-deficient 
enterocolitis,80 and STAT3 deletion in bone marrow-derived cells lead to overly activated 
innate immune responses81 and interfered with the adaptive immune system by inhibiting the 
induction of antigen-specific T cell tolerance.82 
208 
General discussion 
In animal models of experimental colitis, but also in IBD patients, the presence of 
intestinal bacteria and their products leads to a continuously activated immune system. 
Subsequent NF-κB-mediated proinflammatory immune responses can determine the onset and 
perpetuation of colitis in the genetic susceptible host. Mechanisms of interference with NF-κB 
activation are therefore crucial for the development of therapeutic strategies in IBD. Based on our 
findings, we propose a model in which LPS-induced IL-10 production leads to the activation of 
STAT3 and inhibition of IL-12 p40 gene expression by preventing NF-κB access to the gene 
promoter. This negative feedback mechanism is essential for the attenuation of TLR-4 mediated 
LPS-induced innate responses in immune cells. Importantly, Haga et al showed protection of Fas-
mediated liver injury by overexpression of constitutively active STAT3 following intravenous 
administration.83 Thus, enhancing STAT3 signaling may represent a potential therapeutic target to 




Enormous progress has been made in the past decade to elucidate the mechanisms of 
chronic intestinal inflammation as seen in IBD. Novel techniques provided the tools to identify 
genetic mutations, determine the role of specific subsets of immune cells in inflammation, and 
map the intestinal microflora and their responses to therapy. The various ongoing clinical trials 
translate current basic laboratory findings to potential new therapeutic strategies aimed at 
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improving the natural course o
tone of clinical progress in inflammatory bowel diseases and will lead to novel future 
therapies that selectively target defined patient subgroups. A better understanding of the 
mechanisms by which commensal bacterial adjuvants and antigens stimulate pathogenic and 
protective immune responses will help identify optimal subgroups for treatment, therapeutic 
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increase the amount of luminal probiotic bacteria and can prevent colitis in this model. We found 
that the prebiotic combination inulin/oligofructose partially prevented colitis in HLA-B27 
Summary 
Inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn’s disease, have 
a great impact on their victims’ quality of life. Our knowledge about these diseases is limited and 
thus treatment is as well. In an effort to better understand the causes of IBD, this thesis addresses 
(1) the attenuation of bacterial-induced experimental colitis by manipulating the intestinal 
microflora, and (2) the regulation of bacterial-induced innate and adaptive immune responses in 
experimental colitis. 
This thesis has an introductory chapter and the following chapters are divided into two 
parts. Chapter 1 is a general introduction and gives an overview of genetic, microbiological, and 
immunological aspects of the pathogenesis of IBD. Genetic susceptibility is required to develop 
IBD. However, animal models of experimental colitis have shown that intestinal bacteria are also 
required for the induction and perpetuation of disease. This leads to the current hypothesis that 
IBD is the consequence of overly aggressive immune responses to luminal commensal bacteria in 
the genetically susceptible host. Furthermore, chapter 1 describes treatment strategies that can 
alter the microflora, thereby preventing experimental colitis. These strategies include eliminating 
specific bacteria (antibiotics), administration of protective bacteria (probiotics), and stimulating 
the growth of endogenous protective bacteria (prebiotics). Innate immune responses and their 
intracellular pathways are discussed in chapter 2. Innate immunity is crucial as a first line of 
defense against pathogens. Its importance lies in the fact that innate immune responses can direct 
adaptive immunity. 
 
Part I describes prevention and treatment of colitis that develops in HLA-B27 transgenic 
rats and IL-10-/- mice. Antibiotics, probiotics, and prebiotics, were used in order to manipulate the 
intestinal microflora in chapters 3-5, and mechanisms of attenuation of colitis were studied. 
Chapter 3 gives the results of an investigation on whether broad or selective antibiotics 
affect onset and progression of colitis in various regions of IL-10-/- mice. All antibiotics (partially) 
prevented inflammation in the cecum and colon. However, in the treatment study ciprofloxacin 
and vancomycin-imipenem decreased cecal inflammation and reduced luminal E. coli and E. 
faecalis concentrations. In contrast, metronidazole and vancomycin-imipenem reduced colonic 
injury and eliminated anaerobic bacteria including Bacteroides spp. Thus, ciprofloxacin was most 
effective in the treatment of cecal inflammation; metronidazole preferentially treats the colon, 
whereas vancomycin-imipenem definitively treats both regions. These results suggested that 
subsets of aerobic or anaerobic bacteria show regional 
differences in their capacity to mediate experimental colitis in IL-10-/- mice. 
Chapter 4 contains the results of an investigation concerning the prevention of colitis with 
probiotic Lactobacillus GG in HLA-B27 transgenic rats monoassociated with B. vulgatus. We 
determined if Lactobacillus GG or Lactobacillus plantarum could treat established colitis in 
specific pathogen-free HLA-B27 transgenic rats and prevent recurrent disease after antibiotics 
were stopped. Lactobacillus GG did not prevent colitis in B. vulgatus-coassociated transgenic rats 
nor did it treat established disease in specific pathogen-free rats. However, Lactobacillus GG but 
not Lactobacillus plantarum prevented colitis relapse in antibiotic-treated rats. These studies 
suggested that antibiotics and probiotic agents provide synergistic therapeutic effects, perhaps 
mediated by altered immunomodulation with selective activity of different Lactobacillus species. 
The aim of the study described in chapter 5 was to investigate if oral prebiotics can 
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transgenic rats, which correlated with altered intestinal microflora as sho
increases in cecal and colonic Lactobacillus and Bifidobacterium populati
treatme
L-10  mice were assessed. Immune cells were stimulated with bacterial 
product
he study reported in chapter 7 was to investigate the ability to induce colitis 




er transfer into non-transgenic recipients. 




wn by significant 
ons after prebiotic 
nt compared to water-treated transgenic rats. We also observed decreased mucosal 
proinflammatory cytokines and increased cecal TGF-β. These results show promise for prebiotics 
as maintenance therapy for chronic inflammatory bowel diseases. 
 
In Part II, bacterial-induced innate and adaptive immune responses in HLA-B27 
transgenic rats and I -/-
s and cytokine profiles, effects of cell transfers, and intracellular pathways were studied. 
Chapter 6 describes the results of a study of host-dependent immune responses to 
commensal cecal bacteria. We showed that in unfractionated transgenic mesenteric lymph node 
cells stimulated with cecal bacterial lysates, the pro- versus anti-inflammatory ratio is 
significantly higher compared to non-transgenic cells. Furthermore, T cell depletion abolished 
IFN-γ and decreased IL-12 production and conversely, neither IL-10 nor TGF-β was produced in 
cultures of B cell-depleted mesenteric lymph node cells. Interestingly, IL-10 and TGF-β, but not 
IFN-γ, IL-12, and TNF were produced by mesenteric lymph node cells from germ-free transgenic 
rats. These results indicate that the colitis that developed in specific pathogen-free HLA-B27 
transgenic rats was accompanied by activation of IFN-γ-producing CD4+ T cells that responded to 
commensal bacteria. However, B cell-derived cytokine production in response to components of 
commensal intestinal microorganisms occurred in the absence of intestinal inflammation. 
The aim of t
ntaining rnu/+ littermates. We showed that rnu/+ rats that contain T cells, and rnu/rnu 
transgenic rats receiving CD4+ cells from B. vulgatus nu/+ transgenic donor rats, developed 
colitis, whereas rnu/rnu rats without T cells remained disease-free. Taken together, these
 that T cells are required, and CD4+ cells are sufficient, for the development of colitis in 
HLA-B27 transgenic rats monoassociated with the non-pathogenic bacterial strain B. vulgatus. 
The study presented in chapter 8 was designed to assess the relative contribution of 
antigen-presenting cells versus T cells in the development of inflammation. HLA-B27 transgenic 
rnu/rnu recipients receiving either non-transgenic or transgenic mesenteric lymph node cells 
including T cells developed more severe intestinal inflammation compared to rnu/rnu non-
transgenic recipients receiving either transgenic or non-transgenic cells. Interestingly, donor 
transgenic CD4+ cells proliferated and remained at detectable levels eight weeks after adoptive 
transfer into rnu/rnu transgenic recipients but not aft
Therefore, we concluded that T cells from either non-transgenic or trans
n rnu/rnu transgenic but not in non-transgenic recipient rats, suggesting that activation of 
T cells by antigen-presenting cells expressing HLA-B27 is pivotal to the pathogenesis of colitis in 
this model. 
The intracellular mechanisms of the dysregulated IL-12 responses in the absence of IL-10 
in IL-10-/- mice are poorly understood. Chapter 9 reports the results of a study of the intracellular 
pathways NF-κB and STAT3 in LPS-induced IL-12p 40 gene expression in BMDC isolated from 
wild-type and IL-10-/- mice. Surprisingly, LPS-induced NF-κB signaling was similar in IL-10-/- 
and wild-type BMDC. Chromatin immunoprecipitation demonstrated sustained NF-κB binding to 
the IL-12 p40 promoter in IL-10-/- but not wild-type BMDC. Adenoviral gene delivery of a
tively active STAT3 blocked LPS-induced IL-12p 40 gene expression, and NF-κB 
recruitment to the IL-12 p40 promoter. Therefore, we concluded that dysregulated LPS-induced 
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IL-12 p40 gene expression in IL-10-/- mice is due to enhanced and sustained NF-κB recruitment to 
the IL-12 p40 promoter in the absence of activated STAT3. 
In conclusion, this thesis emphasized the importance of bacteria and their products in the 
induction and perpetuation of experimental colitis. Further research is necessary to elucidate the 
underlying mechanisms that mediate the pathogenic and protective effects of intestinal bacteria in 






oegepast om de darmflora te manipuleren, en tevens werden mechanismen van 
bescher





Mechanismen van bacterie-geїnduceerde experimentele colitis 
Chronische inflammatoire darmziekten (IBD) omvatten colitis ulcerosa en de ziekte van 
Crohn, en hebben een grote invloed op de kwaliteit van leven van patiënten. Onze kennis van deze 
chronische ziekten is beperkt, hetzelfde geldt voor de huidige behandelings-strategieën. Om de 
oorzaken van IBD beter te begrijpen besteedt dit proefschrift aandacht aan (1) de verbetering van 
bacterie-geïnduceerde experimentele colitis door middel van manipulatie van de darmflora, en (2) 
de regulatie van bacterie-geïnduceerde verworven en aangeboren immuun reacties in 
experimentele colitis. 
Dit proefschrift begint met een algemene introductie en de daaropvolgende hoofd
pgedeeld in twee delen. Hoofdstuk 1 geeft een overzicht van de genetische, 
immunologische, en microbiologische aspecten bij de pathogenese van IBD. Genetische aanleg is 
een vereiste voor het ontwikkelen van IBD. Onderzoek van experimentele colitis in diermodellen 
heeft echter aangetoond dat ook darmbacteriën vereist zijn voor het ontwikkelen van colitis. Deze 
gegevens hebben geleid tot de huidige hypothese dat IBD het gevolg is van een over-agressieve 
immuunreactie gericht tegen de darmflora van een genetisch gevoelige gastheer. Ook zijn in 
hoofdstuk 1 behandelingsstrategieën besproken die de darmflora kunnen veranderen om zodoen
entele colitis te voorkomen. Voorbeelden hiervan zijn het elimineren van specifieke 
bacteriën (antibiotica), de toename van de concentratie beschermende bacteriën (probiotica) en de 
stimulatie van de groei van endogene beschermende bacteriën (prebiotica). In hoofdstuk 2 wordt 
separaat nog wat dieper ingegaan op de aangeboren immuun reacties en de bijbehorende 
onderliggende intracellulaire mechanismen. Aangeboren immuniteit is cruciaal voor de eerstelijns 
afweer tegen pathogenen. Tevens is aangeboren immuniteit belangrijk voor de sturing van 
verworven immuniteit. 
 
Deel I beschrijft de preventie en behandeling van experimentele colitis in HLA-B27 
transgene ratten en IL-10-/- muizen. In de hoofdstukken 3 t/m 5 werden antibiotica, probiotica, en 
prebiotica t
ming tegen darmontsteking onderzocht. 
In hoofdstuk 3 hebben wij onderzocht of breed- en smalspectrum antibiotica ontsteking in 
de diverse regionen van het colon van IL-10-/- muizen zou kunnen beïnvloeden. Deze studie 
toonde aan dat alle antibiotica ontsteking in zowel het caecum als het colon (gedeeltelijk) konden 
voorkomen. In het behandelingsprotocol bleken ciprofloxacine en vancomycine-imipenem echter 
specifiek de ontsteking te remmen in het caecum en tevens de luminale concentraties van E. coli 
and E. faecalis te reduceren. Daarnaast bleken metronidazol en vancomycine-imipenem de 
ontsteking in het colon te reduceren en in staat anaerobe bacteriën inclusief Bacteroides stammen 
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metronidazol in het colon, en vancomycine-imipenem is effectief in beide regionen. Deze 
resultaten suggereren dat subgroepen van aerobe en anaerobe bacteriën regionale verschillen 
vertone
G danwel Lactobacillus plantarum fulminante colitis in specifiek 
pathogeen-vrije transgene ratten kon behandelen en een recidief kon voorkomen na het stoppen 
van antibiotische behandeling. Lactobacillus GG kon colitis niet voorkomen in B. vulgatus-co-
geassocieerde transgene ratten, en was evenmin in staat om fulm
Lactobacillus GG kon echter een recidief colitis voorkomen in ratte
 
probiotica mogelijk synergistische therapeutische effecten hebben, mogelijk ten gevolge van een 
immun
ename van luminale concentraties van Lactobacillus en Bifidobacterium 
soorten
ale lymfeklier cellen van kiemvrije ratten wel IL-10 en TGF-β, maar geen 
IFN-γ, -12, en TNF. Deze resultaten suggereren dat colitis in HLA-B27 transgene ratten 
samenh
zoeken of B. vulgatus colitis kan veroorzaken in 
monoge
n wat betreft de capaciteit van het onderhouden van colitis in IL-10-/- muizen. 
In hoofdstuk 4 is onderzocht of de probiotische bacterie Lactobacillus GG colitis kan 
voorkomen in HLA-B27 transgene ratten in monoassociatie met B. vulgatus. Tevens werd 
onderzocht of Lactobacillus G
inante colitis te behandelen. 
n behandeld met antibiotica, 
dit gold niet voor Lactobacillus plantarum. Deze resultaten suggereren dat antibiotica en
omodulatoire werking met een selectieve activiteit van de verschillende Lactobacillus 
soorten. 
Het doel van de studie beschreven in hoofdstuk 5 was te onderzoeken of orale prebiotica 
de luminale concentraties van probiotische bacteriën kunnen verhogen en colitis kunnen 
voorkomen. De prebiotische combinatie inuline/oligofructose voorkwam gedeeltelijk colitis in 
HLA-B27 transgene ratten. Dit correleerde met een veranderde darmflora, zoals aangetoond 
middels significante to
, vergeleken met de water controle groep. Tevens vonden wij een afname van intestinale 
pro-inflammatoire cytokinen en een toename van caecale TGF-β. Deze resultaten bevestigen de 
veelbelovende mogelijkheden van prebiotica als potentiële onderhoudstherapie bij patiënten met 
IBD. 
 
In Deel II zijn bacterie-geïnduceerde aangeboren en verworven immuun reacties in HLA-
B27 transgene ratten en IL-10-/- muizen beschreven. Daartoe werden immuun cellen gestimuleerd 
met bacteriële producten en vervolgens werden cytokine profielen, de effecten van cel transfers, 
en intracellulaire signaaltransductie onderzocht. 
In hoofdstuk 6 is aangetoond dat wanneer ongefractioneerde cellen van mesenteriale 
lymfeklieren uit HLA-B27 transgene ratten gestimuleerd worden met caecale bacteriële lysaten 
een grote toename van de pro/anti-inflammatoire cytokine ratio gezien wordt in vergelijking met 
non-transgene cellen. De IFN-γ reacties verdwenen en de IL-12 productie minimaliseerde na 
depletie van T cellen, terwijl B cel depletie de IL-10 en TGF-β productie elimineerde. Tenslotte 
produceerden mesenteri
IL
angt met de activatie van IFN-γ producerende CD4+ T cellen die reageren op commensale 
bacteriën. Daarentegen produceren B cellen anti-inflammatoire cytokinen na stimulatie door 
componenten van intestinale micro-organismen, ook in afwezigheid van ontsteking. 
Het doel van hoofdstuk 7 was te onder
associeerde HLA-B27 transgene rnu/rnu ratten en rnu/+ ratten die T cellen bevatten. In 
dit onderzoek hebben wij aangetoond dat rnu/+ ratten met normale T cel ontwikkeling, en ook 
rnu/rnu transgene ratten na transfer van CD4+ cellen van B. vulgatus rnu/+ transgene donor 
ratten, colitis ontwikkelden. Echter, rnu/rnu ratten zonder T cellen bleven ziekte-vrij. 
Samenvattend blijkt uit deze data dat T cellen vereist zijn en CD4+ T cellen voldoende voor het 
mediëren van colitis door de non-pathogene bacterie B. vulgatus in HLA-B27 transgene ratten. 
De studie beschreven in hoofdstuk 8 werd ontworpen om het relatieve aandeel van 
antigeen-presenterende cellen en T cellen in de ontwikkeling van colitis te bepalen. HLA-B27 
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transgene rnu/rnu ontvangers van non-transgene danwel transgene mesenteriale lymfeklier cellen 
inclusief T cellen ontwikkelden ernstige colitis vergeleken met rnu/rnu non-transgene ontvangers 
van non-transgene danwel transgene cellen. Opvallend genoeg bleken donor transgene CD4+ 
cellen t
nsductie in IL-10-/- en wild-type BMDC. Chromatine immunoprecipitatie analyse 
vertoon
mstig onderzoek is nodig om de onderliggende mechanismen die de de pathogene maar ook 
beschermende werking van darmbacteriën in experimentele colitis en IBD mediëren te verklaren. 
e prolifereren in transgene ontvangers en nog detecteerbaar te zijn na acht weken, dit gold 
niet voor non-transgene ontvangers. Concluderend induceren T cellen van non-transgene en 
transgene donoren colitis in rnu/rnu transgene maar niet in non-transgene ontvangers. Dit 
suggereert dat activatie van T cellen door antigeen-presenterende cellen die HLA-B27 tot 
expressie brengen cruciaal is in de pathogenese van colitis in dit model. 
De intracellulaire mechanismen van ontregelde IL-12 reacties in de afwezigheid van IL-10 
in IL-10-/- muizen zijn onbekend. Daarom hebben wij in hoofdstuk 9 de intracellulaire 
signaaltransductie cascades voor NF-κB en STAT3 onderzocht in relatie tot LPS-geinduceerde 
IL-12 p40 gen expressie in dendritische cellen uit het beenmerg (BMDC) van wild-type en IL-10-/- 
muizen. Verrassend genoeg bleek er geen verschil te zijn tussen LPS-geinduceerde NF-κB 
signaaltra
de een blijvende binding van NF-κB aan de IL-12 p40 promotor in IL-10-/- maar niet in 
wild-type BMDC. Een kunstmatige continue activatie van STAT3 middels een adenovirale gen 
transfer blokkeerde de LPS-geinduceerde IL-12 p40 gen expressie, en tevens de binding van NF-
κB aan IL-12 p40 promotor. Samenvattend is de ontregelde LPS-geinduceerde IL-12 p40 gen 
expressie in IL-10-/- muizen het gevolg van langdurig toegenomen binding van NF-κB aan de IL-
12 p40 promotor bij het ontbreken van geactiveerd STAT3. 
Concluderend benadrukken de resultaten beschreven in dit proefschrift de cruciale rol 























Prof. dr. C.J.J. Mulder, beste Chris. “Het komt goed.” “Geld is rond.” “Prima.” Jouw enorme 
steun, meestal in de vorm van de jouw kenmerkende stenografische e-mails, heeft in belangrijke 
mate de basis gelegd voor dit proefschrift. Jouw rotsvaste vertrouwen en onvoorwaardelijke steun 
waren de basale voorwaarden om dit onderzoek te beginnen en tot een goed einde te brengen. Het 
begon met een plompverloren “Jij gaat naar Amerika,” en eindigde twee jaar later met een net zo 
abrupt “Kom nu maar terug.” Om vervolgens aan te geven dat het proefschrift “wel even” 
geschreven kon worden om alles af te ronden. Bij deze. Ook toonde jij altijd je sociale interesse 
die veel verder ging dan slechts werk, iets wat ik altijd zeer heb gewaardeerd. En nu op naar de 
volgende uitdaging… 
 
Prof. R. B Sartor, dear Balfour. Thank you for the words “you can always come back,” when we 
said goodbye in October 2000. With your enthusiasm, creativity, and scientific curiosity, you 
create an environment that is highly stimulating for anybody who wants to pursue a career in 
science. Not only the science, but also the outdoor activities were outstanding. I sincerely hope 
that we will have an opportunity to work and play together again in the future. 
 
Dr. L.A. Dieleman, beste Leo, jij begeleidde mij in mijn eerste periode in Chapel Hill en gaf mij 
de kans te ruiken aan het echte wetenschappelijke onderzoek. Dat dit aanvankelijk leidde tot 
mislukkingen nam jij voor lief. Uiteindelijk heeft het toch nog tot iets goeds geleid. Tevens 
verdubbelde jouw aanwezigheid de Nederlandse enclave in Chapel Hill voor koninginnedag en 
het EK voetbal. Alhoewel Canada verder van huis is zal onze hechte band blijven, op 
wetenschappelijk gebied, maar ook als vriendschap. 
 
Dr. C. Jobin, dear Christian, “There is always time to talk science,” was your reply when I 
gathered new data I could not interpret. You always made time for me and patiently explained the 
mysteries of cell signaling to me. You helped me developing many bench top skills, which will be 
important for the future. But my pool and tennis games also improved thanks to your challenges. I 
am sure we will stay in touch. 
 
Dr. S.L. Tonkonogy, dear Sue, You started teaching me the basics of experiments, or, what not to 
do. This foundation has been extremely valuable throughout this thesis. Furthermore, no detail 
escaped your attention. Our discussions have always been inspiring and you have always 
encouraged me to work a little harder and a little longer. I appreciate that you were always there, 
even at late hours or during ice storms, helping me finish experiments. 
 
Many thanks to all the people in Sartor and Jobin Lab. Lisa, thanks for keeping the lab (and now 
your little family) running! Dear Sandy, Bo, BiFeng, James, Julia, Kristen, Carol, Brigitte, Joo-
Sung, Brandon, Chad, Susie, Carol, Aaron, Byung Ik, Dirk, Thomas, and many others: thanks so 
much for all the help and fun. 
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most exciting events possible: on the squash court, in the
you can be my paranymph. 
 
Martijn Mandey, op vele manieren ben jij betrokken geweest bij dit proefschrift in de afgelopen 
ppelijke ervaring op te doen. Die ervaring is onmisbaar gebleken in de 
aarop volgende jaren, en heeft een basis gelegd voor mijn wetenschappelijke interesse. 
ear Ken, Su, and Jammie, you probably do not realize what your support, hospitality, and 
relativerende opmerkingen. JW, jij hield het 
elfs een half jaar uit in Chapel Hill, en je schoffelde heel wat Amerikanen onderuit op het 
zwijgende steun was altijd vanzelfsprekend, en dat tekent jullie. De 
9 richting Schiphol kennen jullie ondertussen beter dan je eigen oprit. Mede dankzij jullie ben ik 
 appreciate and 
spect your perseverance, in our relationship, in life. Thank you for being here. 
 you. Hanging out with you is one of the 
 bar, in the hot springs, or at the lab. Glad 
jaren. Nu dus wederom, als paranymph. Je bent zelfs twee keer langsgeweest in Chapel Hill, wat 
steeds een welkome afleiding was. Dank voor je vriendschap. 
 
Beste Ronald en Stefan, jullie onderhielden trouw de banden met het vaderlandse voetbal voor mij 
en zorgden ervoor dat onze vriendschap niet ondersneeuwde. Dank voor jullie morele 
ondersteuning, het betekent veel voor me. Afstand is geen belemmering voor vriendschap. 
 




Ook dank voor de steun van Stichting Wetenschappelijk Onderzoek Ziekenhuis Rijnstate, dat 
het mogelijk maakte om een samenwerkingsverband met UNC op te zetten en tevens het 
beschreven onderzoek uit te voeren. 
 
D
kindness meant to me. Always there to help: moving in, moving out. The many Siedler’s games 
were unforgettable moments, the holidays were special, and the food was always delicious. 
Leaving Carrboro was the most difficult thing to do, and leaving family almost impossible. Thank 
you for supporting us and giving us that chance. 
 
Saskia, Rico, Jan-Willem, dank voor jullie steun en 
z
voetbalveld. Je vertrek uit Chapel Hill was legendarisch: “Brussels, not Amsterdam, I repeat; 
Brussels, not Amsterdam.” Saskia en Rico, na jullie bruiloft alweer spannende maanden op komst, 
iets speciaals om naar uit te kijken! 
 
Lieve papa en mama, jullie stil
A
zo ver gekomen. Ik zal proberen iets dichter bij huis te blijven komende jaren. 
 
Dear Christine, when one leaves family behind and moves overseas to a small rainy country, 
finishing a PhD program suddenly seems small and insignificant. Despite that, you always 
















Frank Hoentjen werd op 23 oktober 1975 geboren te Bennekom. Hij haalde zijn VWO-
diploma aan het Van Lingen College te Arnhem in 1994. In datzelfde jaar begon hij aan de studie 
geneeskunde aan de Katholieke Universiteit Nijmegen, hetgeen in 1999 resulteerde in het 
doctoraal examen met het predikaat cum laude. Gedurende deze periode volgde Frank een 
wetenschappelijke stage van 1996 tot en met 1999 aan de afdeling Maag-Darm-Leverziekten van 
het Academisch Ziekenhuis St. Radboud te Nijmegen, gericht op de regulatie van motoriek en 
secretie van de tractus digestivus. Voor dit werk ontving hij in 2000 de Studentenprijs van de 
Nederlandse Vereniging voor Gastroenterologie. Tijdens zijn co-schappen volgde hij een 
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Tevens volgde hij een klinische tropenstage aan de Gadjah Mada University te Yogyakarta, en de 
University of Indonesia te Jakarta, Indonesië. Het artsexamen werd behaald in 2002, en 
vervolgens werd Frank aangesteld als assistent-geneeskundige in opleiding tot klinisch 
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Hill, USA. Voor dit werk ontving hij onderscheidingen van de Gastroenterology Research Group 
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